MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		
Brief Description of Changes		
Document format amended in line with Hospital Policy POL-GEN-0021		
Changes documented on QPulse and highlighted in grey		
Reason for Change		
Updated Procedure:		
Gynae smears now dispatched to Eurofins due to Coombe not retaining INAB accreditation.		
Histology TAT aim to report 80% of specimens in 15 days		

USER HANDBOOK

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

INDEX

1.	QU		POLICY OF THE PATHOLOGY LABORATORY, MATER PRIVATE HOSPITAL,	
	DU	BLIN		10
2.	MA	TER PF	RIVATE HOSPITAL PATHOLOGY SERVICES	11
	2.1	Info	RMATION AND ADVICE	12
	2.2	ΗΕΑΙ	O OF PATHOLOGY	13
	2.3	Con	SULTANT AND GENERAL ADVISORY SERVICE	13
	2.4	PHLE	вотому	14
		2.4.1	Process for Booking Appointments for Phlebotomy	15
		2.4.2	General Practice	15
	2.5	Тіме	S OF SERVICE AVAILABILITY	15
3.	SPE		I HANDLING	16
	3.1	Con	SUMABLE SUPPLIES	16
	3.2	THE	Request Form	17
		3.2.1	Colour Coded Request Forms	17
		3.2.2	Information to Allow Unique Identity of The Patient	18
	3.3	Spec	IMEN COLLECTION ORDER OF DRAW	19
	3.4	Spec	IMEN COLLECTION AND CONFIRMING THE IDENTITY OF THE PATIENT	19
	3.5	Spec	IMEN COLLECTION	20
		3.5.1	Blood Cultures	20
	3.6	Снес	KING THAT THE PATIENT IS APPROPRIATELY PREPARED	22
	3.7	Снес	KING THAT THE SPECIMEN CONTAINER IS LABELLED CORRECTLY	23
	3.8	Ensu	IRING THAT THE SPECIMEN IS COLLECTED CORRECTLY	23
	3.9	Spec	IMEN CONTAINERS	23
		3.9.1	Type of Specimen and, where appropriate, Anatomical Site of Origin	24
		3.9.2	Investigations Requested	24
		3.9.3	Relevant Clinical Information	25

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

	3.	9.4 Identification of Priority Status	25
	3.10	LABELLING FOR DANGER OF INFECTION: HEPATITIS RISK, HIV RISK AND OTHER HAZARDOUS	
		Pathogens	26
	3.11	Category A Pathogens	26
	3.12	Specimen Transport Bags	26
	3.13	TRANSPORT	27
	3.14	RECEPTION OF SPECIMENS IN THE LABORATORY	28
	3.15	COMMON SAMPLING ISSUES	29
	3.	15.1 Non-Compliant Laboratory Specimen Containers/Request Forms	30
	3.16	USER SATISFACTION & COMPLAINTS	31
	3.17	REPORTS	31
	3.18	Reference Ranges	33
	3.19	PATIENT CONFIDENTIALITY	33
4.	BIOC	CHEMISTRY/ENDOCRINOLOGY	34
	4.1	REPERTOIRE OF THE TESTS	34
	4.2	SAMPLE VOLUME	40
	4.3	TURNAROUND TIMES	41
	4.4	PROCESSING OF FLUIDS FOR ANALYSIS	41
	4.5	"Add –on" Tests and Sample Stability	43
	4.6	ON-CALL SERVICE REPERTOIRE IN BIOCHEMISTRY	43
	4.7	NOTES ON TAKING BLOOD SPECIMENS FOR BIOCHEMISTRY TESTS	44
	4.8	SAMPLE REJECTION CRITERIA	45
	4.8	8.1 Time between Collection and Analysing	45
	4.9	URINE COLLECTIONS	46
	4.10	24 HOUR URINE COLLECTION INSTRUCTIONS	46
	4.	10.1 Preparation	46
	4.	10.2 Collection Method: Day 1 on Waking	47

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

	4.10.3	Collection Method: Day 2 on Waking 47
	4.11 BLOO	d Collection Tubes
	4.11.1	Biochemistry Profiles
	4.12 BLOO	d Gas Analyses
	4.12.1	pH and Blood Gases54
	4.12.2	pH and Fluids
	4.12.3	Lactate
	4.13 EGFF	8
	4.13.1	Stratification of Chronic Kidney Disease by eGFR55
	4.13.2	Important Notes on Estimated GFR in Adults using Formulae
	4.13.3	What we Report
	4.14 DIABE	etes Mellitus
	4.14.1	Procedure for Performing a Modified Glucose Tolerance Test
	4.14.2	Lactose Tolerance Test
	4.15 CALCI	um Disorders
	4.16 TROP	ONIN
	4.17 CLINI	cal and Biochemical Evaluation of a Patient with Potential Secondary Hypertension 67
	4.18 INTER	FERING SUBSTANCES
	4.19 CRITIC	CAL ALERT VALUES
	4.19.1	Uncertainty of Measurement 81
5.	IMMUNOL	OGY/SEROLOGY82
	5.1 Gene	RAL
	5.2 Reper	RTOIRE OF TESTS - IMMUNOLOGY
	5.2.1	Immunoglobulin Levels
	5.2.2	Protein Electrophoresis
	5.2.3	Immunofixation
	5.2.4	Serum Free Light Chains

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

	5.	2.5	Beta 2 Microglobulin	5
	5.3	Speci	MEN STABILITY	7
	5.	3.1	24 Hour Urine Collection Instructions	7
	5.4	Serol	OGY	9
	5.	4.1	Repertoire of Tests	9
	5.5	ON-C	ALL SERVICE REPERTOIRE IN IMMUNOLOGY	0
	5.6	CRITIC	al Values in Immunology	0
6.	HAE	ΜΑΤΟ	LOGY9	1
	6.1	Genei	RAL INFORMATION	1
	6.2	Test F	Repertoire	1
	6.3	Hand	ling Urgent Specimens	3
	6.4	INFOR	MATION ABOUT HAEMATOLOGY TESTS	4
	6.5	TIME	LIMITS FOR REQUESTING ADDITIONAL EXAMINATIONS	5
	6.6	On-C	ALL SERVICE REPERTOIRE IN HAEMATOLOGY	6
	6.7	Critic	AL ALERT VALUES	6
	6.8	Facto	DRS THAT COULD SIGNIFICANTLY AFFECT THE PERFORMANCE OR INTERPRETATION OF THE RESULT 9	6
7.	BLOO	OD TR	ANSFUSION	8
	7.1	Genei	PAL INFORMATION	8
	7.2	BLOO	D TRANSFUSION TESTS	8
	7.3	Bloo	PRODUCTS FOR TRANSFUSION	9
	7.4	DESCF	RIPTION OF BLOOD COMPONENTS / PRODUCTS	0
	7.	4.1	Red Cells 10	0
	7.	4.2	Platelets	1
	7.	4.3	Octaplas/™	1
	7.	4.4	Human Albumin	1
	7.	4.5	Fibrinogen (Riastap ™) 10	1
	7.	4.6	Prothrombin complex concentrate (Octaplex [™])	1

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

	7.	4.7	Recombinant coagulation factor (Novoseven ™)	101
	7.	4.8	Coagulation Factor Concentrates	102
	7.	4.9	Referrals	102
	7.5	Speci	MEN RECEIPT IN THE BLOOD TRANSFUSION LABORATORY	102
	7.6	Two	SEPARATE SPECIMEN REQUIREMENT TO DETERMINE BLOOD GROUP PRE 1ST TRANSFUSION	102
	7.7	Speci	MEN ACCEPTANCE CRITERIA IN BLOOD TRANSFUSION	103
	7.8	Speci	MEN STABILITY	104
	7.9	Orde	RING BLOOD COMPONENTS & PRODUCTS	104
	7.10	COLLE	CTING AND RETURNING BLOOD COMPONENTS & PRODUCTS	105
	7.11	Emer	GENCY GROUP O RH D NEGATIVE	106
	7.12	TRANS	SFUSION REACTION INVESTIGATION	107
	7.13	Haem	IOVIGILANCE SERVICE	109
	7.	13.1	Written Consent for Transfusion	109
8.	MICF	ROBIO	LOGY	111
	8.1	Genei	RAL INFORMATION	111
	8.2	Requ	esting Microbiological Investigations	111
	8.3	ON-C	ALL SERVICE REPERTOIRE IN MICROBIOLOGY	112
	8.4	Repor	RTS	112
	8.5	Speci	MEN COLLECTION	113
	8.6	Refer	RAL ANTIBIOTICS	113
	8.7	Speci	MEN COLLECTION	114
	8.	7.1	COVID-19/Influenza Testing	114
	8.	7.2	Blood Cultures	114
	8.	7.3	Urine	116
	8.	7.4	Viral Testing	117
	8.	7.5	Chlamydia Isolation	118
	8.	7.6	CSF	118

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy 26/09/2023	Document No.: LS-GEN-0007	
Reviewed by: Fiona Errity 26/09/2023	Date of Issue: 26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

8	8.7.7	Pus	
8	8.7.8	Fluids e.g. Pleural, Joints	
8	8.7.9	Sputum	
8	8.7.10	Swabs	
8	8.7.11	Stool Specimens	
8.8	Specii	MEN STABILITY AND STORAGE	
8.9	NOTE	s on the Collection of Specimens for Virus Investigation	
8	8.9.1	Throat Swabs	
8	8.9.2	Throat Washings	
8	8.9.3	Faeces	
8	8.9.4	Sputum	
8.10) Note:	s on Specimens for Bacterial Culture 122	
8.11	L SEPTIC	CAEMIA AND ENDOCARDITIS	
8	8.11.1	Timing and Numbers of Cultures	
8	8.11.2	Method 124	
8	8.11.3	Common Infecting Organisms	
8	8.11.4	Less Common Infecting Organisms 124	
8	8.11.5	Post-Operative Cardiac Surgery 124	
8	8.11.6	Immuno compromised patient 124	
8.12	2 Respir	RATORY INFECTIONS	
8	8.12.1	Upper Respiratory Tract 125	
8	8.12.2	Lower Respiratory Tract	
8.13	B Meni	NGITIS	
8.14	8.14 WOUND SEPSIS		
8.15	8.15 URINARY TRACT INFECTION		
8.16	5 VENER	REAL DISEASE	
8.17	7 Fung	al Infections	

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

	8.18	Gaste	ROENTERITIS		
	8.19	Eye Si	PECIMENS FOR THE PATHOLOGY LABORATORY		
	8.20 Pregnancy Test				
	8.21 Availability of Microbiology Results				
	8.22	MICR	OBIOLOGY CRITICAL VALUES	135	
	8.23	Staff	SELF TESTING	136	
	8.24	Солт	ROL OF ANTIMICROBIAL CHEMOTHERAPY	136	
	8.25	INFEC	TION CONTROL SERVICE	136	
	8.	25.1	Hospital Infection Control Team	136	
	8.	25.2	Notifiable Infectious Diseases	137	
	8.	25.3	Other Infectious Diseases		
	8.	25.4	Reporting Of Suspected Outbreaks of Infection		
9.	HIST	OLOG	Y / CYTOLOGY	143	
	9.1	Genei	RAL INFORMATION	143	
	9.2	Repor	rts & Turnaround Times	143	
	9.	2.1	Histology Turn Around Times		
	9	2.2	Cytology		
	9.3	Medi	cal Advice Outside Normal Working Hours		
	9.4	Cons	ULTANT ADVISORY SERVICE		
	9.5	Ніѕто	PATHOLOGY INVESTIGATIONS	145	
	9.	5.1	Urgent Specimens	145	
	9.6	Speci	MENS REQUIRING SPECIAL HANDLING		
	9.	6.1	Muscle Biopsies		
	9.	6.2	Lymph Nodes		
	9.	6.3	Breast Localization Biopsies		
	9.	6.4	Sural Nerve Biopsies/Peripheral Nerve Biopsies		
	9.	6.5	Specimens Requiring Both Microbiological Culture & Histology	147	

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

9.	6.6	Skin Biopsies for Immunofluorescence	147
9.7	Cytol	OGY INVESTIGATIONS	148
9.	7.1	Breast Cyst Aspirate	148
9.	7.2	Bronchial Aspirates	148
9.	7.3	Brushings From Other Sites	148
9.	7.4	Cerebrospinal Fluid	148
9.	7.5	Fine Needle Aspiration Cytology	148
9.	7.6	Sputum	149
9.	7.7	Urine	149
9.	7.8	Other Cytological Examinations	149
9.8	Notif	ICATION OF CRITICAL RESULTS TO THE REQUESTER	150
10.	POIN	T OF CARE TESTING	151
11.	APPE	NDICES	152

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

1. Quality Policy of the Pathology Laboratory, Mater Private Hospital, Dublin

The Pathology Laboratory provides a histopathology, non-gynae cytology, microbiology, immunology, biochemistry/endocrinology, haematology and blood transfusion service and is committed to promoting and providing the highest quality diagnostic and consultative services for all its users.

In order to ensure that the needs and requirements of users are met, the Pathology laboratory will:-

- Operate a quality management system to integrate the organisation, procedures, processes and resources to ensure the best possible care for the patient.
- Establish & review quality objectives and plans in order to implement this quality policy.
- Ensure that all personnel are familiar with this quality policy and adhere to Hospital policies and procedures to ensure user satisfaction, quality and safety
- Commit to the health, safety and welfare of all its staff. Visitors to the department will be treated with respect and due consideration will be given to their safety while on site.
- Uphold professional values and continue to be committed to good professional practice and ethical conduct and patient confidentiality.

The Pathology Laboratory will comply with the International Standard ISO 15189, EU Directive 2002/98/EC, "Minimum Requirements for Blood Bank Compliance with Article 14 (Traceability) and Article 15 (Notification of Serious Adverse Reactions and Events) of EU Directive 2002/98/EC" (AML-BB), S.I. No 547 of 2006 and S.I. No 360 of 2005, INAB Terms & Conditions, Regulations and Policy Documents & current environmental legislation, for the services and tests defined in the Quality Manual and scope <u>http://www.inab.ie/Directory-of-Accredited-Bodies/Laboratory-Accreditation/Medical-Testing/The-Mater-Private-Hospital.htmlof accreditation and is committed to:-</u>

- Staff recruitment, training, development and retention at all levels to provide a full and effective service to its users.
- The proper procurement and maintenance of such equipment and other resources as are needed for the provision of the service.
- The collection, transport and handling of all specimens in such a way as to ensure the correct performance of laboratory examinations.
- The use of examination procedures that will ensure the highest achievable quality of all tests performed.
- Reporting results of examinations in ways which are timely, confidential, accurate and clinically useful.
- The assessment of user satisfaction, in addition to internal audit and external quality assessment, in order to produce continual quality improvement.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- Monitoring and review of the service through quality indicators, quality objectives and improvements in order to enhance the service provided to the patient.
- The safe testing, distribution and transfusion of blood and blood products, including 100% traceability of blood components.
- The investigation and reporting of serious adverse events and reactions and reporting to the relevant authority, where applicable, in a timely manner.

Approved by:

Null

Dr Niall Mulligan, Laboratory Director

Date: 26/09/2023

Date: 26/09/2023

Kennel

Approved by:

Mr Paul Kennedy Laboratory Manager

2. MATER PRIVATE HOSPITAL PATHOLOGY SERVICES

The Pathology Laboratory is located on the ground floor to the left after the main reception of the Mater Private Hospital. The molecular laboratory is located on the lower ground floor opposite the lifts. All services undergo continuous review through quality assurance and audit activities. The Pathology Laboratory is accredited to ISO 15189 (registration number 191MT) <u>https://www.inab.ie/FileUpload/Medical-Testing/The-Mater-Private-Hospital-</u> <u>191MT.pdf</u> and is in compliance with articles 14 and 15 of the EU Directive 2002/98/EC, thus assuring users of a consistently high quality service.

This manual is designed to give an overall view of the services available in the Pathology Laboratory at the Mater Private Hospital, Dublin. It is intended as a reference guide for all clinical users of the Pathology Laboratory. The MPH Pathology Laboratory is composed of six departments, as follows: Microbiology, Blood Transfusion, Haematology, Biochemistry / Endocrinology, Histopathology / Cytology and Immunology / Serology. There is also a phlebotomy service available for both inpatients and outpatients. Point of Care testing is available in clinical areas. This guide is divided into sections, one for each of the disciplines within the Pathology Laboratory. Refer to the appropriate section for detailed advice.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

The Pathology Department provides routine laboratory and emergency ("on call") service to the Mater Private Hospital, Dublin and a limited pathology service to the Sports Surgery Clinic Santry and to The Mater Private Hospital Cork. In addition, GPs may also use the services of the laboratory, if required.

The Pathology Laboratory refers some tests (including rare and unusual tests) to external laboratories and this manual lists the requirements for those tests referred to external laboratories on an ongoing basis (See LF-GEN-0021 Register of Referral Laboratories). If a clinical user requires a test that is not detailed in this manual or is uncertain about some aspect of requesting or performing a test, they should contact the laboratory in advance of arranging the test.

2.1 Information and Advice

This guide is divided into sections, one for each of the disciplines within the Pathology Laboratory. There is a wide range of pathology tests available - refer to the appropriate section of this manual for detailed advice, facts and guidance. For internal users, this manual is available on the Hospital Intranet. It is also available on the internet on <u>www.materprivate.ie</u> This Manual details the following:

- The Location of the Laboratory
- The Phlebotomy Service
- The request forms and specimen containers
- Information necessary for the correct labelling of forms and containers
- The examinations available within the Laboratory
- A description of each discipline's repertoire within the Pathology Laboratory including turnaround times
- Availability of clinical advice
- User Satisfaction & Complaints

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

2.2 Head of Pathology

General matters which relate to more than one department should be addressed to: The Laboratory Manager - Mr. Paul Kennedy (01 2481840 or paul.kennedy@materprivate.ie) or the Director of Pathology – Dr Niall Mulligan (ext. 8137 or nmulligan@materprivate.ie)

2.3 Consultant and General Advisory Service

A comprehensive range of investigative and advisory services are offered by the different departments within Pathology.

The Pathology Laboratory has Consultants for all Departments to provide appropriate clinical advice and expertise to the users of the service. These Consultants can be contacted, where required, for advice on the appropriate choice of examinations and their clinical indications, the limitations of examination procedures and appropriate test frequency. They also provide consultation, where required, on individual clinical cases and interpretation of laboratory examinations. If Pathology Consultants cannot be contacted at extension 8137, in cases of urgency, the relevant consultant can be contacted elsewhere through the hospital reception.

Please note for general immunology advice, the Consultant Immunologist may be contacted. For advice specifically on serology testing, users may contact Consultant Microbiologist. See Table 1 for list of Consultants within Pathology Laboratory

Position	Name
Laboratory Director	Dr Niall Mulligan
Consultant Haematologist (with responsibility for Blood Transfusion)	Dr Michael Fay
Consultant Haematologists	Dr Peter O'Gorma
Consultant Immunologist	Dr Con Feighery
Consultant Biochemist	Dr Maria Fitzgibbon Dr Graham Lee

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Position	Name
Consultant Microbiologist	Dr Maureen Lynch / Dr Margaret Hannan /
	Dr Ursula Nusgen - (6 monthly rota for lead consultant)
Consultant Histopathologist	Dr Niall Mulligan (Laboratory Director),
	Dr Ann Treacy (Lead),
	Prof Conor O'Keane,
	Dr Ciara Barrett,
	Dr Susie Conlan,
	Dr Eamon Leen,
	Dr John Aird
	Dr Owen MacEneaney

Table 1: Consultants within Pathology Laboratory

2.4 Phlebotomy

The Phlebotomy Department is located on the ground floor of the Mater Private Hospital to the right of the main reception desk. The Phlebotomy waiting area is accessible for wheelchairs and the Phlebotomy room has movable trolleys so as to enable the staff to make a workstation around wheelchair. A Phlebotomy inpatient service is available from 7am until 4.45pm Monday to Friday. There is also a phlebotomy inpatient service from 7am to 1 pm on Saturdays and 7am to 12pmSundays/Bank Holidays. There is a "walk-in" Phlebotomy outpatient service with no appointment necessary, however a referral letter from a doctor is required. Outpatient phlebotomy services are available from 8am to 4.00pm Monday to Friday and Saturday 9am to 1.00pm by appointment only. For most routine laboratory procedures, consent can be inferred when the patient presents himself or herself at phlebotomy with a referral request from a doctor and willingly submits to venepuncture. Patients in a hospital bed can refuse venepuncture. Contact Phlebotomy on ext. 8165 for details of the service provided.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023 Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023	Date of issue. 20/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

2.4.1 Process for Booking Appointments for Phlebotomy.

Patients wishing to book a Covid Antibody blood test can do so by phoning 8858739 or emailing <u>covidantibodytest@materprivate.ie</u>. Patient attends Phlebotomy at appointed time, is registered, invoiced and receipted. Blood sample is taken by Phlebotomist and sent to Laboratory for testing. An encrypted report is emailed to patient. A copy may be sent to the patient's doctor if requested.

2.4.2 General Practice

General Practitioners may send appropriately packaged patient blood specimens by post/courier or they may ask the patients to attend the phlebotomy department with a referral letter.

2.5 Times of Service Availability

The routine working hours of the Pathology Department of the Mater Private Hospital are as follows:

Discipline	Monday to Friday	Saturday	Contact Numbers
Laboratory Office	8am to 6 pm	N/A	8138/8139
Biochemistry/Endocrinology	8am to 6 pm	9am to 12.30pm	8134
Haematology	8am to 6 pm	9am to 12.30pm	8132
Histology	8am to 5 pm	No service.	8136
Microbiology	8am to 6 pm	9am to 12.30pm	8133
Molecular Microbiology	8am to 6 pm	N/A	1898/8133
Blood Transfusion	8am to 6 pm	9am to 12.30pm	8131
Immunology	8:30am 4:30pm	No service	8140
Phlebotomy Inpatient	7am to 4.45pm	7am to 12pm	8165
Phlebotomy Outpatient	8am to 4.00pm	9am to 1pm by appointment	8166
Specimen Reception	8am to 5pm	9am to 12.30pm	8281

 Table 2: Routine Working Hours within the Pathology Laboratory

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Outside of routine working hours, an emergency service is provided (on-call) as follows:

Monday to Thursday:	6pm to 8am
Friday	6pm to 9am
Saturday:	12.30pm to 9am Sunday
Sundays and Bank Holiday Mond	lays: 9am to 8am the following day
	•

Sundays of Bank Holiday: 9am to 9am

See individual department sections for repertoire of tests provided on-call.

There is a porter delivery service on Saturdays. It is essential that specimens for analysis arrive in the laboratory before 10.00am.

3. SPECIMEN HANDLING

3.1 Consumable Supplies

Sufficient consumable supplies can be obtained from stores during working hours.

Stores supply the following:

- Plain swabs
- Copan Dual swabs for VRE screening
- UTM for COVID / Influenza / Respiratory pathogen testing (small supply retained for emergency testing in lab)
- Containers for sputum and mid-stream urines
- Request forms
- All tubes for blood collection
- Biopsy vials containing formalin. (Refer to the histology section of this manual for advice on the care necessary with formalin).

The Laboratory supply the following:

• Timed urine collection containers, which may contain no preservative (plain) or 20ml of 0.5M molar hydrochloric acid as necessary for various investigations.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- Histology pots, with and without formalin, in a variety of sizes.
- Porphyrin containers
- Blood culture bottles
- Collection kits for Chlamydia/Gonorrhoea testing
- Specimen bottles for Quantiferon testing
- Swabs for viral investigations and transport swabs

3.2 The Request Form

The request form forms the basis of the contract between the Pathology Laboratory and it's users. Correctly designed and properly completed request forms are essential for the performance of all laboratory tests to the benefit of the patient and the satisfaction of the requesting physician.

A member of nursing staff or medical staff completes the appropriate request form for in house patients. If the test requires a blood specimen, the appropriate request card is sent to Phlebotomy or the phlebotomist is contacted by mobile phone. If the request is out of these hours, the house doctor or a member of the nursing staff must take the specimen. Administration staff located in phlebotomy complete the appropriate request forms for tests requested on an outpatient or day patient, using a referral letter from the GP or Consultant.

3.2.1 Colour Coded Request Forms

Use the correct colour-coded request form: Biochemistry: **Blue** or General Blue Request From *ref.* : LF-BIO-0071 Haematology: **Pink** *ref.:* LF-HAEM-0064 Blood Transfusion: **Purple** *ref.*: LF-BT-0047 Blood Transfusion ordering form **Grey** *Ref.:* LF-BT-0050 Histopathology: **Olive Green** *ref.*: LF-HIST-0074 Histopathology/ Breast: **Highlighter pink** *ref.:* LF-HIST-0089

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Microbiology: **Yellow** *ref*.: LF-MICRO-0054

Immunology: Green ref.: LF-IMM-0026

General (for referral tests): Blue ref.: LF-GEN-0030

3.2.2 Information to Allow Unique Identity of The Patient

It is essential to have the following details recorded on the **request form** to ensure unique patient identity:

- Medical Record Number
- Forename & Surname
- Sex
- Date of Birth
- Address
- Ward
- Date of specimen collection
- Clinician (or GP name for out-patients)
- Signature of person drawing specimen (essential for Blood Transfusion only)
- Specimen site (for swabs or histology specimens)
- Specimen type / nature of specimen
- Priority Status when Urgent

Where possible, the following information should be provided on the request form also:

- Clinical Details
- Time of specimen collection (completed by person taking specimen)
- Signature/initials of person drawing specimen

Note: Blood Transfusion request forms must be completed in full and signed as per

instruction see section 7.7 for additional information required for the adequate completion

of blood transfusion request forms.

NOTE: If there is an absence of detail the requester must be contacted to reconcile the discrepancy. Only then can the specimen be analysed.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

3.3 Specimen Collection Order of Draw

The Monovette System of drawing blood from patients is used. This consists of either 1 inch long, 21 & 22 gauge sterile needles and Safety Multifly Set and Monovette bottles, both manufactured by Sarstedt. Blood Monovettes are sterile tubes of various sizes, the insides of which may or may not be coated with an anticoagulant, (see Table 3 below for order of draw):

Colour Code on	Anticoagulant Present	Use
Monovette		
Blood Cultures,	N/A	Culture of Bacterial / Fungal
Drawn first to prevent		pathogens,
bacterial		
contamination.		
Clear (serum)	None	Sugars & General Use (Haem,
		Immuno tests), drug levels
Brown (Serum Gel)	None	All Bio tests (with exception digoxin,
		vancomycin & gentamicin)
		Haem, Immunology/Serology Tests
Green	Sodium Citrate	Coagulation tests only
Orange	Lithium Heparin	Bio - MMH
Pink (Large)	EDTA	Transfusion only
Pink (Small)	EDTA	Haematology tests
Red	Pseudothrombocytopenia	Haematology test
	Thrombo Exact	
Purple	Sodium Citrate	ESR only
Yellow	Fluoride Oxalate	Sugars & Alcohol level tests

 Table 3 : Order of Draw Ref: EX-PHL-0001

3.4 Specimen Collection and Confirming the Identity of the Patient

The person collecting the specimen (phlebotomist, nursing staff or house doctor) must identify the patient verbally and must also check the patient's wristband in the case of inpatients. Identification is carried out verbally in the case of outpatients.

1. The patient must be informed of the reason for collection of the specimen.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- 2. For most routine laboratory procedures, consent can be inferred when the patient presents himself or herself at phlebotomy with a referral request from a doctor and willingly submits to venepuncture. Patients in a hospital bed can refuse venepuncture.
- The phlebotomist confirms with the patient that they meet the pre-examination requirements (e.g. fasting status, medication status, specimen collection at predetermined time etc.). Note: Fasting for 12 hours is required for fasting bloods(e.g. Lipid Profile, Glucose)
- 4. The patient must be verbally identified (where possible) by asking their forename, surname and date of birth.
- It must be ensured that the identity bracelet contains the correct forename, surname, date of birth and a unique hospital number.
- 6. A small addressograph label is affixed to the specimen bottle/container

NOTE: In the case of Blood Transfusion, the details are handwritten onto the specimen bottles.

7. In the case of Blood transfusion the phlebotomists signs both the specimen and the request form, for all other specimens the phlebotomist just signs the request form to identify the individual taking the specimen.

3.5 Specimen Collection

3.5.1 Blood Cultures

- 1. Obtain 2 blood culture bottles and 1 blood culture pack from the Specimen Reception area of the Pathology Laboratory.
 - Note: The BacT/Alert 3D blood culture system is used in the Mater Private Hospital. Two bottles are used; FA for aerobic and facultative anaerobic microorganisms and FN for anaerobic microorganisms. FN contains contain 32ml of complex media and 8ml of a charcoal suspension. Bottles contain an atmosphere of nitrogen under vacuum. FA contains 22ml of complex media and

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

8ml of a charcoal suspension, Bottles contain an atmosphere of CO2 in oxygen. It is suitable for the isolation of aerobic, anaerobic organisms and fungi.

- 2. Prior to use, the BacT/ALERT FN/ FN Culture Bottles should be examined for evidence of damage or deterioration (discoloration). Bottles exhibiting evidence of damage, leakage, or deterioration should be discarded. The media in undisturbed bottles should be clear, but there may be a slight opalescence or a trace of precipitate due to the anticoagulant SPS.
- 3. Check Name and D.O.B. with patient and same details including MRN on patients ID band and specimen card.
- 4. Prior to touching a patient, hand hygiene must be completed by the phlebotomist, by washing hands or using alcohol hand rub (moment 1 before patient contact). Identify a suitable vein (usually on the arm) from which to draw blood from the patient. Clean hands.
- 5. Open sterile pack and set up sterile field, attaching the devices needed together in preparation for the procedure
- Apply the single use Tourniquet above the blood-sampling site and swab the skin over the vein vigorously for 1 minute with a 2% chlorhexidine in 70% alcohol single use sponge/swab (chloraprep). Allow to dry for 30 seconds.
- 7. Remove the flip-lid seal from the blood culture bottles and swab the rubber stopper thoroughly with sanicloth CHG 2% swab. Clean hands using alcohol hand gel or by washing them and Apply sterile gloves. Then using aseptic non-touch technique, take a sterile butterfly safety device, Insert the butterfly into the vein of the patient, taking care not to contaminate, repalpate or touch the needle insertion site and obtain up to a 10ml blood specimen (4ml for a paediatric bottle). If you need to palpate the vein again it's important to remove gloves, re-clean hands and apply a new set of sterile gloves.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- 8. Place the collection cap over the blood culture bottle and fill to the required level. Then repeat for bottle two. Always collect aerobic (green) before anerobic (orange). (If you need to collect the blood via a syringe and not from the closed circuit you should enter the blood into the anerobic bottle first and then the aerobic bottle).
- Once the blood is collected, disconnect blood culture section and proceed to take any blood samples needed
- 10. Remove the tourniquet first, Then carefully remove the butterfly, ensuring the safety cover is applied as you remove it
- 11. Place a plaster or dressing over the blood-sampling site.
- 12. Place used needles and sharps into the CinBin provided. Any other clinical waste must be disposed of directly into yellow risk waste bin.
- 13. Remove gloves, clean hands.
- 14. Write patient details on bottles and samples. Place barcode from bottles onto request cards. Use Phlebotomy labels if available and then place in the plastic sleeve of the test request card and seal the sleeve.
- 15. Write the date and time of collection on the card and specimen type i.e. peripheral or specific site e.g. taken from left arm, and transfer the samples directly to the Microbiology discipline of the Pathology Laboratory. Never send Blood culture bottles in the Chute system.
- 16. Outside of routine working hours: Please bleep a porter as soon as possible after collecting the specimen. The porter will transport the blood culture bottles to the laboratory and load the bottles on to the Bac-T alert system.

3.6 Checking that the Patient is Appropriately Prepared

The appropriate preparation of the patient for the requested test and the correct specimen collection is the responsibility of the individuals requesting / collecting the specimen.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

3.7 Checking that the Specimen Container is Labelled Correctly

Having positively identified the patient, the person collecting the specimen (phlebotomist, nursing staff or house doctor) must collect the specimen and correctly label the container with unique patient details. It must be ensured that there can be no confusion regarding the identity of the patient or the specimen.

This is the first step in positive specimen identification. The identification data affixed to the specimen / container at source remains with that specimen throughout analysis. The laboratory must receive a request card with each specimen.

3.8 Ensuring that the Specimen is Collected Correctly

Always ensure the blood is collected into the appropriate tube with the correct anticoagulant, if any, and that where possible, when using the "monovette" system, that the specimen container is filled to the correct volume to allow for anticoagulant blood mix ratio. In the event that a test requested is not listed, the relevant laboratory is contacted, as some of the less common tests require special collection and handling procedures.

Ref.: CM-PHL-0001 Blood Sampling in the Phlebotomy Department

Ref.: CM-PHL-0002 Glucose Tolerance Test

3.9 Specimen Containers

The minimum patient data required on a specimen container is:

- Medical Record Number and Date of Birth
- Surname
- Forename

On Blood Transfusion specimen containers the following additional information must be provided:

- Signature of person drawing specimen
- Date and time of specimen collection

On Microbiology swabs, specimen site must also be provided on the specimen.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY			
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007			
26/09/2023			
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023		
26/09/2023			
Authorised by: Fiona O'Brien	Edition No.: 20		
26/09/2023	(Review Date 26/09/2024)		
ISO 15189:2012 / JCI Standards AOP.5			

The use of *addressograph labels* on Blood Transfusion specimens is *unacceptable* and demographics must be HANDWRITTEN. Specimens received in the Blood Transfusion department labelled with an addressograph label will be rejected and a fresh specimen requested.

Specimen must be attached to the request cards. This is important so that specimen containers and request forms are closely associated during transportation.

If in doubt, refer to the relevant department for specific information on appropriate specimens and collection conditions for particular tests.

Please note:

- Blood cultures must be sent to the laboratory within four hours of collection to be loaded onto the Bac-T Alert automated system.
- 2. Histology specimens in buffered formalin should be stored at room temperature. Do not refrigerate.
- 3. Specimens for potassium deteriorate less rapidly at room temperature than when refrigerated.
- 4. Specimens requiring immediate preparation should be collected within normal hours.
- 5. Ensure safe disposal of materials used in specimen collection in the nearest CINBIN.

3.9.1 Type of Specimen and, where appropriate, Anatomical Site of Origin

The specimen type should be recorded on all request forms for each of the Pathology Departments. However, in Microbiology & Histology, the specimen type <u>and</u> anatomical site of origin must be recorded on the request form to ensure that appropriate tests are performed, this is important in the interpretation of results and is an important step in the audit trail.

3.9.2 Investigations Requested

Investigation requests for Biochemistry/ Endocrinology, Blood Transfusion, Microbiology, Immunology/Serology, Haematology / Cytology and are listed on the request form and requested by means of a 'tick-box'. Other investigation requests must be clearly written on

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007				
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

the request form. Histology requests must also be clearly written on the request form. Verbal requests may be made for additional examinations depending on the specimen type and time frame, see individual departmental sections in this User Handbook for information on specimen stability. Verbal requests must be followed up with a completed request form.

3.9.3 Relevant Clinical Information

Clinical detail is required on the request form in order to justify the test request, to ensure appropriate result interpretation or perhaps to ensure the selection of appropriate followon tests and analytical methods.

Clinical detail is also an important factor in an audit.

3.9.4 Identification of Priority Status

- Urgent requests must be restricted to those necessary for the immediate clinical management of the patient.
- 2. In case of doubt, the clinician must make direct contact with the Laboratory.
- 3. The clinician and laboratory must agree:
 - Which tests are necessary
 - The target time for test completion/when results will be available on the Clinisys LIMS.
 - Where reports are to be directed
- In the case of an urgent request, the request form must be clearly marked 'URGENT'.
 Failure to make verbal contact with the laboratory outside routine working hours will result in delay and possible specimen degradation.

All requests from Day Oncology have a blue circular sticker to identify urgent status. A red sticker may be applied to certain specimens requiring urgent testing due to the patient requiring priority discharge from the hospital, this extra measure helps laboratory staff in identifying such specimen.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY			
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007			
26/09/2023			
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023		
26/09/2023			
Authorised by: Fiona O'Brien	Edition No.: 20		
26/09/2023	(Review Date 26/09/2024)		
ISO 15189:2012 / JCI Standards AOP.5			

- 5. Urgent requests for blood or blood products must be preceded by a telephone call from the requesting Clinician or Healthcare Professional informing the Medical Scientist what product and quantity is required and the time frame in which it is required. If red cells are required urgently before the time required for crossmatch, they may be issued following the emergency protocol in the laboratory at the requesting Clinician's discretion.
- 6. Transport arrangements are the responsibility of the requesting ward.
- In exceptional circumstances urgent biopsies requiring histological opinion may be processed rapidly but only after consultation with the Histopathologist.
 (See section 9).

3.10 Labelling for Danger of infection: Hepatitis Risk, HIV Risk and Other Hazardous Pathogens

All specimens must be treated as potentially infectious and universal precautions must be taken by all staff.

3.11 Category A Pathogens

Only laboratories, which have notified the Health and Safety Authority (H.S.A) may provide a diagnostic service for listed pathogens. In cases where a listed pathogen is discovered unexpectedly, the HSA must be notified immediately.

All samples from suspected TB patients must be labelled as "suspected TB". as per Hospital policy INF-GEN-016. This will help to minimise the exposure to the laboratory staff and allow samples to be handled in a safe manner.

3.12 Specimen Transport Bags

Most specimens are transported to the Pathology Laboratory contained in a transport bag attached to the appropriate request form. The transport bag must be sealed by means of an integral sealing strip. and the transport bags must not be used more than once. In the case of Microbiology, batches of samples are received from Santry Sports Surgery Clinic and MPH

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY			
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007			
26/09/2023			
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023		
26/09/2023			
Authorised by: Fiona O'Brien	Edition No.: 20		
26/09/2023	(Review Date 26/09/2024)		
ISO 15189:2012 / JCI Standards AOP.5			

Cork, packaged as detailed above, using secure transport boxes. Histology samples received from Santry Sports Surgery Clinic and MPH Cork are packaged as detailed above, using secure transport boxes.

Liquid samples containing possible respiratory pathogens (Influenza / RSV and SARS-CoV-2) must be further placed in a sealable biohazard bag, and transported individually.

The use of the above means of transport ensures the following:

- 1. Limiting all unnecessary hand contact with specimen containers;
- 2. Making it easy to identify a leaking container among a batch;
- Preventing a leaking container from contaminating other containers, request forms, the hands of the person sorting a batch, and the immediate environment.
- 4. Special secure specimen transport carriers must be used, such as boxes or deep-sided trays. They must not be over-filled.
- 5. The specimen transport boxes or trays must not be used for any purpose other than carrying specimens.
- 6. The boxes or trays must be made of a smooth impervious material such as plastic or metal which can be easily disinfected and cleaned and must retain liquid in the event of leakage of a specimen.
- 7. The boxes or trays must be disinfected and cleaned after each week in use and whenever contaminated.

3.13 Transport

Most analytical work takes place in the Pathology Laboratory. Some specimens are sent to outside laboratories (See LF-GEN-0021 Register of Referral Laboratories).

Nurses, porters and phlebotomists undertake transport of reports and consumables to and from Pathology. Transport of Specimens to the laboratory is mainly via the pneumatic chute system. Blood cultures and Respiratory specimens (SARS-CoV-2 (COVID-19) and Influenza testing) must never be sent via the pneumatic tube system and urines should <u>not</u> be sent via

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY			
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007			
26/09/2023			
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023		
26/09/2023			
Authorised by: Fiona O'Brien	Edition No.: 20		
26/09/2023	(Review Date 26/09/2024)		
ISO 15189:2012 / JCI Standards AOP.5			

this system out of hours. Transport boxes are available in the lab and wards to safely transport repertory specimen to the lab. All other urgent specimens are transported via the pneumatic chute system. The relevant department should be contacted to alert the laboratory staff to the pending receipt of an urgent specimen in Specimen Reception. See individual departmental sections of this handbook for specimens that MUST be delivered to the Laboratory within a certain time period (e.g. Biochemistry : Section 4.11 Blood Gas Analysis)

Ref.: LF-GEN-0021 Register of Referral Laboratories

3.14 Reception of Specimens in the Laboratory

Specimens arrive to the laboratory via the pneumatic chute system or are hand delivered. The specimen transportation systems ensure the timely arrival of specimens in the optimal condition, to the correct destination, and in a manner that does not pose a threat to the health and safety of persons, property and the environment and is in compliance with relevant regulations. They are dispatched to the relevant departments for analysis or sent to referral laboratories. Transport is undertaken by Phlebotomists, Medical Staff, Nursing Staff, Administration Staff, G.P. Patients, Courier (road and air), Rail System, Post, Laboratory Staff, and Hospital porters and clerks.

Samples that should **not** be sent in the "chute" include the following....

- Specimens that are not easily repeated e.g. CSF's or Bronchial washings
- Any Histology specimens
- Units of Blood
- Blood Culture bottles
- Blood Gases
- Covid Swabs

Ref.: EX-GEN-0043 Aerocom AC3000 Service Manual & SS-HS-048 Overarching Safety Statement Mater Private Network

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY			
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007			
26/09/2023			
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023		
26/09/2023			
Authorised by: Fiona O'Brien	Edition No.: 20		
26/09/2023	(Review Date 26/09/2024)		
ISO 15189:2012 / JCI Standards AOP.5			

Urgent requests must be brought to the attention of the relevant laboratory staff. Outside

of routine opening hours, the Medical Scientist on-call must be contacted by reception or security and will deal with the urgent requests. Portering staff deal with the following:

- Collection , transportation & loading of blood cultures to the laboratory out of routine hours
- Microbiological specimens in the relevant fridge.

3.15 Common Sampling Issues

For blood specimens the 'Monovette' system is preferred.

Some common problems and errors are:

- 1. Use of the wrong specimen container refer to the relevant department for details.
- 2. Contaminating a 'clotted blood' tube with EDTA from a red top tube, which affects iron, calcium, potassium etc.
- 3. Collection of a specimen from an arm with a 'drip'.
- 4. Ejection of blood through a needle causing haemolysis.
- 5. Failure to gently mix, dissolve and distribute anticoagulants and preservatives.
- 6. Failing to prepare the patient correctly e.g. fasting, collection at the wrong time of day, day of menstrual cycle, gestational age etc.
- 7. Failing to deliver the specimen to the Laboratory in the time required for the investigation. Refer to the relevant department for further information.
- 8. Failing to label specimen with name, time, etc.
- 9. Failure to collect timed or MSU specimens correctly. Guidance notes are available from the Biochemistry, Microbiology, Immunology sections of this manual.
- 10. Failure to keep the gel biochemistry specimen containers upright until the specimen has clotted.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	er / Date: Paul Kennedy Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

3.15.1 Non-Compliant Laboratory Specimen Containers/Request Forms

All specimens are important, for minor discrepancies (non-compliances) on request forms/ specimen containers e.g. spelling mistake, missing digit on medical record number or absence of detail, the specimen cannot be processed until the person who took the specimen is notified and comes to the laboratory to identify and correct the discrepancy, only then can it be processed. It is laboratory policy that unlabelled immunology, haematology, blood transfusion, microbiology or biochemistry specimens will not be processed. They will however, be labelled with a unique laboratory number and recorded on the LIMS (Laboratory information Management System) as unlabelled and a report to this effect will be dispatched to the requester. A repeat specimen will be requested by telephone.

However, some are particularly critical and invasive e.g. CSF's, bronchial washings, histology specimens, blood gases, pleural aspirates and knee fluids, and may not be easily repeated. Therefore, it is laboratory policy to attempt to resolve any discrepancies on these specimens, containers or forms, before a specimen is rejected.

In the case of **unlabelled critical/invasive specimens**, which cannot be repeated (e.g. histology/CSF) proceed as follows:

- 1. Contact must be made with the requesting clinician.
- 2. The clinician/requester must be requested to identify and label the specimen and request form properly and to resolve any discrepancies.
- 3. The clinician/requester must also complete LF-GEN-0028 Non-Compliance Disclaimer Form. The fact that specimen/patient details have been amended is recorded as a comment on LIMS and the amendments that have been made/confirmed and by whom.
- 4. Histology: This LF-GEN-0028 Non-Compliance Disclaimer Form is filed with a copy of the patient request card (Please note on LF-GEN-0028 Non-Compliance Disclaimer Form the laboratory non-conformance number associated with this event. A copy of

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY			
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007			
26/09/2023			
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023		
26/09/2023			
Authorised by: Fiona O'Brien	Edition No.: 20		
26/09/2023	(Review Date 26/09/2024)		
ISO 15189:2012 / JCI Standards AOP.5			

LF-GEN-0028 associated with the non-conformance is scanned & uploaded as

attachment on Q-pulse

Microbiology & Biochemistry: A copy of LF-GEN-0028 associated with the nonconformance is scanned & uploaded as attachment on Q-Pulse associated with the non-conformance.

5. If the demographics cannot be confirmed the specimen is rejected and is booked on to LIMS and a report is issued stating that specimen could not be identified.

Ref.: LS-SR-0001 Specimen Reception Procedure

Ref.: LF-GEN-0028 Non-Compliance Disclaimer Form

NOTE: Any non-conformances associated with specimen containers, request forms, specimen collection, handling and transport will be recorded on Q-Pulse as a non-conformance.

3.16 User Satisfaction & Complaints

The Laboratory Quality Co-ordinator distributes an annual questionnaire to the Wards &/or Consultants who use the service of the Pathology Laboratory of the MPH. The aim of the user satisfaction surveys (Clinical Audits) is to achieve continuous improvement in all aspects of the pathology laboratory resulting in improved clinical effectiveness. Complaints, comments or other feedback may also be received from patients, staff or other parties throughout the year either directly to the Laboratory Manager (01 2481840 or paul.kennedy@materprivate.ie), Quality Coordinator (ext 8346 or labquality@materprivate.ie), any member of staff or via Q-Pulse non-conformance. User comments, both positive and negative, are recorded on Q-Pulse.

3.17 Reports

Each department has its own distinctive reports. Wards within house have direct access to patient results on Ward Enquiry once authorised. Please check status of results on Ward Enquiry prior to contacting the laboratory by phone. Phoning of the laboratory for results is

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007				
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

discouraged due to the risk of transcription errors. However, it is the policy of the Pathology Laboratory to phone urgent requests and when specific parameters have reached critical alert values. "Critical alert values" are when examination parameters are significantly outside the normal reference range and may indicate a high risk of a life threatening condition. Clinical personnel responsible for the patient care will be immediately notified when examination results for critical properties fall within established "critical intervals". This includes results received on specimens sent to referral laboratories.

The Critical alert values are documented in each individual department specific section of this manual. Printed reports are available for collection at specimen reception in the Laboratory. General Practices receive reports by post

• Biochemistry/ Endocrinology - Blue Reports

Results outside of reference ranges appear in dark print with an * beside the result. Reference ranges are printed on the form. Results are available in the wards and on-line post-authorisation by the laboratory.

• Haematology - Pink Reports

Results outside of reference ranges appear in dark print with an * beside the result Routine Haematology results are available on the wards and on-line, post-authorisation by the laboratory. Reference ranges are printed on the form.

• Microbiology – Yellow Reports

Results on urgent requests are phoned to the requesting clinician or the microbiology consultant as soon as the result is available. Important results e.g. positive blood cultures are phoned immediately.

Results are available on the wards and on-line post-authorisation by the laboratory.

• Histopathology – Pale Green Reports

All histopathology specimens aim to be reported within 12 Working Days.

• Immunology/Serology – Dark Green Reports

Generally all tests are batched and are available within one week.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007				
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

Tests may be processed urgently in special circumstances by contacting the Immunology Department.

• Blood Transfusion – Red Reports

Specimens processed immediately, otherwise stored @ 4°C overnight and processed within 24 hours of specimen collection.

3.18 Reference Ranges

The manufacturer of the reagents and the technology utilised to carry out the examination defines the reference ranges. Where appropriate, these reference ranges are age and gender related. In certain situations, reference ranges may be taken from reference books or the laboratory establishes its own reference ranges. Any changes in reference ranges are notified to the users prior to implementation and for a certain period of time on the report. The laboratory calculates the "uncertainty of measurement" where applicable . These estimates of uncertainty of measurement are available to laboratory users on request.

3.19 Patient Confidentiality

The confidentiality of patient records forms part of the ancient Hippocratic Oath, and is central to the ethical tradition of medicine and health care. The Mater Private Hospital has a documented procedure "Hospital Ethical Framework" to ensure that the confidentiality of patient information is maintained at all times. Access to and from the Pathology Laboratory and to the Laboratory Information Management System are safeguarded against unauthorised access. *Ref.: POL-GEN-069 Hospital Ethical Framework*"

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY			
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007			
26/09/2023			
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023		
26/09/2023			
Authorised by: Fiona O'Brien	Edition No.: 20		
26/09/2023	(Review Date 26/09/2024)		
ISO 15189:2012 / JCI Standards AOP.5			

4. BIOCHEMISTRY/ENDOCRINOLOGY

4.1 Repertoire of the Tests

The following table contains a repertoire of the tests assayed in the Biochemistry Department. Many other tests are carried out or referred to appropriate specialist laboratories when required.

Test	Abbr.	Sample Type	Special Precautions	ТАТ	Adult Reference Ranges
Alanine Amino- transferase	ALT	Serum-Gel 7.5ml	Analyse as soon as possible or	2.5hrs or 70 Minutes	M <41 IU/L F <33 IU/L
	-		spin/separate	STAT	
Albumin		Serum-Gel 7.5ml	Analyse as soon as		<14yr 38-54 g/L
			possible or	Minutes	14-18yr 32-45 g/L
			spin/separate	STAT	>18yr 35-52 g/L
Alkaline	ALP	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	<10yr 142-335 IU/L
Phosphatase			possible or	Minutes	10-<13yr 129-417 IU/L
			spin/separate	STAT	13-15yr M 116-468 IU/L
					13-15yr F 57-254 IU/L
					15-17 M 82-331 IU/L
					15-17 F 50-117 IU/L
					17-19 M 55-149 IU/L
					17-19 F 45-87 IU/L
					>19 M 40-130 IU/L
					>19 F 35-105 IU/L
Amylase	ΑΜΥ	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	28-100 IU/L
-			possible or	Minutes	
			spin/separate	STAT	
Arterial Blood	ABG	ABG Heparin	Ensure there are no air	30 Minutes	PH: 7.35 -7.45 kPa
Gas		Syringe	bubbles and analyse		PCO2: 4.5-6.0 kPa
			immediately. Use		PO2: 11.0-14.5 kPa
			Lithium Hep. Syringe		Std. Bicarb: 22.4-
			. , 0		25.8mmol/L
					O2 Sat: 95-98%
					Base Excess -2.3-+2.3 mmol/L

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007				
26/09/2023					
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023				
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

Test	Abbr.	Sample Type	Special Precautions	ТАТ	Adult Reference Ranges
Aspartate	AST	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	M <40 IU/L
Amino-			possible or	Minutes	F <32 IU/L
transferase			spin/separate	STAT	
Bicarbonate	ECO2	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	22-29 mmol/L
			possible or	Minutes	
			spin/separate	STAT	
Calcium	СА	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	2-12yr 2.20-2.70 mmol/L
			possible or	Minutes	18-60yr 2.2-2.55 mmol/L
			spin/separate	STAT	60-90yr 2.20-2.55 mmol/L
					>90yr 2.05-2.40 mmol/L
Cancer	C125	Serum-Gel 7.5ml	Analyse as soon as	Daily	0-35U/ml
antigen125			possible or	(Weekdays)	
_			spin/separate		
Cancer	C153	Serum-Gel 7.5m	Analyse as soon as	Daily	<26.4 U/ml
antigen153			possible or	(Weekdays)	
_			spin/separate		
Carcino-	CEA	Serum-Gel 7.5ml	Analyse as soon as	Daily	0.0-5.2 μg/l
embryonic			possible or	(Weekdays)	
antigen			spin/separate		
	CL	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	95-108 mmol/L
			possible or	Minutes	
			spin/separate	STAT	
Cholesterol	CHOL	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs	<5.0 mmol/L optimal
			possible or		
			spin/separate		
Cortisol	CORL	Serum-Gel 7.5ml	Analyse as soon as	Daily	133-537 nmol/L for
			possible or	(Weekdays)	morning samples (6-
			spin/separate	90mins	10am)
			• • •	STAT	
C-Reactive	CRP	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	0-5.0 mg/L
Protein			possible or	Minutes	
			spin/separate	STAT	
Creatine Kinase	СК	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	M=39-308 IU/L
			possible or	Minutes	F=26-192 IU/L
			spin/separate	STAT	-

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007				
26/09/2023					
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023				
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

Test	Abbr.	Sample Type	Special Precautions	ТАТ	Adult Reference Ranges
Creatinine	CREA	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	5-7yr 25-42 μmol/L
		possible or	Minutes	7-9yr 30-47 μmol/L	
			spin/separate	STAT	9-11yr 29-56 µmol/L
					11-13yr 39-60 µmol/L
					13-15yr 40-68 µmol/L
					F : 45-84 µmol/L
				M: 59-104 μmol/L	
CSF Protein &	CSF	1.0ml CSF	Send to Laboratory	70 Minutes	15-45 mg/dL
Glucose			immediately.		2.22-3.89 mmol/L
Digoxin	DGNA	Clotted 7.5ml	Analyse as soon as	2.5hrs or 70	0.77-1.5 nmol/L
		(plain)	possible or	Minutes	
			spin/separate	STAT	
Ferritin FER	FERR	Serum-Gel 7.5ml	Analyse as soon as	Daily	M: 30 – 400ug/L
			possible or	(Weekdays)	F: 13 – 150 ug/L
			spin/separate		
Folate	FOL	Serum-Gel 7.5ml	Analyse as soon as	Daily	3.9 – 26.8 ng/mL
			possible or	(Weekdays)	
			spin/separate		
Gamma	δGT	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	M: 10-71 U/L
Glutamyl			possible or	Minutes	F: 6-42 U/L
Transferase			spin/separate	STAT	
Gentamicin	GEN	Clotted 7.5ml	Analyse as soon as	2.5hrs or 70	Refer to Consultant
		(Plain)	possible or	Minutes	Microbiologist
			1 / 1	STAT	
Glucose	GLU	Fluoride Oxalate	12 hour fast. Analyse as	2.5hrs or 70	3.85-6.10 mmol/L
		Bottle 2.5ml	soon as possible. Serum	Minutes	
			•	STAT	
			received within one		
			hour of venepuncture.		
			Fluoride Oxalate tubes		
			should be used		
Glucose	GTT			2.5hrs	Fasting <6.1 mmol/L
Tolerance Test		Fluoride Oxalate	modified GTT testing.		2hrs pp <7.8 mmol/L
		Bottle			
Haemoglobin	HBA1	Whole Blood	Use EDTA Sample	Daily	20-42 mmol/mol
A1C	С	(EDTA) 2.5mls		(Weekday)	1

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

Test	Abbr.	Sample Type	Special Precautions	ТАТ	Adult Reference Ranges
High Density Lipoprotein	HDL	Serum-Gel 7.5mls	Analyse as soon as possible or spin/separate	2.5hrs	>1.00 mmol/L Optimal
Hs-Troponin T	TRO	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	Minutes STAT.	0-14 ng/L Female 0-22 ng/L Male Values > 300 ng/L indicates a significant degree of myocardial damage, which may be consistent with MI. Values 22-300 ng/L In patients with symptoms of ACS requires Clinical Correlation.
Human chorionic gonadotropin beta	BHCG	Serum-Gel 7.5mls	Analyse as soon as possible or spin/separate	Daily or 90 mins STAT	<5 IU/L Can be up to 9 in menopausal woman due to pituitary secretion
Inorganic Phosphate	PHOS	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	4-6yr 1.05-1.80 mmol/L M:7-9yr 0.95-1.75mmol/L F:7-9yr 1.00-1.80 mmol/L M:10-12yr 1.05-1.85 mmol/L F:10-12yr 1.05-1.70 mmol/L M:13-15yr 0.95-1.65 mmol/L F:13-15yr 0.90-1.55 mmol/L M:16-18yr 0.85-1.60 mmol/L F:16-18 0.80-1.55 mmol/L Adult 0.81-1.45 mmol/L
Iron	FE	Serum-Gel 7.5m	Analyse as soon as possible or spin/separate.	2.5hrs	5.83-34.5 μmol/L

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

Test	Abbr.	Sample Type	Special Precautions	ТАТ	Adult Reference Ranges
Lactate	LAC	ABG Heparin Syringe (venous/ arterial sample)	Analyse as soon as possible Must be received in lab within 30mins of venepuncture.	30 Minutes	0.5-2.0mmol/l
Lactate Dehydrogenase	LDH	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	2-15yr 120-300 IU/L F: 135-214 IU/L M: 135-225 IU/L
Low Density Lipoprotein	LDL	Serum-Gel Cl 7.5mls	Analyse as soon as possible or spin/separate	2.5hrs	<3.0 mmol/L optimal
Magnesium	MG	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	6-12yr 0.70-0.86 mmol/L 12-20yr 0.70-0.91 mmol/L 20-60yr 0.66-1.07 mmol/L 60-90yr 0.66-0.99 mmol/L >90yr 0.70-0.95 mmol/L
Non-HDL Cholesterol	NHDL	Serum-Gel 7.5ml	Calculated test	2.5hrs	<3.4 Optimal
NTproB-type natriuretic peptide	BNP	Serum-Gel 7.5mls	Analyse as soon as possible or spin/separate	2.5hrs or 70 mins STAT	<125 pg/ml
Potassium	К	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	3.5-5.3 mmol/L
Prostate Specific Antigen	PSA	Serum-Gel 7.5mls	Analyse as soon as possible or spin/separate	Daily (Weekdays)	0-2.9 ug/L <50 yrs 0-2.9 ug/L 50-59 yrs 0-3.9 ug/L 60-69 yrs 0-5 ug/L >70yrs
Protein/ Creatinine Ratio	UPCR	MSU	UK eCKD guidelines	Daily (weekdays)	1-15 mg/mmol
РТН	РТН	Whole Blood (EDTA) 2.5mls	Analyse as soon as possible or spin/separate	Daily (Weekdays)	1.6-6.9 pmol/L
Sodium	NA	Serum-Gel Clotted 7.5ml	Analyse as soon as possible or spin/separate.	2.5hrs or 70 Minutes STAT	133-146 mmol/L
Synacthen	SST	Serum-Gel 7.5ml	See section 4.13.3	Daily (Weekdays)	>450 nmol/L

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

Test	Abbr.	Sample Type	Special Precautions	TAT	Adult Reference Ranges
Thyroid	TSH	Serum-Gel 7.5ml	Analyse as soon as	Daily	0.270-4.45 mIU/L
Simulating			possible or	(Weekdays)	
Hormone			spin/separate		
Thyroxine		Serum-Gel 7.5ml	Analyse as soon as	Daily	12-22 pmol/L
Free T4	FT4		possible or	(Weekdays)	
			spin/separate		
Total Bilirubin	TBIL	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	M <24 μmol/L
			possible or	Minutes	F <15 μmol/L
			spin/separate	STAT	
Total Protein	ТР	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 70	60-80 g/L
			possible or	Minutes	
			spin/separate	STAT	
Transferrin	TRNS	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs	2.0-3.6 g/L
			possible or		
			spin/separate		
Triglycerides	TRIG	Serum-Gel 7.5ml	Should be fasting.	2.5hrs	<1.7 mmol/L
			Analyse as soon as		
			possible or		
			spin/separate		
Urate	URNA	Serum-Gel 7.5ml	Analyse as soon as	2.5hrs or 80	M: 202-417 μmol/L
			possible or	Minutes	F: 142-339 µmol/L
			spin/separate	STAT	
Urea	BUN	Serum Gel 7.5ml	Analyse as soon as	2.5hrs or 70	18-60yr 2.14-7.14 mmol/L
			possible or	Minutes	60-90yr 2.86-8.21 mmol/L
			spin/separate	STAT	
Urinary Amylase	UAMS	MSU Container	Analyse as soon as	2.5 hrs	M: 16-491 U/L
			possible		F: 21-447 U/L
Urinary Calcium	UCAS	24hr acid	Analyse as soon as	Daily	2.5-7.5 mmol/24hr
		container	possible or place in the	(weekdays)	
			fridge		
Urinary	UCRE	24hr	Analyse as soon as	Daily	M: 3540-24600 μmol/L
Creatinine		container/MSU	possible or place in the	(weekdays)	F: 2550-20000 µmol/L
Creatinine	CCLR	container	fridge		
Clearance					66-143 ml/min
Urinary	UNS	24hr/MSU	Analyse as soon as	2.5hrs	N/a
electrolytes	UKS	container	possible or place in the		
(Na,K,CL)	UCS		fridge		
Urinary Glucose	URGS	MSU container	Analyse as soon as	2.5 hrs	0.06-0.083 mmol/L
			possible		

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

Test	Abbr.	Sample Type	Special Precautions	ТАТ	Adult Reference Ranges
Urinary Protein	UCFP	24 hr urine container	Analyse as soon as possible or place in the fridge	Daily (weekdays)	<0.14 g/24 Hours
Urinary Urea	UBUN	24hr Plain Urine container/MSU	Analyse as soon as possible or place in the fridge	Daily (weekdays)	428-741 mmol/24hrs
Vancomycin	VANC	Clotted 7.5ml Sample to be taken 5 minutes pre-dose and 1 hour post dose	Analyse as soon as possible or spin/separate	2.5hrs or 80 Minutes STAT	Refer to Consultant Microbiologist
Vitamin B12	B12	Serum-Gel 7.5mls	Analyse as soon as possible or spin/separate	Daily (Weekdays)	197 – 771 pg/mL
Vitamin D	VTD	Serum-Gel 7.5mls	Analyse as soon as possible or spin/separate(Protect from light)	Daily (Weekdays)	>50 nmol/L

Tube Type	Colour Key	Tests
Serum Gel (SST)		Most Clinical Chemistry Analytes except
		those stated below. Glucose if testing is
		not delayed > 1hr
EDTA tube		HbA1c, PTH
Fluoride Oxalate/CSF/MSU		Glucose (if testing delayed > 1 hr) MSU
ABG Syringe		ABG, Fluids for pH, ionised calcium.
Serum (Plain)/Urine		All Therapeutic drugs e.g. Gentamicin,
		Vancomycin, Digoxin

Table 4: Repertoire of Test Services:

*Ref.:*WI-BIO-0008 Biochemistry Reference Ranges

4.2 Sample Volume

It is preferable that blood tubes, especially those containing preservative, are filled to the stated capacity. This reduces the risk of insufficiency or interference from a preservative.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

We will always try to maximise the use of any sample, however where a sample is less than half full please indicate the tests that are of greatest importance.

The departments repertoire and test strategies have been evolved with due regard for clinical need, available resources etc. Please contact the senior member of the department for advice regarding availability and clinical application of Clinical Chemistry tests.

4.3 Turnaround Times

Clinically urgent specimens will be processed within 70 minutes were possible. This would include the tests for Renal Profile, Liver Profile, CK, Bone Profile, Glucose, Magnesium, CRP, LDH, NTproBNP. Troponin TAT is 75 minutes and this applies to all locations.

Any additional tests or necessary dilutions will delay the turnaround times. Samples from Urgent cardiac care and the Emergency department are always treated as urgent. Urgent requests on samples outside these locations should be made by phone call to ensure a fast TAT within 70 minutes. Samples from Day oncology, Heart centre day unit, X-ray and ITU are treated as priority and processed within 80 minutes were possible. Any additional tests requested beyond the critical tests stated above or necessary dilutions will delay the TAT. All other non-urgent samples and chemistry tests are processed within 2.5 hours. Tumour markers, endocrinology and 24 hour urine samples are run in batches so the TAT is one day during routine hours unless an urgent request is made.

4.4 Processing of Fluids for Analysis

Fluids should be sent to the lab in a sterile universal container. Samples for glucose where testing is delayed > 1 hr must be sent in fluoride oxalate. Samples for pH should be transferred to a heparinised ABG syringe and sent to the laboratory immediately for analysis.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

Pleural Fluids

All samples from suspected TB patients must be labelled as "suspected TB". as per Hospital policy INF-GEN-016. This will help to minimise the exposure to the laboratory staff and allow samples to be handled in a safe manner.

FLUID TYPE	ANALYTES MEASURED
Cerebrospinal Fluid (CSF)	Glucose, Protein. Preserve glucose if testing is
	delayed by > 1 hour.
Pleural Fluid	Glucose, Protein, LDH, pH. pH only- as soon as
	fluid is collected, take a sample into blood gas
	tube and expel all air. Serum should be tested
	for protein and LDH at the same time.
	Preserve glucose if testing is delayed by > 1
	hour.
Peritoneal Fluid/Ascitic Fluid	Protein, LDH, Albumin, Amylase, Triglycerides.
	Serum and Fluid samples should be taken
	concurrently.
Knee Aspirate	Protein, LDH
Synovial Fluid	Protein, LDH
Wound or abscess drain	Protein
Drain Fluid(Robinsons)	Creatinine, Urea
Pericardial	Glucose, Protein, LDH, pH.
	pH only- as soon as fluid is collected, take a
	sample into blood gas tube and expel all air.
	Preserve glucose if testing is delayed by > 1
	hour.

 Table 5: Fluid Type & Analytes Measured

CSF's are always handled by Microbiology to maintain sterility for culture and sensitivity testing. An aliquot is then dispatched into Biochemistry with the corresponding Microbiology specimen number for protein and glucose analysis.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

4.5 "Add –on" Tests and Sample Stability

Likely sample stability for some common investigations:

- Samples received into the Biochemistry Department for routine testing are usually serum gel separated tubes.
- Clotted blood samples received into Biochemistry are labelled up and centrifuged within one hour.
- Some additional tests may be performed on this original sample within a 48 hour period. Blood samples are retained for 48 hours after a final report has been issued.
- Glucose should be measured in serum samples within 1 hr of venepuncture. Fluoride
 Oxalate tubes should be used if testing will be delayed > 1 hour.
- Tests that require specimens with special preservatives are:
 - 1. Glucose Fluoride/Oxalate tube
 - 2. HBA1C EDTA
 - 3. PTH EDTA
- Urine samples are stable for three to four days depending on the test required when stored at 4 degrees Celsius.
- Additional tests or Add-on test must be requested by sending a form to the Biochemistry department. A member of the biochemistry staff will assess whether the sample is still acceptable for analysis.

4.6 On-Call Service Repertoire in Biochemistry

All routine Biochemistry tests are carried out during on-call hours with the exception of the following: Routine Endocrinology (TFT, Cortisol, PTH, Vitamin D), Tumour markers (TPSA, CA125, CA153, CEA), Haematinics(Ferritin, Folate, B12) and HbA1c.

Outside normal working hours the emergency service is covered by the Medical Laboratory Scientist on call, who is contactable by mobile phone through reception or security. All tests

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

authorised are available on ward look up and the LIMS. Samples may be delivered to the laboratory via the pneumatic tube system.

4.7 Notes on Taking Blood Specimens for Biochemistry Tests

- Correct labelling of specimens is mandatory. Always apply labels to request forms immediately and write patients Name, DOB and MRN or apply ID label on the patient sample after collection.
- 2. Relevant information (e.g. time of collection, hours fasting) should be written on the request form.
- 3. 7.5mls blood (serum gel tubes) is the recommended volume for the majority of assays performed in the Biochemistry Department.
- 4. Contamination errors are most commonly caused by drawing blood from the arm of a patient which is already facilitating an I.V Line or pouring blood from one bottle into another e.g. EDTA into Heparin. Also the correct order of draw when taking samples.
- 5. For pH/Blood gases a pre-heparinised blood-gas monovette is recommended. Exclude all air, and mix in the heparin by rolling rapidly between the palms, to prevent clotting. If a sample clots it cannot be assayed and may cause a blockage on the blood gas analyser.
- 6. Blood gas samples with large air bubbles should not be sent to the Laboratory as pCO_2 and pO_2 are affected.
- 7. Blood gas samples should be analysed immediately. If this is not possible, analyse the sample within 30 minutes.
- Samples for venous or arterial Lactate should be assayed on the blood gas analysers using blood gas heparin syringes within 30 minutes. If analysed within 30 to 90 minutes the result will come with a warning comment.
- 9. Blood gas specimens should not be sent in the pneumatic tube system or with needles attached to the Laboratory.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

4.8 Sample Rejection Criteria

While every effort is made to minimise rejection of samples, however some samples will be deemed unsuitable for analysis or will yield inaccurate results. These include:

- Unlabelled or incorrectly labelled samples.
- Incorrect sample type or incorrect additive used in the case of 24 hr urines.
 All 24 Urines or timed urine collections must be checked for proper container suitability i.e. plain container or acid container.
- Inadequate sample volumes.
- Grossly haemolysed samples. Depending on the degree of haemolysis these samples may be unsuitable for analysis and may need to be repeated. In grossly haemolysed samples the following assays should not be reported K, AST, ALT, ALP, GGT, LDH, Iron, Troponin and in some cases phosphate depending on the severity of the haemolysis. Grossly Lipaemic samples may give abnormal reactions for some assays. AST and ALT are the most commonly affected and may not be reported. In more severely-affected samples most assays will be unacceptable and samples should be repeated.
- Contaminated Samples due to incorrect order of draw. If a EDTA sample is taken before the Biochemistry it can affect the Potassium and Calcium measurement.
- Samples taken from an arm with an infusion or a line may yield falsely elevated or decreased results.
- Sample/ Analytes that may have deteriorated due to a prolonged transit time.

4.8.1 Time between Collection and Analysing

Sample Transport may affect testing. The following factors should be considered:

- Timing: off-site blood drawing, delayed centrifugation, leakage of RBCs.
- Temperature (ABGs and K)
- Light exposure (bilirubin, vitamins, porphyrins)
- Clots, Air bubbles(ABG)

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

• Gross haemolysis, Icterus, Lipaemia

Assays which may be affected include the following but are not limited to:

- Glucose measurement is effected in serum left unseparated at room temperature for
 > 1hr. Where this might occur fluoride oxalate tubes should be used. Serum samples
 greater than one hour should not be used for glucose measurement.
- Samples where intracellular concentrations of an analyte (i.e. K,AST,PHOS, LDH,MG, CK and Iron) may increase as a result if sample is left unseparated should be sent to the laboratory promptly.

If a sample has to be rejected the source is informed and a repeat sample must be taken. If a sample is non-compliant a Non-conformance/Quality Event Form is generated on q-pulse.

4.9 Urine Collections

Urine containers are available in the Biochemistry Laboratory. The containers available contain acid or no preservative.

4.10 24 Hour Urine Collection Instructions

4.10.1 Preparation

- Before you begin the collection you will be given a container or containers and a form.
 The containers available may contain acid or no preservative.
- Ensure the container and form contains all details. These must include your full name, date of birth and hospital number if available. If your container is not labelled properly you may be asked to repeat the collection.
- Ensure the form and container also includes the start and end date and time of the urine collection.
- During collection keep the container refrigerated until you bring the sample back to the hospital. If this is not possible keep in a cool dry area.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- Some tests require an acid preservative. These containers will have a red acid preservative danger label with instructions to keep upright, avoid contact with acid fumes and do not pass urine directly into container. The acid is vital for the test so do not empty the container.
- For collection in the acid container collect urine in a clean receptacle (jug/vessel) and transfer. Pour slowly and carefully in to the acid container.

4.10.2 Collection Method: Day 1 on Waking

- Start the 24 hour urine test by emptying your bladder directly into the toilet. The collection begins now. Write the start date and time on the container.
- For the next 24 hours all urine passed (no matter how small) must be collected in the container or by receptacle and transferred carefully to the container. If you do not collect all the urine passed in the 24hr your test result may be inaccurate and you may have to repeat the collection again.
- You may need to use more than one container during the 24 hour period. Only when the first container is full should you collect into the second container.

4.10.3 Collection Method: Day 2 on Waking

- Collect the first urine sample into the container. This is the end of the test.
- Write the date and time the test ended on the container.
- Bring the 24 hour collection to the hospitals specimen reception as soon as possible.
- To prevent leaks ensure the cap is on tightly and the container is stored upright.
- If travelling a long distance transport on ice or in a cooler.

Notes

- 1. Ensure that urine and faeces are passed separately.
- 2. If the container is full before completion of collection, use a second container with the same preservative, and send both to the laboratory. Label containers 1 of 2, 2 of 2 etc.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- 3. If any specimen of urine is not collected or accidentally discarded during the collection, discontinue the test and start again.
- 4. Patients should be cautioned not to urinate directly into a bottle containing acid preservative. Below is a list of the appropriate containers for use for each test:

Test	Plain	HCL	Spot
Amylase	YES		YES
Calcium	YES	YES	YES
Chloride	YES		YES
Creatinine	YES		
Potassium	YES		YES
Protein	YES		YES
Sodium	YES		YES
Urea	YES		YES
Glucose			YES
Protein creatinine ratio			YES

Table 6: List of Appropriate Containers for Use for Each Test

Samples for Creatinine, Urea and Urate (if taken into plain container) and BJP should be sent to the laboratory promptly. The container should be stored in the refrigerator during the collection. For 24 hour specimens the request form should state the start time and end time of the collection. If more than one container is used over this period they should be sent to the lab together once the collection is finished.

Urine sodium should be interpreted in the light of serum levels and intake. Urine sodium cannot be meaningfully interpreted in patients on saline infusions.

Note: If sending patient home to complete 24 hour urine collection refer to WI-BIO-0033 Patient Instructions for 24 hour Urine collections.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

4.11 Blood Collection Tubes

4.11.1 Biochemistry Profiles

Renal Profile

Requires 5ml of blood in a serum-gel tube mixed gently.

The profile includes sodium, potassium, chloride, total carbon dioxide, urea, creatinine and eGFR. Note that bicarbonate decreases in serum with time and the difference in time between phlebotomy and assay of the sample may cause a drop in total CO₂ of 5 mmol/l or more. For accurate assay, the sample should be delivered promptly to the laboratory. Potassium may be increased in haemolysed samples and EDTA contamination.

• Liver Profile

Requires 5ml of blood in a serum-gel tube mixed gently. The profile includes protein, albumin, bilirubin, alkaline phosphatase, AST, ALT and GGT.

False low albumin results may be caused by aspirin. Elevated values of ALT may be produced by a wide range of drugs, which have hepatoxic side effects. Samples for ALT and AST should be taken before administration of Sulfasalazine and Sulfapyridine as there may be chemical interference with these analytes . Falsely elevated levels of AST may occur as the result of haemolysis. Repeat specimen is recommended.

Bilirubin is sensitive to light and thus prompt delivery of the specimen to the laboratory is recommended. Cyanokit (Hydroxcobalamin) may cause falsely low results. Samples containing indocyanine green must not be measured. No significant interference from Immunoglobulins was found up to 28g/L, levels above 60 g/L have the potential to give a greater than 40% positive deviation.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

• Bone Profile

Requires 5ml of blood in a serum-gel tube, mixed gently.

The profile includes albumin, calcium, phosphate and alkaline phosphatase. Calcium may be decreased in samples contaminated with EDTA. Adjusted calcium will not be reported if Albumin result is below 20.

• Lipid Profile

Requires 5ml of blood in a serum-gel tube, taken after a fast of at least 12 hours.

The profile includes cholesterol, triglycerides, HDL-Cholesterol, LDL-cholesterol and Non-HDL Cholesterol.

Optimal target value are taken from the European society of Cardiology (ESC) dyslipidaemia guidelines for low risk cardiovascular disease prevention.

- Cholesterol: <5.0 mmol/L optimal (lower levels are recommended in patients with diabetes, hypertension and cardiovascular disease)
- Triglycerides: <1.7 mmol/L optimal
- HDL Cholesterol: >1.00 mmol/l optimal
- LDL Cholesterol: <3.0 mmol/l optimal
- Non-HDL Cholesterol <3.4 mmol/L optimal
- Full Iron Profile

Requires 5ml of blood in a serum-gel tube mixed gently. This includes Iron, Transferrin and % transferrin saturation (a calculation based on these two assays).

Haematinics

Requires 5ml of blood in a serum-gel tube mixed gently. This includes Ferritin, Folate and Vitamin B12. Mainly used for evaluation of blood cell haematopoiesis.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

• Thyroid Function Tests

Measure Free Thyroxine (FT4) and Thyroid Stimulating Hormone (TSH) as a combined test of thyroid function assayed on the Roche immunoassay e601 platform. The Roche platform is susceptible to Biotin interference, but newer versions of the tests have reduced this. Patients on high Biotin doses must wait 8 hours following last Biotin administration before TFT testing. The Laboratory can arrange to have discordant results repeated on an alternative platform to rule out suspected assay interference, please contact the Biochemistry laboratory directly to arrange this.

As many drugs and treatments affect TFT details of all drugs or other treatment must be provided in order for the Laboratory to initiate further tests as appropriate. Please indicate on request form if the patient is on thyroid replacement therapy. Autoantibodies to thyroid hormones can interfere with the assay.

• Creatinine Clearance

Requires both 5ml blood in a serum-gel tube mixed gently and a 24 hour urine collection (no preservative needed). It is IMPORTANT to take the blood during the period of the urine collection and to send both samples to the laboratory together.

• Digoxin (includes Lanoxin)

Required 5ml blood in plain tube (no gel), drawn six hours after the most recent oral dose of digoxin. Used to treat heart failure and atrial fibrillation. Time of collection should be written on the tube label, and on the request form if used.

• Vancomycin/Gentamycin

Required 5ml blood in plain tube (no gel). Antibiotics used to treat a wide variety of bacterial infections

Refer to consultant Microbiologist for therapeutic range.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

• CRP

Requires 5ml of blood in a serum-gel mixed well but gently.

An acute phase protein that rises during a general unspecific response to infection and inflammation.

Glucose

Requires 2.5ml blood in fluoride-oxalate tube (yellow label), mixed well but gently. Serum samples are also acceptable if sent immediately to Laboratory and centrifuged within 1 hour. Also measured in cerebrospinal fluid (CSF).

• Haemoglobin A1C

Requires 3ml blood in EDTA tube. Used to assess your average blood glucose concentration over a 2-3 month period.

• TPSA

Requires 5ml of blood in a serum-gel mixed well but gently.

Used to aid in the detection and management of Prostate Cancer.

• CEA

Requires 5ml of blood in a serum-gel mixed well but gently.

Tested as an aid in the prognosis and management of Cancer patients were changing CEA is observed, which can be seen in many digestive tract cancers.

• CA153

Requires 5ml of blood in a serum-gel mixed well but gently.

Primarily used as an aid in management of stage II and III breast cancer patients

• CA125

Requires 5ml of blood in a serum-gel mixed well but gently.

Primarily used in monitoring response to treatment in ovarian cancer.

• NTproBNP

The natriuretic peptides are used in the evaluation and monitoring of patients with established or suspected heart failure. NTproBNP and BNP have similar clinical utility but

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

results are not interchangeable. There is significant diversity in circulated natriuretic peptides due in part to proBNP processing, glycosylation, complex molecular biology of Heart Failure and lack of harmonisation of immunoassays. NTproBNP is considered a suitable biomarker for monitoring patients receiving NEP inhibitors. NTproBNP rises physiologically with age.

• PTH

Requires 3ml blood in EDTA tube. Its secreted by the parathyroid glands in response to decreased extracellular concentrations of ionised calcium. Parathyroid disorders lead to elevated or depressed blood calcium levels.

HCG beta

Requires 5ml of blood in a serum-gel mixed well but gently. Used in the early detection and monitoring of pregnancy. Also can be used in the management of patients with trophoblastic diseases.

• Vitamin D

Requires 5ml blood in serum-gel tube. It is essential for bone health and is mainly produced in the skin from exposure to sunlight.

4.12 Blood Gas Analyses

There are four blood gas analysers in the hospital, one in ITU, one in the Emergency department, one in Theatre and one in St Joseph's. Staff in these areas have been trained to operate these analysers. Samples from all other areas must be hand delivered promptly to the laboratory and must be brought to the attention of a member of staff. The protocol for ABG analysis is as follows:

- A heparinised syringe should contain the patient identifiers i.e. Name, D.O.B and MRN.
- Any air in the syringe must be expelled.
- The needle must be removed before transport and the syringe capped immediately.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

4.12.1 pH and Blood Gases

Requires 3ml arterial blood in air-free heparinised syringe, well mixed.

Reference values: (Arterial)

- 1. pH: 7.35 to 7.45
- 2. P_{CO2}: 4.5 to 6.0 kPa
- 3. P_{O2}: 11.0 to 14.5 kPa
- 4. Base Excess: -2.3 to + 2.3 mmol/l
- 5. Std Bicarbonate: 22.4 to 25.8 mmol/l
- 6. Oxygen Saturation: 95 to 98%

4.12.2 pH and Fluids

Requires a sample of any appropriate body fluid, transferred to a heparnised ABG syringe for testing on the blood gas analyser. Alternatively it can be tested on serum with the Siemens multistix teststrips.

4.12.3 Lactate

Measured by the ABL90 Flex plus Blood Gas Analyser.

Arterial or Venous blood collected in a blood gas syringe (safe PICO Aspirator). Can also be measures in a serum sample once centrifuged within 30 minutes. Samples should be tested within 30 minutes of venepuncture. If longer than 30 minutes but less than 90 minutes samples can still be run but reported with a warning comment. Reference values (in fasting venous/arterial whole blood): 0.5-2.0 mmol/l

4.13 EGFR

The Irish and UK guidelines on classification and monitoring of Chronic Kidney Disease (CKD) recommend assessing renal function based on a estimated glomerular filtration rate, the eGFR. CKD has been classified into five stages based on the Patient's eGFR and other evidence of renal impairment such as proteinuria. The eGFR is based on the formula derived in the "Modification of Diet in Renal Disease" (MDRD) Study. The MDRD equation is based

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona ErrityDate of Issue: 26/09/2023		
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

on 4 variables: Serum creatinine, Age, Gender and ethnicity. Serial measurement of eGFR is essential in assessing the severity of any renal condition. The eGFR will replace creatinine Clearance in many patients see below.

4.13.1 Stratification of Chronic Kidney Disease by eGFR

Stage Description GFR (ml/min/1.73m²)

- 1. Kidney damage with normal GFR >90 with other evidence of chronic kidney damage*
- 2. Mild reduction in GFR GFR 60-89 with other evidence of chronic kidney damage*
- 3. Moderate reduction in GFR GFR 30-59
- 4. Severe reduction in GFR GFR 15-29
- 5. Kidney Failure GFR <15 or RRT

*The other evidence of chronic kidney damage may be one of the following:

- Persistent microalbuminuria.
- Persistent Proteinuria
- Persistent haematuria (after exclusion of other causes e.g. Urological disease).
- Structural abnormalities of the kidneys demonstrated on radiological tests or ultrasound scanning e.g. Polcystic Kidney disease.

CKD is defined as either kidney damage (proteinuria, haematuria or anatomical

abnormality) or GFR< 60 mL/min/1.73m² present on at least 2 occasions for \ge 3 months.

• Specimen Type:

Serum for creatinine analysis

• Turnaround Time:

Availability of assay: daily, throughout 24 hours.

• Reference Range:

> 60 mL/min/1.73m²

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity Date of Issue: 26/09/2023		
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

4.13.2 Important Notes on Estimated GFR in Adults using Formulae

- (1) Estimated GFR is calculated using the 4v-MDRD Formula
- (2) Estimates of GFR are unreliable in acute renal failure due to the kinetics of creatinine accumulation.
- (3) GFR estimates between 60 and 89 mL/min/1.73m² do not indicate CKD unless there is other laboratory/clinical evidence of disease.
- (4) Estimated GFR should be multiplied by 1.212 for patients of African ethnicity.
- (5) The formula is applicable to adult patients (i.e. patients >18 years old).

Note: eGFR formula differs slightly depending on the method used for measuring creatinine. eGFR (mL/min/1.73 m²) = 175 x (serum creatinine (μ mol/L) x 0.011312)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African ethnicity)

4.13.3 What we Report

Values will not be given for results of eGFR >60ml/min/1.73m²

The reason is that the MDRD equation was derived in patients with CKD and the formula has proven to be inaccurate in that it underestimates the GFR at higher values.

Creatinine Clearance with timed urine collection is still necessary in certain circumstances:

- Extremes of body sizes and age e.g. severe malnutrition or obesity, elderly or children <18 years.
- Pregnancy, vegan diet, Creatine supplements.
- Skeletal muscle disease e.g. muscular dystrophy, amputee.
- Prior to dosing with nephrotoxic or chemotoxic drugs.
- Microalbuminuria is still the gold standard for detecting early renal disease in patients with Diabetes Mellitus.

4.14 Diabetes Mellitus

The following Table summarises the 2006 & 2011 WHO recommendations for the diagnostic criteria for diabetes and intermediate hyperglycaemia.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

	Normal	Impaired	Impaired Glucose	Diabetes Mellitus
		Fasting Glucose	Tolerance	
Fasting	<6.1	6.1-6.9	<7.0	≥ 7.0
	and	and	and	And / or
2 Hour	<7.8	<7.8	>7.8-11.0	≥ 11.1
				<i>Note</i> : if at least one other abnormal plasma glucose level on another occasion, or HbA1c >48 mmol/mol, then a diagnosis of DM can be made.

Table 7: Diagnostic criteria for diabetes and intermediate hyperglycaemia Adapted fromWHO Guidelines 2006 and 2011.

• Diabetes

Fasting plasma/serum glucose ≥7.0mmol/l

or

2–h plasma/serum glucose* ≥11.1mmol/l

• Impaired Glucose Tolerance (IGT)

Fasting plasma/serum glucose <7.0mmol/l

and

2–h plasma/serum glucose* ≥7.8 and <11.1mmol/l

• Impaired Fasting Glucose (IFG)

Fasting plasma/serum glucose 6.1 to 6.9 mmol/l

2-h plasma/serum glucose* <7.8mmol/l (140mg/dl)

* Venous plasma/serum glucose 2-h after ingestion of 75g oral glucose load

An OGTT should be used in individuals with fasting plasma/serum glucose 6.1–6.9mmol/l to determine glucose tolerance status. * If 2–h plasma glucose is not measured, status is uncertain as diabetes or IGT cannot be excluded

HbA1c reflects average plasma/serum glucose over the previous 2–3 months in a single measurement which can be performed at any time of the day and does not require any special preparation such as fasting. These properties have made it the gold standard for

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

assessing glycaemic control in people with diabetes and have resulted in its consideration as an option for assessing glucose tolerance in people without diagnosed diabetes.

4.14.1 Procedure for Performing a Modified Glucose Tolerance Test

The glucose drink is supplied as a pre-planned pouch with 75g anhydrous glucose in 300ml water.

Ref.: CM-PHL-0002 Glucose Tolerance Test)

4.14.1.1 <u>Sampling Procedure</u>

- Prior to starting the fasting patient should eat their normal diet.
- Ensure patient is fasting at least 9 hours but no more than 12 hours, and patient may drink water.
- Take blood samples as per procedure for blood sampling
- Take off first sample & label as fasting, with the time & date of specimen collection.
- Allow patient to drink full contents of Rapilose Oral GTT solution, over 5-10 minutes.
- During the test ensure patient must remain seated in waiting room and refrain from eating, smoking and walking around.
- After exactly 2 hours repeat blood sample to complete the test and label as 2 hour sample, with the time & date of sample collection.

Ref.: CM-PHL-0001 Blood Sampling in the Phlebotomy Department.

Samples taken in fluoride oxalate tubes and sent to the laboratory for analysis.

4.14.2 Lactose Tolerance Test

Patient Preparation: Patient should fast 8 hours before testing. No smoking or chewing gum during test. Patient is encouraged to drink a moderate amount, 1-2 glasses of water during test. Patient should also remain seated during test.

Fasting Sample taken at time zero (Fluoride Oxalate), then.

Adults: A lactose load is given orally to a fasting patient 100g in 300ml of water. If severe deficiency is suspected, the dose should be lowered.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Collect blood samples at 15,30,60,90 and 120 minutes following administration.

Ensure all tubes are labelled correctly with times taken.

Interpretation:

Normal:	Rise in plasma/serum glucose of more than 1.7mmol/l over	
	baseline (fasting)	
Lactose deficiency:	Rise in plasma glucose of less than 1.1mmol/l over baseline	
Inconclusive:	Rise of 1.1 to 1.7 mmol/l over baseline	

4.13.3 Short SynACTHen Test

Indication:

- Diagnosis of primary adrenocortical insufficiency.
- Diagnosis of Congenital Adrenal Hyperplasia (CAH). (17 (OH)-progesterone is also measured in this case).

If the basal (i.e. 8am) cortisol is **>450 nmol/**L then adrenal insufficiency is **excluded.** If the basal (i.e. 8am) cortisol is **<80 nmol/L** then adrenal insufficiency exists and there is no need to do a Short Synacthen test in these settings.

Contraindications:

- Pregnancy: It is not advised to perform the Short Synacthen test (SST) during pregnancy. If patient is of child-bearing age, please confirm patient is not pregnant
- Hypersensitivity to Tetracosactide and / or ACTH or to any of the excipients
- Manufacturer states contraindicated in allergic disorders, e.g. asthma. See position statement of Society of Endocrinology Sept 2011
- Avoid in ICU and critically ill patients. Assessment of salivary cortisol may provide an alternative option.

Adverse Effects: Hypersensitivity reactions- tend to be more severe in patients susceptible to allergies and may include injection site reactions, dizziness, nausea, vomiting, utricaria, pruritis, flushing and dyspnoea.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

What you need:

- Tetracosactide (SynACTHen[®]) 250 microgram vial (Order in advance through Pharmacy MPH. Should be stored in fridge until use)
- One I.V. cannula and adhesive (if administering Tetracosactide (Synacthen[®]) intravenously, a second IV cannula is required)
- NaCl 0.9% 10ml ampoules (IV line flushes)
- Serum sample blood tubes x 3
- Serum blood tubes (white for 17 (OH)-progesterone, if applicable).
- One EDTA tube (pink) for ACTH. Must be taken in cold gel bag and transported to the Clinical Biochemistry Laboratory immediately
- Syringes

In the unlikely event of an adverse issue, ensure resuscitation equipment is available close

by.

Pre-Procedure Notes:

- Discontinuation of OCP/HRT for 6 weeks prior to testing is recommended. If this is not possible discuss with Consultant Clinical Biochemist (Contact through MPH switchboard)
- Prednisolone and hydrocortisone will cross react in the assay and should be stopped for at least 24 hours before testing.
- Enquire about history of asthma or other allergic disorders (see contraindications above and Society of Endocrinology Statement below)
- Enquire if any previous untoward reaction to Synacthen and avoid in these patients.
- There is no requirement for fasting. Ideally, perform the test between 8 and 10 am and no later than 12 midday.
- Take samples for baseline ACTH (ETDA bottle, <u>must go to lab in cool gel bag</u> <u>immediately</u>) and basal plasma cortisol (time 0).

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Maintain patency of indwelling IV line by flushing with 2 ml NaCl 0.9% (from NaCl 0.9% ampoules) each time blood sample is taken. Prior to taking blood samples, withdraw 2 ml of blood and discard this blood sample to ensure that the dead space is removed prior to obtaining blood samples.

Procedure:

- 1. Wash hands.
- 2. Take samples for basal ACTH and plasma cortisol as outlined above.
- 3. Administer 250 microgram Tetracosactide (Synacthen[®]) at time 0 (IM is preferred). If using the IV route, you will need separate IV access to the indwelling cannula for blood draws and flush with 2 ml of NaCl 0.9%.
- 4. Take further samples for serum Cortisol levels at 30 minutes and 60 minutes post Synacthen injection.
- 5. If Congenital Adrenal Hyperplasia (CAH) is suspected, request and take blood samples for 17(OH) progesterone at times 0 (baseline), 30 minutes and 60 minutes.

	Std SST	SST for Dx of CAH	Std SST	
Time (minutes)	Plasma Cortisol	17-OH Progesterone (if	ACTH	
		suspect CAH)		
0	Х	Х	Х	
Injec	Inject 250 microgram tetracosactide (SynACTHen®) IM/IV			
30	Х	Х		
60	Х	Х		
Total number of	3 serum tubes (for cortisol), +/- 3 white serum tubes for 17(OH)			
blood bottles	prog, 1 EDTA tube (for ACTH),			

Table 8: Protocol for Short Synacthen Testing

Interpretation of Results:

• Normal cortisol response following Synacthen stimulation is >450 nmol/L.

Interpretation based on stopping OCP/HRT 6weeks before testing

• An abnormal response confirms adrenocortical failure but does not indicate whether the adrenal failure is primary or secondary

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- Serum ACTH will be raised in primary adrenocortical insufficiency and low in secondary failure (normal ACTH <46ng/L)
- Interpretation of SST for the investigation of CAH Refer to Consultant Clinical Biochemist

Assay Methods:

Cortisol is measured by Roche ECLIA method on Cobas e601 which cross reacts as follows:

- Prednisolone: 7.98%at a concentration of 0.1microgram/ml
- 11-deoxycortisol during metyrapon stimulation testing.

ACTH is measured by Roche Cobas at MMUH

If you have any queries, please contact the Clinical Biochemistry Laboratory Ph: 8858134 or the Consultant Clinical Biochemist through the Mater Private switchboard.

4.13.4 Overnight Dexamethasone Suppression (Screening) Test

Indication:

Used to screen for Cushing's syndrome. Usually performed as an outpatient test.

Contraindications:

None

<u>Note:</u> The oral contraceptive pill (OCP) increases the Cortisol Binding Globulin (CBG) in the circulation. Recommendation: stop OCP for 6 weeks to allow the CBG to return to normal.

Side Effects:

None of note

What you need:

- Dexamethasone tablets 1 mg (Pharmacy)
- One serum gel tube

How to perform test:

1. Request an early morning cortisol and please STATE clearly on the request form that this is a sample following administration of dexamethasone. This is essential, if the

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

laboratory is not aware Dexamethasone was administered, they will phone a low cortisol result as urgent.

- 2. Administer 1 mg Dexamethasone orally at 12 midnight.
- 3. Draw serum Cortisol at 8-9 am the following morning.

Interpretation of Results:

Normal response: Plasma Cortisol should suppress to <50 nmol/L. Sensitivity 98-100%.

Abnormal Response: Plasma Cortisol does not suppress

False positives (i.e. failure to suppress) may occur in:

Patients on enzyme inducing drugs may rapidly metabolise Dexamethasone, e.g.

Carbamezepine, Phenytoin, Phenobarbitone, Primidone, Rifampicin, Alcohol

Oestrogens (pregnancy, OCP), hormone replacement therapy (HRT) and Mitotane may

induce Cortisol Binding Globulin and increase total Cortisol levels

Patients undergoing dialysis due to rapid clearance of dexamethasone.

False negatives (i.e. suppression) may occur in:

Patients with chronic renal and liver failure due to a failure to clear dexamethasone

Cortisol not suppressed - consider:

Cushing's syndrome (further investigations required)

Non-compliance with oral Dexamethasone

Stress during the night

Increases in Cortisol Binding Globulin

Patient taking anti-convulsant drugs or other enzyme inducing agents

Severe depression

Obesity

4.15 Calcium Disorders

Hypercalaemia: Check Serum Calcium, Phosphate, Alkaline Phosphatase and Albumin on several occasions.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

If Calcium is consistently above 2.67 mmols/l, investigate further. Check 24 hour Urinary Calcium, Serum PTH, FBC, ESR, TFT's, X-rays, Screen for myeloma, and measure acid base balance. Hyperparathyroidism is diagnosed by positive features (low serum Phosphate, relatively low 24 hour urine Calcium, elevated PTH. Hyperchloraemic acidosis, a sometimes indication of long standing hypercalcaemia such as renal calculi).

Lung, GI, ovary, thyroid, renal tumours may secrete parathyroid hormone-related peptide(PTHrP), which mimics the action pf PTH, raising serum Calcium. PTHrP is not detected by the PTH assay, so the raised Calcium is accompanied by a decrease in PTH in these cancer patients.

Hypocalcaemia: For persistent hypocalcaemia, check renal function, Serum Magnesium GI absorptive function, Phosphate, Vit D and PTH level. Hypoparathyrodism , caused by a deficiency in PTH resulting in hypocalcaemia.

EDTA contamination can give falsely decreased calcium levels. Always take serum samples before EDTA samples.

4.16 Troponin

Clinical Significance

Clinical studies have demonstrated the release of the protein Troponin T(cTnT) into the blood stream within hours following acute myocardial infarctions (AMI) or ischemic damage. Elevated levels of cTnT (above the values established for non-AMI specimens) are detectable in serum within 4 to 6 hours after the onset of chest pain, reach peak concentrations in approximately 8 to 28 hours, and remain elevated for 3 to 10 days following AMI. The temporal pattern of cTnT release following an infarction thus extends across the diagnostic windows of both creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH). The clinical utility of cTnT measurements for the assessment of myocardial damage has been demonstrated in several clinical studies indicating improved

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

cardiac specificity of cTnT over CK-MB. The high specificity of cTnT measurements is beneficial in identifying cardiac injury for clinical conditions involving skeletal muscle injury resulting from surgery, trauma, extensive exercise, or muscular disease.

The World Health Organization (WHO) criteria for defining AMI are the presence of two of the following three elements: unequivocal ECG changes, unequivocal serum cardiac enzyme changes, and prolonged chest pain.

Universal Definition of Myocardial Infarction

The current (Fourth) Universal definition of MI accommodates the use of high-sensitivity cardiac Troponin. Hs-TnT is measured in the Biochemistry department on the Roche Cobas e601.

Detection of an elevated cTnT value above the 99th percentile upper reference limit (URL) is defined as Myocardial injury. The injury is considered acute if there is a rise and/ or fall of cTnT values.

Type 1 MI includes the detection of a rise and/ or fall of cTnT values accompanied with at least one of the following:

- Symptoms of acute myocardial ischaemia
- New ischemic electrocardiographic (ECG) changes.
- Development of pathological Q-waves
- Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
- Identification of intracoronary thrombus by angiography or autopsy.

(Thygesen, et al. Fourth Universal Definition of Myocardial Infarction. J Am Coll Cardiol 2018;Aug 25)

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY			
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007			
26/09/2023			
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023		
26/09/2023			
Authorised by: Fiona O'Brien	Edition No.: 20		
26/09/2023	(Review Date 26/09/2024)		
ISO 15189:2012 / JCI Standards AOP.5			

Diagnostic decision cut-offs

The improved precision of the high-sensitivity hs-cTnT assay means that the 99th percentile URL is defined at a lower level than previously, with clear differences between cTnT levels in men and women. This supports lower, gender-specific diagnostic thresholds for diagnosis of myocardial infarction, with a raised cTnT defined as:

>22 ng/L in men

>14 ng/L in women

Although cTnT is highly specific for myocardial injury, there are many mechanisms and disease states other than coronary heart disease lead to myocardial injury with small increases in hs-cTnT found in both acute and chronic illness (e.g. Septicaemia, chronic renal disease, congestive heart failure). It is therefore important the test is **only requested in patients with presentation suggestive of acute coronary symptoms** and that it is not requested as part of a routine screen.

When to measure cardiac troponin T

In patients with suspected acute coronary syndrome taken a blood sample for hs-cTnT

- On **admission** and
- **6 hours** following onset of symptoms in patients identified as low risk using the GRACE score **OR**

12 hours following onset of symptoms in patients identified as high risk using the GRACE score (Global Registry of Acute Coronary Events- which uses eight factors to predict risk of heart attack and/or death. Age, Heart Rate, Systolic Blood Pressure, Renal Function, Congestive Heart Failure, S-segment Elevation, Cardiac Arrest and finally Elevated Biomarkers i.e. hsTnT.)

Clinical Biochemistry contact details; Ph: 8858134 or Dr Maria Fitzgibbon, Consultant Clinical Biochemist contact details available from Biochemistry.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

4.17 Clinical and Biochemical Evaluation of a Patient with Potential Secondary

Hypertension

This clinical and biochemical guideline is designed to outline the investigations of patients with hypertension for primary aldosteronism and phaeochromocytoma

<u>Primary aldosteronism (PA)</u> is usually diagnosed in patients aged between 20 and 60 years of age. The prevalence is estimated to be ~ 5% in patients with hypertension. Aldosteroneproducing adenoma (APA) and bilateral idiopathic hyperaldosteronism are the commonest subtypes of PA. Hypokaleamia is present in less than 30% of patients.

<u>Phaeochromocytoma/paraganglioma (PPLGs)</u> are rare neuroendocrine tumours arising from adrenal and extra-adrenal chromaffin cells and are generally surgically curable. It is the unregulated secretion of catecholamines that is largely responsible for the hypertension and symptomatology.

A first-line secondary hypertension work-up generally includes clinical and biochemical assessment. Clinical assessment includes detailed BP studies, full cardiac evaluation, weight and metabolic assessment. Obstructive sleep apnoea should be noted and if present should be investigated.

Biochemical investigations include assessments of renal, liver, bone, glucose metabolism, including HbA1c, thyroid function and specialist testing as indicated by clinical symptomatology.

Patient Assessment

Who to test

Patients with early onset hypertension (< 30 years of age), in the absence of hypertension risk factors, such as obesity, metabolic syndrome, familial history) Those with resistant hypertension Those with sudden deterioration in BP control

Hypertensive crisis

Adrenal "incidentaloma" with hypertension

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY			
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007			
26/09/2023			
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023		
26/09/2023			
Authorised by: Fiona O'Brien	Edition No.: 20		
26/09/2023	(Review Date 26/09/2024)		
ISO 15189:2012 / JCI Standards AOP.5			

Primary aldosteronism (PA) investigations (Pre-analytical)

Aldosterone, Renin and Aldosterone: Renin ratio (ARR) are screening tests and

confirmatory testing is advised if results are abnormal or equivocal.

PATIENT PREPARATION

No need to fast.

Best practice is to **WITHDRAW** agents that **MARKEDLY** affect ARR as per below;

		nsive Therapies	
Volume	Loop diuretics (K*-wasting diuretics)	furosemide	stop 4wk prior to ARR, SIT, AVS
management	Thiazide diuretics	<u>bendroflumethazide</u>	
	K ⁺ -sparing diuretics (incl aldo antagonists)	spironolactone, amiloride, triameterene, eplerenone	stop 4wk prior to ARR, SIT, AVS
RAAS agents	ACE inhibitors	captopril, ramipril	stop 2 weeks prio
	Angiotensin II receptor blockers (ARBs)	isostartan	to ARR, SIT, AVS
	Renin inhibitors	aliskiren	
Direct cardiac	β-blockers	metoprolol, nebivolol, bisoprolol	stop 2wk prior to ARR, SIT, AVS
blockers	non-dihydropyridine Ca*+ channel blockers (selective for myocardium)	verapamil*	
Vasodilators	dihydropyridine Ca ⁺⁺ channel blockers (selective for vascular smooth muscle)	amlodipine, nifedipine, lercanidipine	stop 2wk prior to ARR, SIT, AVS
	α1 adrenergic antagonists	doxazosin*	

*Suitable for temporary management of HTN in patients undergoing ARR, SIT and AVS. All others likely to alter renin and aldosterone levels and confound results.

MUST correct severe hypokalaemia (< 3.0 mmol/L) first, as hypokalaemia will reduce aldosterone secretion.

Patient should be ambulatory / upright (sitting, standing or walking) for at least 2 hours

prior to the test, however samples best taken between 07:00 – 09:00 hrs during the diurnal

peak of aldosterone secretion, then seated for 15 minutes.

Ensure NORMAL hydration and ADEQUATE salt intake – not restriction.

If you wish to screen a patient whilst on medications please note the medications on the request form.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Drug (minimal effect on ARR)	Class
Verapamil slow release	Non-dihydropyridine calcium antagonist
e.g. Isoptin SR 120 mg OD to max dose 240	
mg BD	
Doxazosin	Alpha-adrenergic blocker
e.g. Cardura XL (doxazosin prolonged	
release) 4 mg OD to max dose 8 mg OD	
e.g. Cardura (doxazosin) 16 mg OD max dose	
Prazosin hydrochloride (not commonly used)	Alpha-adrenergic blocker
e.g. Minipress	
Terazosin	
Hydralazine (unlicensed)	Vasodilator
e.g. Hydralazine 25 mg BD to max dose 100	
mg BD (greater doses may provoke lupus-	
like reaction	

Table 9: Drugs that have minimal effects on ARR and can be used to control hypertension during screening and confirmation tests for PA.

Drug	Effect	Effect on ARR
Hypokalaemia	↑renin ↓aldosterone	↓ (FN)
Potassium loading	↓renin ↑aldosterone	个 (FP)
Sodium restricted	个个 renin 个aldosterone	↓ (FN)
Sodium loaded	$\downarrow \downarrow$ renin \downarrow aldosterone	个 (FP)
ACEI / Angiotensin II receptor antagonist (ARB) e.g. ramipril, losartan	↑renin ↓aldosterone	↓ (FN)
Mineralocorticoid receptor antagonists (K+ sparing diuretics) e.g. spironolactone, eplerenone Stop 6 weeks	个个renin 个aldosterone (variable effect)	↓ (FN)
K+ sparing diuretics e.g. amiloride	个个renin 个aldosterone	↓ (FN)
K+ wasting diuretics e.g. furosemide	个个renin 个aldosterone	↓ (FN)
Renin inhibitors	$\uparrow \downarrow$ renin* \downarrow aldosterone	
Interferes with the catalytic action of renin & prevents conversion of angiotensin to angiotensin 1	* renin inhibitors raise DRC (direct renin concentration) ↑ renin* ↓aldosterone	DRC ↓ (FN)

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Drug	Effect	Effect on ARR
	* renin inhibitors lower PRA	PRA 个 (FP)
Effect depends on how renin is	(plasma renin activity)	
measured	\downarrow renin* \downarrow aldosterone	
βeta-blockers	↓↓renin ↓aldosterone	个 (FP)
e.g. metoprolol		
Dihydropyridine calcium channel	\uparrow renin \downarrow aldosterone (acutely)	↓ (FN)
blockers		
e.g. amlodipine, nifedipine	? No effect long term	
NSAIDs	↓↓renin ↓aldosterone	个 (FP)
e.g. diclofenac		
Oestrogen-containing oral	\downarrow DRC and causes false positive	个 (FP)
contraceptives and HRT	ARR , 个aldosterone	
Central alpha-2 agonists	↓↓renin ↓aldosterone	个 (FP)
e.g. clonidine, α-methyldopa		
SSRIs	个个renin 个aldosterone	↓ (FN)
e.g. sertraline, escitalopram		
Advancing age	↓↓renin ↓aldosterone	个 (FP)
Pregnancy	个个renin 个aldosterone	↓ (FN)
Renovascular hypertension	个个renin 个aldosterone	↓ (FN)
Renal dysfunction	↓renin ↑aldosterone	个 (FP)
Malignant hypertension	个个renin 个aldosterone	↓ (FN)
Pseudohypoaldosteronism type 2	↓renin – aldosterone	个 (FP)

Table 10: Factors that may affect ARR and thus lead to false positive (FP) or false negative(FN) results.

PERFORMING TEST (aldosterone and renin) (note for phlebotomy)

Sit patient quietly for 15 minutes prior to venepuncture.

Take a blood sample: one EDTA plasma tube for **BOTH** aldosterone and renin. Send sample

URGENTLY to lab (within half an hour).

Note: DO NOT USE ICE for renin samples: ice will cause cryoactivation (conversion of

prorenin into renin), giving a falsely high apparent renin activity.

Take a serum sample for Sodium (Na⁺) and Potassium (K⁺)

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

INTERPRETATION OF RESULTS

Samples for aldosterone and renin are currently sent to Imperial Trust (Charing Cross

Hospital)

Analyses of aldosterone and renin are performed by liquid chromatography tandem mass

spectrometry methods.

(Turnaround time is 2-3 weeks)

TEST (CHARING CROSS HOSPITAL)	REFERENCE RANGES
Aldosterone (pmol/L)	90 – 700 pmol/L
Plasma Renin Activity (PRA) (nmol/L/hr)	0.5 – 3.5 nmol/L/hr
Aldosterone Renin Ratio (ARR)	 < 680: Primary Hyperaldosteronism unlikely > 850: Primary Hyperaldosteronism possible, investigate further > 1700: Primary Hyperaldosteronism very likely

The presence of an elevated Aldosterone Concentration > 400 pmol/L occurring together with a positive ARR increases the sensitivity and specificity to about 90%.

Normal or high renin excludes the diagnosis of PA in almost all cases. Consider secondary hyperaldosteronism with high renin.

A suppressed renin with normal aldosterone level may be pathological.

Interpretative comments are provided on reports.

If you wish to screen a patient who is taking anti-hypertensive medications, please inform the laboratory and results can be interpreted with respect to the specific medications.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

INTERPRETATION OF PATIENTS RESULTS WHO REMAIN ON ANTI-HYPERTENSIVE

MEDICATIONS

Please document all anti-hypertensive, diuretic and NSAID medications that a patient is receiving.

It is important to note that anti-hypertensive medications can potentially cause falsenegative results, no medication can cause fasle positive results when a cut-off for aldosterone is used.

Calcium channel blockers and α 1-adrenergic receptor blockers, potassium-sparing diuretics (amiloride and triamterene) do not affect the diagnostic accuracy in most cases.

Interpretation of results in patients receiving ACEi and ARBs;

ACEi and ARBs have the potential to elevate PRA in patients with mild PA

A PRA level ≥0.5 nmol/L/hr or a PRC that is not suppressed in a patient taking an ACE

inhibitor or ARB does not exclude the diagnosis of PA

A PRA level <0.5 nmol/L/hr or a PRC below the reference range in a patient taking an ACE inhibitor or ARB is diagnostic of low-renin hypertension and possible PA

Interpretation of results in patients receiving MRAs;

MRAs (spironolactone and eplerenone) prevent aldosterone from activating the receptor,

resulting sequentially in sodium loss, a decrease in plasma volume and an elevation in renin which will reduce the utility of the ARR

If PRA (or Plasma Renin concentration (PRC)) is not suppressed in a patient treated with an MRA, then no further PA-related testing can be performed and the MRA should be discontinued for 6 weeks before re-testing

However, If the patient is hypokalaemic despite treatment with MRA, then the mineralocorticoid receptors are not fully blocked and PRA (or PRC) should be suppressed in such a patient with PA

In addition, most patients with PA who are treated with mineralocorticoid receptor antagonists are given sub-therapeutic doses. Thus, PAC and PRA should be measured in

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

patients treated with MRA, and if PRA is suppressed, these medications are not interfering

Thus, if PRA is suppressed, case-detection testing, confirmatory testing, and adrenal vein sampling (AVS) can be performed without discontinuing the mineralocorticoid receptor antagonists

Phaeochromocytoma/paraganglioma (PPGLs) investigations (Pre-analytical)

Who to test

Patients with hypertension (particularly paroxysmal hypertension)

Patients who present with palpitations, headaches and hyperhidrosis

Those with resistant hypertension

Those with sudden deterioration in BP control

Hypertensive crisis

Adrenal "incidentaloma" with hypertension

Plasma metanephrines have been shown to be superior over other tests in the diagnosis of PPGLs.

Patient preparation and sampling (note for phlebotomy)

Patients should avoid caffeine and smoking for 12 hours (overnight) prior to testing. Fasting is advised if 3-methoxytyramine (dopamine metabolite) is being assessed. If a patient has not fasted and has had caffeine (or nicotine) please proceed with taking the samples and note this on the request form.

Because some medications only increase the likelihood of false-positive results their withdrawal prior to testing is not necessary but should be discussed if unexpected elevated results are found. It is necessary to LIST current medications on the request form to the biochemistry lab for informed interpretation of results.

Patient should be seated for 15 minutes prior to venepuncture.

Plasma metanephrines taken into EDTA blood tube and placed **ON ICE** or brought directly to the laboratory and given to the medical scientist to be separated.

Plasma metanephrines, normetanephrine, metanephrine and 3-methoxytyramine are

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

performed using liquid chromatography with tandem mass spectrometry (LC-MS/MS) at the Clinical Biochemistry Laboratory, Mater University Hospital.

In certain circumstances urine metanephrines may be tested but plasma metanephrines are superior.

Urine metanephrines (24-hour collection) are currently analysed at the Clinical Biochemistry Dept., RVI, Newcastle-on-Tyne, UK.

There is no additional role in the measurement of plasma or urine catecholamines in evaluating an adult with hypertension and requests for catecholamines will be analysed for metanephrines.

INTERPRETATION OF PLASMA METANEPHRINE RESULTS

Plasma methanephrines have a sensitivity of (99%) and specificity of (89%) in the diagnosis of phaeochromocytoma.

Plasma reference interval (seated) Metanephrine: 61 – 377 pmol/L Normetanephrine: 182 – 867 pmol/L 3-Methoxytyramine (3-MT): < 185 pmol/L

Note: MPH and MMUH reference range is established in seated patients as supine generally impractical for phlebotomy.

It was difficult to get healthy older subjects for reference range studies and the upper reference limit may be higher in older age groups.

MEDICATIONS AND DIETARY INTERFERENCES

The most troublesome causes of false-positives results are from medications that block neuronal uptake of catecholamines, including TCAs and related drugs used to treat depression, neuropathic pain and other conditions.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

The following drug classes may cause false-positive results through pharmacophysiological

effects on plasma metanephrine assessment.

Drug	Examples
TCAs	Amitriptyline, clomipramine, dosulepin
SSRIs	Citalopram, fluoxetine, sertraline
Serotonin/Norad reuptake	Venlafaxine, duloxetine
inhibitors	
Monoamine oxidase	Isocarboxazid, phenelzine, selegiline
inhibitors	
α-adrenergic receptor	Phenoxybenzamine, doxazosin, indoramin
blockers	
Stimulant/Sympathomimetics	Amphetamine, cocaine, nicotine, caffeine

Major physical stress can also increase metanephrines.

ANALYTICAL INTERFERENCES

Although analytical interferences are minimised when LC-MS/MS is the technology utilised to measure plasma (and urine) metanephrines, there is evidence of interference from the vasopressor midodrine with this method.

INTERPRETATION OF RESULTS

Elevated results should be interpreted with knowledge of a patient's medications.

The most common causes of false-positive results for measurement of plasma metanephrines is associated with sympathoadrenal activation, this can occur when blood sampling is performed when the patient is seated rather than supine.

Where it is not feasible to investigate all patients in a supine position, those with unexplained elevated metanephrine results should have blood drawn after an overnight fast and following 30 minutes of supine rest. Studies have shown that testing in supine position reduces the false positive rate from 18.3% to 3.3%.

If you have received results that are above the upper reference interval and you wish to discuss medication effects on results or you wish to repeat the testing in a supine patient,

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

please contact Prof Maria Fitzgibbon. Please note that reference intervals for supine testing are different to seated reference intervals and we must be aware of this for appropriate interpretation.

Contact Details

Clinical Biochemistry Laboratory Phone: 01885 8134

Gerry Cox, Chief Medical Scientist, email: gerry.cox@materprivate.ie

Colm Carolan, Senior Medical Scientist, email colm.carolan@materprivate.ie and

Grace Creighton, Senior Medical Scientist, email grace.creighton@materprivate.ie


Professor Maria Fitzgibbon, Consultant Clinical Biochemist Phone: 01 885 8888 Email: mariafitzgibbon@materprivate.ie

Dr Roger Byrne, Consultant Cardiologist email: roger.byrne@materprivate.ie

References

Young W F Diagnosis and treatment of primary aldosteronism: practical and clinical perspectives Journal of Internal Medicine 285; 2019, 126-148 2019 Eisenhofer G and M Peitzsch Laboratory evaluation of Phaeochromocytoma and Paraganglioma Clinical Chemistry 2014, 1486-1499 International Society of Hypertension Global Hypertension Practice Guidelines 2020 ESC/ESH Clinical Practice Guidelines for the Management of Arterial Hypertension 2018

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	



Basic testing algorithm


Appendix 2

Interpretation of previous results from method used to investigate aldosterone and renin at Mater University Hospital (2016- 2019)

TEST (MMUH – SUSPENDED)	REFERENCE RANGES
Aldosterone (pmol/L)	Males: < 1 – 670 pmol/L
	Females: < 138 – 1179 pmol/L
Direct Renin Concentration (mIU/L)	Males: 9.0-103.5 mIU/L
	Females: 6.1 – 62.7 mIU/L
Aldosterone Renin Ratio (ARR)	ARR
	 < 30: Primary Hyperaldosteronism
	unlikely
	 30 – 37: Possibly primary
	Hyperaldosteronism, investigate
	further
	 > 37: Primary Hyperaldosteronism
	more likely, investigate further

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

The reference ranges in the table below were established in a cohort of 207 ambulatory individuals at MMUH and GUH, aged \geq 18 years, BMI < 30kg/m2, BP < 140/90, normal renal function and not taking any medications.



Protocol devised by Professor Maria Fitzgibbon, Consultant Clinical Biochemist and Dr Roger Byrne, Consultant Cardiologist, Mater Private Network

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

4.18 Interfering Substances

Many tests are subject to interference. This may be biological , where the offending substance alters the true concentration within the body, or analytical, where the method is not specific. The report will outline the more common interfering substances such as haemolyis, Icteria (bilirubin interference) and Lipaemia. Depending on the degree of interference, some assays may not be reportable.

Factors in performing venepuncture, which may account for haemolysis include:

- Using a needle with a small diameter.
- Using a small needle with a large vacutainer tube.
- Using an improperly attached needle and syringe so that frothing occurs as the blood enters the syringe.
- Pulling the plunger of a syringe back too quickly.
- Shaking or vigorous mixing of blood collection tubes.
- Forcing blood from a syringe into a blood collection tube, especially through a needle.
- Failure to allow the blood to run down the side of the tube when using a syringe to fill the tube.
- Failure to allow alcohol swab to dry.
- Drawing from site of haematoma.
- Very slow flow into tube.
- Drawing blood from indwelling line.

4.19 Critical Alert Values

Critical level results from the Biochemistry Department must be phoned immediately to requestor when results become available so that intervention may take place promptly. Ensure to document name of member of staff notified of critical result on WinPath phone log. Once a critical value has been phoned to the Nurse or doctor looking after that patient

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

subsequent critical test results for the patients stay/episode are no longer phoned but still logged on WinPath as Not Required- Patient under observation'.

All phoned critical results must be phoned immediately when results become available so that intervention may take place promptly and must be logged on the LIS including name of attending nurse/doctor. It is the aim of the laboratory to ensure these critical / alert values reach the clinical team within 30 minutes of the result being reported where possible. The process for phone a critical result is as follows:

- Phone the ward mobile phone/requesting source with the critical result within 30 minutes.
- 2. If uncontactable, repeat process two further times.
- 3. If no response from the ward mobile phone/requesting source, contact the CNM over the area (EX-GEN-233).
- 4. If the CNM is uncontactable, phone the clinical site manager (EX-GEN-233) and raise a non-conformance against the ward on Q-Pulse.

Always record the following details in the WinPath phone log when critical /alert values are notified to the ward:

- 1. Name of staff member phoning the result
- 2. Name of member of staff notified of critical result
- 3. Time phoned to the ward

Note: The name of member of staff phoning result and time phoned is captured on entry of details to Winpath phone log. Ensure to save entry after details have been entered.

In the event that the medical scientist is unable to make contact with the requesting clinician or clinical personnel responsible for patient, for example in an outpatient capacity, the medical scientist must contact the Consultant Biochemist on-duty.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

For the most up to date Critical Alert Values, please see the home page of the Hospital Intranet / Lab Handbook & Critical Alert Values. If you are unable to access the intranet, please contact the relevant department.

Ref.: LS-BIO-0020 Clinical Authorisation and Reporting of Results in the Biochemistry Department, WI-BIO-0005 Biochemistry Critical Values and LS-GEN-0005 Reporting of Results

4.19.1 Uncertainty of Measurement

Many factors contribute to the uncertainty of results produced by automated instruments. Factors that contribute to the uncertainty would include, but are not limited to:

(1) **Pre-analytical factors:** for example phlebotomy technique, sample transportation and sample storage prior to analysis. While these need to be considered, they are variables that are beyond the scope of this procedure and will not be discussed further.

(2) **Analytical factors:** uncertainty of measurement due to variables in the reagents, calibrators, controls and sample handling (pipetting, tubing, sample cuvettes) by the instrument. These variables are the subject of this procedure.

The Uncertainty of Measurement is available for each analyte on request from the Biochemistry Dept.

<u>Please note that patients should avoid taking any Biotin supplements for 24 hours prior to</u> <u>testing as Biotin can cause assay immunoassay interferences on Roche instruments.</u>

Biochemistry Laboratory contact details: Ph: 885 8134 Clinical advice: Professor Maria Fitzgibbon, Consultant Clinical Biochemist, Ph MPH switchboard or Clinical Biochemistry Dept.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

5. IMMUNOLOGY/SEROLOGY

5.1 General

Immunological tests can be graded according to their usefulness in patient care. Some tests are essential for diagnosis and monitoring of disease activity and some are useful for routine investigation. The following table contains a repertoire of tests analysed in the immunology department.

Serology testing is carried out within the Immunology department.-see section 5.4 1 for repertoire of serology tests.

TEST	ABBR.	SPECIMEN	SPECIAL	TAT	REFERENCE	Source
		VOLUME	PRECAUTIONS		RANGES	
Cryoglobulin	CRYG	2 x 7.5ML clotted 1 x 2.7ml	Contact phlebotomist regarding special	1 Week	Positive/Negative	N/A
		EDTA	requirements			
Immunoglobulin s	IMG	7.5ml clotted	Spin and store at 2-8°C	1 Week	lgG 6.10-16.16g/L lgA 0.85-4.99 g/L lgM 0.35-2.42g/L	The Binding Site
Protein Electrophoresis	PEL PEL	7.5 ml clotted	Spin, separate and store at 2-8°C	1 Week	Total Protein 64-82	Sebia
Quantitative Paraprotein					g/L Albumin 35-50 g/L Alpha-1 1-2 g/L Alpha-2 6-9 g/L Beta-1 4-7 g/L Beta-2 2-5 g/L Gammaglobulin 6- 13 g/L Interpretative comment	
Immunofixation	IEP	7.5 ml	Spin, separate and	2 Weeks	Interpretative	N/A
of serum.		clotted	store at 2-8°C		comment	

5.2 Repertoire of Tests - Immunology

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007				
26/09/2023					
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023				
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

TEST	ABBR.	SPECIMEN VOLUME	SPECIAL PRECAUTIONS	ТАТ	REFERENCE RANGES	Source
Bence Jones Protein	BJP	24 hr urine collection (Plain Container)	Urines should be fresh for analysis and stored at 2- 8°C. A 24 Hour collection is preferable. An early morning urine specimen may be analysed. However, if Bence Jones protein is present it cannot be quantified.	1 Week	Positive/Negative	N/A
Immunofixation of urine	IEP	24 hr urine collection (Plain Container)	As Above	2 Weeks	Interpretative Comment	N/A
Serum Free Light Chains	SFC	7.5ml clotted	Spin, and store at 2-8°C	1 week	Kappa: 3.3-19.40 mg/L Lambda: 5.71-26.30 mg/L K/L Ratio: 0.26-1.65	The Binding Site
Beta-2 Microglobulin	B2MG	7.5ml clotted	Spin, and store at 2-8°C	1 week	0.8-2.4 mg/L	The Binding Site
Autoantibody Tests (Phadia Analyser	CELE ANC GBM CTD ENAS DNAA M2AB PCAB INTA	4.9ml clotted	Spin, and store at 2-8°C	1 week	Positive/Negative	Phadia

Table 11: Repertoire of Immunology Tests

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007				
26/09/2023 Reviewed by: Fiona Errity	Date of Issue: 26/09/2023				
26/09/2023	Date of issue. 20/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

5.2.1 Specific Proteins

5.2.1.1 Immunoglobulin Levels

Immunoglobulins are formed as a humoral response to contact of the immune system with antigens. The initial reaction is production of IgM antibodies, followed later by IgG and IgA antibodies. Quantitative determination of immunoglobulins can provide important information on the humoral immune system. All requests for immunoglobulin levels automatically include protein electrophoresis analysis. One exception is oncology patients where protein electrophoresis has been performed on the initial specimen and the oncology clinician requires only the immunoglobulin levels on subsequent specimens.

5.2.1.2 Protein Electrophoresis

Serum or urine may be screened for protein abnormalities using protein electrophoresis. Serum can be separated into well-defined fractions by electrophoresis, stained and the stained electrophoretic separations can be evaluated visually for pattern abnormalities. Urine specimens can be run for the detection of Bence Jones proteins. Combined with the quantification of serum total protein and immunoglobulin levels, protein electrophoresis is an essential aid to the diagnosis and therapeutic follow-up of acute diseases especially the malignant monoclonal gammopathies and immunoglobulin level cuantitation.

5.2.1.3 Immunofixation

Immunofixation is the procedure for typing paraproteins according to their heavy and/or light chains. If a paraprotein is detected following protein electrophoresis, the laboratory proceeds with typing and quantitation. There is no indication for the routine request for immunofixation.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007				
26/09/2023					
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023				
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

5.2.1.4 Serum Free Light Chains

Measurement of serum free light chains aids in the diagnosis and monitoring of multiple Myeloma, Lymphocytic neoplasms, Waldenstroms macroglobulinaema,, AL amyloidosis, light chain deposition disease and connective tissue disease.

5.2.1.5 Beta 2 Microglobulin

Beta 2 Microglobulin is a protein found on the surface of most nucleated cells. It is eliminated through the kidneys. Normally only trace amounts are excreted in the urine, however this is markedly increased in tubule-interstitial disease. Raised levels of Beta 2 Microglobulin are associated with renal disease and rheumatoid arthritis, Systemic Lupus Erythematosus , malignant lymphoma and myeloma.

5.2.2 Autoantibody Screening

5.2.2.1 Coeliac Screening

Tissue transglutaminase has been identified as the major autoantigen in coeliac disease. IgA antibodies against tTG are highly disease specific serological markers for coeliac disease and dermatitis herpetiformis. Samples are screened for Anti-tTG and referred for Endomysial antibodies if positive

5.2.2.2 ANCA/GBM (Vasculitis) Screening

If autoimmune vasculitis is suspected, samples can be screened for anti neutrophil cytoplasmic antibodies (ANCA) which involves testing for antibodies to Proteinase 3 (PR3)/ Myeloperoxidase (MPO) and if required, antibodies to glomerular basement membrane (GBM).

 Antibodies to PR3 are highly sensitive and specific for granulomatosis with polangiitis (GPA/ Wegener's granulomatosis). Antibodies to PR3 can also be an indicator of microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA/ Churg-Strauss syndrome). PR3 antibodies may also occur in patients with necrotizing glomerulonephritis (NCGN).

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

- Antibodies to MPO can be found in patients with NCGN without immune deposits (pauci-immune), NCGN associated with systemic vasculitis, either GPA/ Wegener's granulomatosis or MPA and in EGPA/ Churg-Strauss syndrome).
- Antibodies to GBM can be fount in patient's with Goodpasture Syndrome, Anti-GBM disease and ANCA associated vasculitis.

5.2.2.3 Connective Tissue disease Screening

The determination of antinuclear antibodies (ANA) is of central importance for the clinical diagnosis of connective tissue diseases (CTD), which are systemic inflammatory diseases with a chronic course of disease. Connective tissue diseases exhibit overlapping symptomatic features that render an accurate diagnosis difficult. The CTD, Extractable nuclear antigen (ENA) and double stranded DNA (dsDNA) screens are intended for the in vitro qualitative measurement of antinuclear IgG antibodies in human serum and plasma as an aid in the clinical diagnosis of CTD's such assystemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjögren's syndrome, scleroderma and polymyositis/dermatomyositis. Samples are screened using the CTD screen and are referred for an ENA and a dsDNA screen if positive.

5.2.2.4 Inflammatory Arthritis Screening

Samples from patients with suspected inflammatory arthritis can be screened for Rheumatoid Factor (RhF) and cyclic citrullinated peptide antibodies (Anti-CCP).. Both antibodies are an indicator of rheumatoid arthritis and can be used in the diagnosis and prognosis of the disease.

5.2.2.5 <u>Autoimmune liver antibody screening (Anti-M2/Anti-LKM)</u>

- Mitochondrial antibodies (Anti-M2) are useful in the diagnosis of Primary Biliary Cirrhosis (PBC)
- Liver Kidney Microsomal antibodies (Anti-LKM) can be useful in the diagnosis of autoimmune liver diseases such as autoimmune hepatitis type 2 (AIH-2)

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007				
26/09/2023					
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023				
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

5.2.2.6 Parietal Cell/Intrinsic Factor antibodies

Parietal cell and intrinsic factor antibodies (Anti-PCA & Anti-IF) are useful in the diagnosis and prognosis of pernicious anaemia.

5.3 Specimen Stability

5.3.1 Serum Specimen Requirements

Immunology serum specimens are spun and stored at 2-8°C. Samples are discarded 48 hours after the final report has been issued. separated and stored frozen for approximately 1 month after the date of receipt. Additional tests can be requested up to 48 hours after the final report has been issued. The exception to this is cryoglobulin testing For cryoglobulin assay the unclotted specimen should be taken immediately to the laboratory and allowed to clot at 37°C because cryoglobulins may precipitate at ambient temperature and be lost in centrifugation.

Urine Specimen Requirements:

A morning void is sufficient for the <u>detection</u> of BJP but a 24 hr collection is necessary for <u>quantitation</u>.

5.3.2 24 Hour Urine Collection Instructions

Urine containers are available in the Pathology Laboratory.

Accurately timed, complete urine collections are a vital part of many tests, Careful attention to detail, especially by the ward, is necessary. See Table 11 for tests which require 24 hours urine collections.

Obtain a urine container. Choose a convenient time to start the collection usually in the early morning, e.g. 8am. If collecting on a ward, it is convenient to have a routine time for starting all collections. If results are required on the day of completion, specimens must be received in the laboratory by 10am.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007				
26/09/2023					
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023				
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

<u>Day 1</u>

- 8am
- Ask the patient to empty their bladder completely and discard this specimen. Thereafter collect all urine passed into this container for the next 24 hours.

<u>Day 2</u>

- 8am
- Ask the patient to empty their bladder completely and add this specimen to the collection.
- Collect no more urine.
- Ensure the sample is fully labelled:
 - a) PATIENT'S FULL NAME
 - b) DATE OF BIRTH
 - c) HOSPITAL NUMBER/ MRN
 - d) START TIME AND DATE OF COLLECTION
 - e) FINISH TIME AND DATE OF COLLECTION

Notes

- 1. Ensure that urine and faeces are passed separately.
- 2. If the container is full before completion of collection, use a second one and send both to the laboratory. Label containers 1 of 2, 2 of 2 etc.
- 3. If any specimen of urine is not collected or accidentally discarded during the collection, discontinue the test and start again
- 4. Patients should be cautioned not to urinate directly into a bottle containing acid preservative. Below is a list of the appropriate containers for use for each test:

The container should be stored in the refrigerator during the collection. For 24 hour specimens the request form should state the start time and end time of the collection. If more than one container is used over this period they should be sent to the lab together once the collection is finished.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007				
26/09/2023					
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023				
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

5.4 Serology

5.4.1 General

Serology tests can be used to diagnose infections by assessing the patient's antibody response to a particular infective agent. The department offers a comprehensive range of serological screening investigations (Syphilis, HIV, Hepatitis A, B and C). The service is for the purposes of screening specimens including pre-dialysis screening, routine dialysis screening, visa applications, insurance purposes, pre-adoption screening, college applications, staff samples etc. The laboratory also offers an urgent 24 hour needle stick injury service (5.5 Emergency Service)- consent for Needle stick injury specimens from the patients will be obtained at ward level Any clinically relevant reactive specimens will be forwarded onto the National Virus Reference Laboratory for confirmatory testing.

TEST	ABBR.	SPECIMEN VOLUME	SPECIAL PRECAUTIONS		REFERENCE RANGES	Source
HIV	HIV		Spin and store	3 Days	Positive/Not	Roche
Hepatitis A	HEPA		at 2-8°C		detected	
Hepatitis B	НЕРВ					
(HBsAg)						
Anti-HBc	НВС					
Hepatitis C	HEPC					
Syphillis	SYPH					
Anti-HBs	НВТ	7.5 ml clotted	Spin and store	3 Days	<10 IU/mL:	Roche
			at 2-8°C		Not Detected	
					(If vaccinated this	
					patient has not	
					responded to	
					vaccination	
					> 10 lu/mL	

5.4.2 Repertoire of Tests

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007				
26/09/2023					
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023				
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

TEST	ABBR.	SPECIMEN VOLUME	SPECIAL PRECAUTIONS	ΤΑΤ	REFERENCE RANGES	Source
					Positive	
					Adequate Anti-HBs	
					response. No need	
					for further	
					testing)	

Table 12: Repertoire of Serology Tests

5.4.3 Serum Specimen Requirements

Serology serum specimens are spun and stored at 2-8°C. Samples are discarded 48 hours after the final report has been issued. separated and stored frozen for approximately 1 month after the date of receipt. Additional tests can be requested up to 48 hours after the final report has been issued.

5.5 On-Call Service Repertoire in Immunology

The Immunology Laboratory offers an urgent 24 hour service for needle-stick injury **source** specimens. In the event of a needlestick injury with **a known source**, the laboratory must be contacted directly and informed that there is an urgent specimen on the way. The **source** specimens are processed immediately and the Occupational Health Department are informed immediately of any reactive specimens. All other requests (including samples from a needlestick injury with **an unknown source**) can be processed during routine laboratory hours.

5.6 Critical Values in Immunology

For the most up to date Critical Alert Values, please see the home page of the Hospital Intranet / Lab Handbook & Critical Alert Values. If you are unable to access the intranet, please contact the relevant department.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

6. HAEMATOLOGY

6.1 General Information

The procedures carried out in the Haematology Dept broadly fall into the categories of:

- (i) Screening a blood specimen for an abnormality
- (ii) Making a diagnosis of a blood disorder
- (iii) Investigating in detail a patient in which a tentative diagnosis of a particular blood disorder has been made and subsequent treatment is warranted, initiated, to be monitored.

6.2 Test Repertoire

Test	Abbr.	Specimen Type	Turn Around Time	Reference Ranges	Source
Activated Partial Thromboplast in Time	APTT	Na Citrate 9NC 3 ml	2 Hours	25.1-32.9 seconds	Established in lab
Correction Studies		Na Citrate 9NC 3 ml	½ Day	Reduction of Original Results (secs)	N/A
D Dimers		Na Citrate 9NC 3ml	2 Hours	<0.50ug/ml	Established in lab
Differential		K EDTA 2.7 ml	Same Day	6 years 2.00-6.00 x 10 ^{9/} L	Dacie and Lewis Practical Haematology

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Test	Abbr.	Specimen Type	Turn Around Time	Reference Ranges	Source
				<u>BASO</u> 0.00-0.10 x 10 ⁹ L	
Erythrocyte Sedimentatio n Rate	ESR	Na Citrate 4NC 3.5	2 Hours	0-10 Male 0-20 Female	
Fibrinogen		Na Citrate 9NC 3 ml	2 Hours	2.0-4.0 g/l.	
Full Blood Count	FBC	K EDTA 2.7 ml	1 Hour	WBC 12 years $4.5-13.5 \times 10^{9/L}$ Adult $4.00-11.00 \times 10^{9/L}$ RBC 12 years $4.00-5.40 \times 10^{12/L}$ Adult $(f)3.80-5.80 \times 10^{12/L}$ Adult Adult $(f)3.80-5.80 \times 10^{12/L}$ Adult Adult $(m)4.50-6.50 \times 10^{12/L}$ Adult HGB 12 years $11.5-14.5 \text{ g/dL}$ Adult (f) $11.5-16.5 \text{ g/dL}$ Adult (f) $13.0-18.0 \text{ g/dL}$ Adult (m) $13.0-18.0 \text{ g/dL}$ HCT 12 years $0.37-0.47 \times L/L$ Adult (f) $0.37-0.47 \times L/L$ Adult (m) $0.40-0.54 \times L/L$ MCV 12 years $77.0-91.0 f/L$ Adult $80.0-100.0 f/L$ MCH 12 years $24.0-30.0pg$ Adult $28.0-32.0pg$ MCHC	Dacie and Lewis Practical Haematology
International Normalised Ratio	INR	Na Citrate 9NC 3 ml	2 Hours	Determined by clinical state	N/A
Blood Film Review		-	2 Working Days	N/A	N/A

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Test	Abbr.	1.	Turn	Reference Ranges	Source
		Туре	Around		
			Time		
Iron Stain		Bone	2 Working	Reduced/Normal/Raised	N/A
		Marrow	Days		
		Aspirate			
		Slide			
Prothrombin	РТ	Na Citrate	2 Hours	11.4-15.0 seconds	Established in lab
Time		9NC			
		3 ml			
Reticulocytes		K EDTA	Same Day	35-132x109/L	Dacie and Lewis
		2.7 ml			Practical
					Haematology
Sickledex		K EDTA	Same Day	Positive/Negative	N/A
		2.7 ml			

Table 13: Repertoire of Haematology Tests

Malarial Screens are sent for referral testing to MMUH.

The Medical Scientists and medical staff provide a wide range of test results. The provision of clinical details and discussion of problems contribute to a good service.

6.3 Handling Urgent Specimens

To achieve an overall effective service urgent requests are kept to a minimum and are

essentially those necessary for the immediate clinical management of the patient.

Time limits of analysis, while documented are monitored through turnaround times,

reflecting actual practice and addressed locally to meet service needs.

In the Haematology department a number of sources are given priority i.e. Day Oncology,

Intensive Care Unit, ED, Chest Pain

• The Sickle Screen test is treated as urgent

All other specimens will be processed routinely unless

- The request form is clearly marked URGENT
- Direct contact has been made with the laboratory by the Clinician/ healthcare professional with responsibilities for care of the patient.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- The Clinician/healthcare professional must agree
 - Which tests are necessary
 - The target time for completion
 - Where reports are to be directed
 - Method of report acquisition-
 - hard copy through the chute
 - Look up on the WinPath system
 - A phoned report

6.4 Information about Haematology Tests

- 1. Full Blood Count (FBC), results given for white cell count including differential, red cell counts, haemoglobin, haematocrit (HCT) red cell indices and platelet count.
- 2. From the results of red cell indices, anaemia can be classified as normochromic, hypochromic, microcytic or macrocytic and further investigations organised.
- 3. Phoned reports are kept to a minimum as they are available on-line.
- 4. Blood film will be examined if requested with relevant clinical information or if indicated by the FBC. In the presence of a normal FBC, there are few indications for routine film examination e.g. possible infectious mononucleosis.
- Reticulocyte counts are useful to check for increased red cell production e.g. haemorrhage, haemolysis, haematinic therapy (iron, V. B12 or folic acid) or investigating unexplained anaemia.
- Eosinophil counts will be determined with the differential and expressed as an absolute number. A variety of conditions can lead to an increased count e.g. hypersensitivity states, parasitic infections or skin disease.
- 7. Erythrocyte sedimentation rate (ESR) is not a reliable test for confirming health or diagnosing disease. It has a role indicating inflammation and following the effects of therapy e.g. giant cell arteritis (GCA). Except in the case of GCA it is not an emergency test.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- 8. Bone marrow studies aspirate, trephine smear, sections and karyotype have a major role investigating macrocytosis, leukaemia etc. Unless skilfully performed these procedures can be unnecessarily painful, dangerous and unsuccessful. Spreading of marrow aspirate is difficult. Please arrange with haematology medical staff.
- 9. Coagulation studies can be confusing if their management is not informed. For the most reliable results, blood must be in the laboratory within one hour of sampling and not taken from heparinised I.V. lines or bungs.
- 10. PT/INR, APTT, fibrinogen and FBC (for platelet count) are the most frequently used tests for initial screening of haemostasis.
- 11. D-Dimers are a reliable indicator of thrombosis.
- 12. INR monitors anticoagulant therapy with Vit. K antagonists. The INR will also be prolonged with excess heparin anticoagulation, disseminated intravascular coagulation (DIC) and in rare coagulation factor deficiencies e.g. Factor VII.
- 13. APTT is the most useful measure of heparin therapy. APTT results should be 1.5 to 2.5 times patient's baseline value or the midpoint of the reference range. Prolonged values in moderate to severe haemophilia, Christmas or Von Willebrand's disease. Rarely DIC or circulating anticoagulants e.g. lupus are found to cause prolonged values.

6.5 Time Limits for Requesting Additional Examinations

TEST/ EXAMINATIONS	TIME LIMIT (FROM ORIGINAL SPECIMEN RECEIVED)
Reticulocyte Count	8 hours
Blood Film	Same day as collection
Sickle Cell Testing	48 hours @ 2-8 degrees
Correction Studies	4 hours
D-Dimers	8 hours@ RT
PT/APTT/INR	4 hours
Fibrinogen	8 hours

Table 14: Time limits for requesting additional tests

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

6.6 On-Call Service Repertoire in Haematology

The following is the repertoire of tests available in Haematology outside of routine working hours

- FBC
- PT/INR, APTT, Fibrinogen, D Dimers.
- Sickle screen are referred externally to the Mater Misericordiae Hospital, once confirmation of the urgency has been confirmed by the healthcare professional looking after the patient.

Note: All other requests are processed during routine laboratory hours.

6.7 Critical Alert Values

Any test results that are significantly outside the normal reference range may indicate a high risk of life threatening condition. Clinical personnel responsible for the patient care will be immediately notified when examination results for critical properties fall within established "critical intervals". This includes results received on specimens sent to referral laboratories. Critical Result criteria: For the most up to date Critical Alert Values, please see the home page of the Hospital Intranet / Lab Handbook & Critical Alert Values. If you are unable to access the intranet, please contact the relevant department.

Ref.: LS-HAEM-0016 The Handling of Specimens in the Haematology Department & WI-HAEM-0001 Haematology Critical Alert Values

In Haematology all requests from Day Oncology, St. Elizabeth's and ITU are processed urgently. All requests that are marked urgent are processed immediately.

6.8 Factors that could significantly affect the performance or interpretation of the result

Haemoglobin: it is important to avoid haemolysis either during or after the collection of the blood specimen, otherwise the result is invalid.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Red cell count: there is a moderate fluctuation during the 24 hours of about 4 per cent probably related to exercise meals and fluid intake etc. Strong emotions such as fear cause a temporary increase in the red cell count.

Platelets: pseudothrombocytopenia due to platelet aggregation (clumping) in EDTA blood may be found . This artefact is of no clinical significance ,can be identified in the laboratory and resolved by supplying Thromboexact specimen for platelet count only.

While red cell white cell and platelet numbers are stable for at least 24hours in EDTA,

progressive morphological changes in a blood film are however inevitable.

Prolonged INR's may be due to relative overdose or increased sensitivity by the patient. This may be a consequence in severe illness, interaction with a potentiating drug, and withdrawal of antagonistic drugs.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

7. BLOOD TRANSFUSION

7.1 General Information

The Blood Transfusion Laboratory performs tests to ascertain the blood group of patients and to determine whether patients' plasma contains antibodies to red cell antigens. The presence of these unexpected antibodies needs to be investigated and the antibody or antibodies must be identified. Compatibility testing is carried out in order that suitable blood components are readily available for surgical patients and patients requiring blood component therapy.

Blood Product	Specimen	Specimen Requi	rements		Where available	Turnaround Time
Туре	Туре	Additive	<u>Volume</u>	<u>Container</u>		
		<u>Required</u>	<u>Required ml</u>	<u>Type</u>		
Red Cells /CMV Neg	Blood	EDTA	7.5	Blood	Blood	3 hours
Irradiated				Tube	Transfusion	
					laboratory	
Type and Screen	Blood	EDTA	7.5	Blood	None	Same Day (2
				Tube		hour if
						requested
						urgently)
Type and	Blood	EDTA	7.5	Blood	None	3hours
Crossmatch (blood				Tube		
group unknown)						
Additional request	Blood	EDTA	7.5	Blood	None	1 hour
for red cells				Tube		
Direct Coombs Test	Blood	EDTA	7.5	Blood	None	Same Day
				Tube		
Transfusion	Blood	EDTA /	7.5	Blood	See Section	7 days
Reaction		clotted/serum		Tube /	7.12	
Investigation		sample		Clotted		
Antibody	Blood	EDTA	7.5	Blood	None	4 hours
Identification				Tube		
Red Cell	Blood	EDTA	7.5	Blood	None	4 hours
Phenotyping				Tube		

7.2 Blood Transfusion Tests

Table 15: Blood Transfusion Repertoire of Tests

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

Note: A Blood grouping report is issued on completion of pre-transfusion testing. Where an antibody(s) have been identified in the patient's plasma and blood may be require for surgery or transfusion, please be aware that additional time will be required for the provision of antigen negative compatible blood.

7.3 Blood Products for Transfusion

* If the patient has a CMV- Irradiated special requirement units may need to be ordered from the IBTS (delivery time approx. 1 hour)

**A Type and Screen sample is required if the blood group has not been previously established by the MP laboratory.

Blood Product	Specimen Type	Specimen Requirements			Where available	Turnaround Time
	Type	<u>Additive</u> <u>Required</u>	<u>Volume</u> <u>Required ml</u>	<u>Container</u> <u>Type</u>		Time
Red Cells /CMV Negative Irradiated*	Blood	EDTA	7.5	Blood Tube	Blood Transfusion laboratory	3 hours (non- urgent) 1 hour (urgent)
Solvent Detergent Plasma** (Octaplas)	Blood	EDTA	7.5	Blood Tube	Blood Transfusion laboratory	30 minutes
Platelets** (Pooled, Apheresis or HLA Matched)	Blood	EDTA	7.5	Blood Tube	Available on request (IBTS)	2 hours
Octaplex	none	none	none	none	Blood Transfusion lab	20 mins
Fibrinogen concentrate	none	none	none	none	Blood Transfusion lab	20 mins
Recombinant VIIa (Novoseven)	none	none	none	none	Available from Blood Transfusion lab on a	20 mins

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

Blood Product	Specimen Type			Where available	Turnaround Time	
	Type	<u>Additive</u> <u>Required</u>	<u>Volume</u> <u>Required ml</u>	<u>Container</u> <u>Type</u>		Time
					limited basis for specific patients following consultatio n with Consultant Haematolog ist	
Albumin	None	None	None	None	Blood transfusion laboratory	20 mins
Coagulation Factor Concentrates e.g. Wilate=VW factor Advate=Factor VIII	None	None	None	None	Available following consultatio n with the Consultant Haematolog ist- ordered in advance	2 – 4 hours

Table 16: Blood products/components available from Blood Transfusion Laboratory

7.4 Description of Blood Components /Products

7.4.1 Red Cells

RCC (red cell concentrate) are supplied by the IBTS. Stock of the various blood groups (A, B, O, AB) is held refrigerated in the Blood Transfusion Laboratory. RCCs have a shelf life of 35 days. Minimum stock levels have been defined; these ensure an adequate supply of blood for routine & emergency use, while at the same time minimise wastage due to outdating. Note: CMV negative, irradiated red cells are stocked on a limited basis, and can be obtained from the IBTS on an as needed basis.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

7.4.2 Platelets

Due to their relative short shelf life (5 days) & challenges surrounding supply these are only ordered from the IBTS as required. To ensure viability they are stored at 22°C on an agitator in the Blood Transfusion laboratory. Once removed from the laboratory, platelets must be transfused immediately.

7.4.3 Octaplas/™

Octaplas is a pooled human plasma product, containing plasma proteins. A stock is held continuously at MPH. This product is frozen & so has a long shelf life (2-4 years), however once thawed must be administered within 8 hours.

7.4.4 Human Albumin

Blood Transfusion Laboratory holds a constant supply of 5% & 20% albumin. It is stored in the laboratory until ready for infusion.

7.4.5 Fibrinogen (Riastap ™)

Fibrinogen concentrate is made from pooled plasma, which is available in 1gram amounts. Stock is held in the Blood Transfusion laboratory, and when requested is available within 15 minutes. If possible, a specimen should be reserved for measurement of fibrinogen level by the Haematology Department.

7.4.6 Prothrombin complex concentrate (Octaplex[™])

Octaplex is a coagulation factor concentrate, specifically Prothrombin complex concentrate. A limited stock is held in Blood Transfusion laboratory. Consultation with a Consultant Haematologist is required prior to administration of this product.

7.4.7 Recombinant coagulation factor (Novoseven ™)

Novoseven is a recombinant coagulation factor, specifically factor VIIa. It is available in 2 mg solution for reconstitution & is available from the laboratory on a limited basis for specific

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

patients. Consultation with a Consultant Haematologist is required prior to administration of this product.

7.4.8 Coagulation Factor Concentrates

Wilate (Von-Willibrand factor), Advate (factor VIII). Such products are available only following consultation with Consultant Haematologist.

Further information regarding indication for use, dosage and specific administration guidelines are available on the MPH intranet, specifically policy entitled NUR-HAE-001.

7.4.9 Referrals

Occasionally a sample may need to be referred from the Blood Transfusion Lab to the Irish Blood Transfusion Service (IBTS) reference lab for additional testing/ crossmatching. This could result in a delay in blood provision. If a sample needs to be referred to the IBTS, BT staff/ On-call staff will notify the nurse in charge of patient.

7.5 Specimen Receipt in the Blood Transfusion Laboratory

Specimens from patients for elective surgery ideally should be received before 14.00 hours on the first routine working day before surgery. If specimens are received after this deadline, grouping, screening and if necessary crossmatching may not be complete before 10.30 the following day.

7.6 Two Separate Specimen Requirement to Determine Blood Group Pre 1st Transfusion

All patients should have had two blood groups confirmed on the lab information system pre their 1st transfusion. This is to eliminate the risk of an ABO incompatible transfusion due to sampling error. These specimens have to be taken on two separate occasions, ideally by two different people if same is possible.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

7.7 Specimen Acceptance Criteria in Blood Transfusion

 The patient's Type & Screen specimen (7.5 mls EDTA) arrives in the Blood Transfusion Department in a sealed bag attached to the relevant blood transfusion request form. (MPH 4319)

Ref.: LS-GEN-0001 Specimen Collection & Handling

Ref.: LS-GEN-0002 Specimen Transportation

- 2. The specimen must contain the following details:
- Patients Surname and First name
- Date of birth
- Medical Record Number (MRN)
- Date and time of specimen collection
- The signature of the person taking the specimen
- 3. The blood transfusion request form must contain the following minimum information:
- Patient's Surname and First name
- Date of Birth
- Medical Record Number (MRN)
- Gender
- Consultant
- Location
- Test required
 - a) Type and Screen
 - b) Crossmatch, including clinical details, component, number of units, date and time required
 - c) Direct Coombs Test/ Direct Antiglobulin Test
- Any special requirements e.g. CMV negative, irradiated
- Signature of person reserving specimen

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

• Date and time specimen taken

The form should also contain details of previous transfusions, red cell antibodies, obstetric history, and any adverse reactions.

Signature of the person completing the form should also be included. If a telephone request is made in an emergency, it must be followed up with a written request

Note: For the unconscious/ unidentified patient, the minimum information necessary on the request form is the patient's MRN and gender.

- 4. If the information on the request form and the specimen do not match with regard to the patient's name, DOB and/or MRN, the specimen will not be processed.
- 5. If a specimen is rejected, the relevant ward will be informed of rejection and a repeat specimen requested.
- 6. Unlabelled specimens and specimens with addressograph labels, or insufficient specimens will be rejected and a repeat specimen requested.
- Grossly haemolysed or lipaemic specimens or incorrect specimen container type are not suitable for testing. Relevant wards will be notified of rejection and request repeat specimen.

7.8 Specimen Stability

Patients' specimens are refrigerated at 2-8oC after testing, and may be used for further cross-matching once the request is received and the transfusion will be complete within 72 hours of the specimen being taken.

7.9 Ordering Blood Components & Products

Red cells are ordered by ticking the appropriate box on the blood transfusion Request Form accompanying the specimen. The number of units required, the date the blood is required for, any special requirements e.g. CMV seronegative, irradiated, and the reason for the request must be indicated on the request form.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY				
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007			
26/09/2023				
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023			
26/09/2023				
Authorised by: Fiona O'Brien	Edition No.: 20			
26/09/2023	(Review Date 26/09/2024)			
ISO 15189:2012 / JCI Standards AOP.5				

If additional crossmatching or product issue is required on the primary specimen, a request may be made initially by phone to the Blood Transfusion Laboratory stating the name of the patient, MRN and additional tests and/or product and quantity required. A request form signed by the person ordering the tests/products must follow such a request. There is a dedicated telephone line for use by Theatre only, the number is 8399.

7.10 Collecting and Returning Blood Components & Products

Storage of issued blood components/products for collection along with the laboratory report is as follows in the Blood Transfusion Lab .

Component/Product	Temperature	Storage
Red Cells	4ºC	Blood Issue Fridge
Platelets	22ºC	Platelet agitator
Octaplas	4ºC	Blood Issue Fridge
Fibrinogen concentrate	4ºC	Blood Issue Fridge
Albumin	<25ºC	Blood Issue Fridge
Recombinant VIIa Novoseven	<25ºC	Blood Issue Fridge
Octaplex (PCC)	<25ºC	Blood Issue Fridge

Table 17: Storage of Blood Components Products

The nurse or requester of the blood components / products must bleep the porter and request the collection of blood. A blood collection slip containing the patient's details and the quantity of product required must be given to the porter. Alternatively the completed collection slip may be sent to the laboratory in the chute where the porter collects it on entering the Pathology Department.

The porter proceeds to the Blood Transfusion Laboratory, removes the blood component/product from the relevant storage area as outlined above, checking the patient's name, MRN and date of birth on the collection slip, laboratory report and label on the issued component/product. The porter must scan the blood component/product out of the laboratory using the Blood Track system. In the event of a blood track malfunction/

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

break down please use LF-BT-0049 Logbook of manual tracking of blood components/products in the event of blood transfusion Blood Track System Failure. The blood components/products are transported within the hospital in the specific blood transport bag. The blood components/products are delivered to the ward required where the nurse/requester must sign the "Accepted by" column of the laboratory report accompanying the blood/product.

In the event that the nurse/requester is not present to accept the blood components/products or if the porter is requested to return them to the blood transfusion fridge, the blood components/products must be returned to the Blood Transfusion Lab and scanned back into fridge and placed in the storage area where first acquired (see Table 17 above).

Any blood components/products which are not going to be used immediately must be returned to the laboratory.

7.11 Emergency Group O Rh D Negative

In the event of an emergency situation, four Group O Rh D Negative un-cross-matched red cells are available for immediate use. Where possible a type & screen specimen from the patient should be sent to the laboratory **before** the blood is transfused to establish the patients' pre transfused blood group. If the patient has a historical blood group once this sample is processed and all criteria for electronic issue are met blood can be issued electronically. Where the patient has no known blood group , two separate samples are required see section 7.6.

These units should be collected by trained staff members who must scan their ID badge into Blood Track and select the 'Emergency Blood' icon on the screen. Patient details are not required in this instance when removing this blood.

Where a patient has special requirements e.g. CMV-Irradiated and /or antibodies, the responsibility to transfuse this emergency Group O Rh D Negative red cell lies with the

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Medical Officer in charge. All incidents where blood is issued as an emergency before compatibility testing is complete are audited by Haemovigilance.

7.12 Transfusion Reaction Investigation

Any unfavourable response by a patient to the transfusion of blood components/products may be described as a transfusion reaction or Serious Adverse Reaction (SAR). Not all reactions are associated with red cell destruction following in vivo formation of antigenantibody complexes, however, transfusion reactions that are caused by such destruction are among the more serious that can occur. Transfusion reactions (SARs) may be divided into four broad categories

- Acute immunologic
- Acute nonimmunologic
- Delayed immunologic
- Delayed nonimmunologic

If a transfusion reaction is suspected, the transfusion should be stopped promptly to limit the volume of blood infused.

It is the responsibility of the Mater Private Hospital to ensure that the organization complies with the requirement of the EU Blood Directive in identifying, investigating, managing and reporting any adverse event or reaction that has occurred with the transfusion of blood or blood products.

It is the responsibility of the medical and nursing staff:

- To educate patients with regard to the possible reactions associated with the transfusion of blood or blood products.
- To correctly identify, fully investigate and manage any reaction, adverse event or near miss.
- To report all transfusion reactions and adverse events, near misses and noncompliances to the Haemovigilance Officer, hospital blood transfusion laboratory (as

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

appropriate) and also the hospital quality team by completing the hospital Q pulse

report

In cases where there is suspected transfusion reaction, a full investigation as to the cause must be undertaken.

• The transfusion should be stopped immediately, keeping the blood pack and its contents, together with blood administration set for examination by the staff of the blood transfusion department.

The following should be sent to the Blood Transfusion Laboratory as part of the investigation of the suspected reaction:

- A post transfusion Type and Screen specimen, EDTA and clotted specimens
- The implicated blood components/products
- The giving sets used
- Specimens for an FBC, coagulation, Urea & Electrolytes LDH & liver profile, blood cultures and the first voided urine specimen.
- All required tests should be completed at the time of reaction and sent to the laboratory accompanied by the Transfusion Reaction Form (MPH-HAE-095) Refer to form for all tests & specimens required
- Alert Haemovigilance Staff or in their absence the staff of the blood transfusion laboratory. and follow policy NUR-HAE-013 " Policy on the management and reporting of reactions, adverse events, near misses and non-compliances associated with the transfusion of blood and blood products". Haemovigilance will follow up and discuss all adverse events, reactions, near misses and non-compliances with the Haematologist at the monthly Haemovigilance/Quality meeting or the Blood Transfusion Committee meeting. Each event will reported on, have relevant corrective and preventative actions carried out and each event closed out.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Ref.: NUR-HAE-013 Policy on the management of reactions, adverse events, near misses and non compliances associated with the transfusion of blood and blood products. The IBTS is immediately contacted and the Rapid Alert Notification System is implemented

where the following reactions are suspected:

- Bacterial contamination of blood components/ products transfused
- Transfusion related acute lung injury
- Post transfusion viral infection
- Other post transfusion infections e.g. malaria

7.13 Haemovigilance Service

A Haemovigilance service is available in the hospital. All Haemovigilance policies and procedures are available on the hospital MPH intranet under the heading "Documentation";, then "Haemovigilance". Further information can be obtained by paging the Haemovigilance Nurse at 8311 or by contacting the hospital blood transfusion laboratory at 8131.

7.13.1 Written Consent for Transfusion

Except in emergencies the patient must be prepared for the transfusion by explaining the reason for transfusion. Discussion must include the benefits, risks and alternatives to transfusion as appropriate and allow for any questions/ concerns the patient may have. Ensure the patient has read and understands the hospital patient information leaflet on Blood Transfusion.

7.13.1.1 Consent at Time of Admission

The admitting or PAC nurse must give all surgical patients (who require a type & screen), oncology and haematology patients a patient information leaflet on blood transfusion and document this on page 1 of their patient assessment record.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

7.13.1.2 Consent for Surgical Patients

Written informed consent must be obtained as part of the patients surgical consent process. This surgical consent covers the patients consent for blood transfusion if a transfusion is required as part of their treatment..

This consent for blood transfusion is also valid in the post operative ward setting for 90 days from date of signing consent.

7.13.1.3 Consent for Elective Transfusions

Written informed consent for elective transfusion is obtained from the patient on each current admission and must be documented on the blood/blood component prescription and transfusion record.

Documentation to include:

- Record of patient information leaflet given to patient (if given by admission nurse, document 'given by admission nurse')
- Signature of nurse, date.
- Written consent obtained (yes/no)
- If no consent, state reason (e/g. consent obtained as part of surgical consent)
- Patient signature, date if written consent obtained
- RMO signature, date if written consent obtained.

Ref.: NUR-HAE-001 Policy on the Use of Blood And Blood Products & Blood transfusion patient information leaflet MPH 2154 Patient assessment & reassessment screening for referrals documentation. MPH 5788 Blood /blood component prescription and transfusion record MPH-HAE-0034 Surgical consent form MPH 4300

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

8. MICROBIOLOGY

8.1 General Information

The extension for Microbiology is 8133.

The extension for Molecular Microbiology is 8118 (office) /1898 (Lab).

To request a microbiology consult please contact the laboratory with the patients details, preferably before 12.00. The details will be passed on to the consultant. Results will generally be available from 11am. Please refrain from calling the laboratory before this time. Check Winpath (ward enquiry).

8.2 Requesting Microbiological Investigations

- 1. Please use the yellow request forms for Microbiology.
- Urgent request must be accompanied by a verbal request and handed to a medical scientist.
- Always ensure that the request forms are fully completed and if you have used a printed label, always ensure that the ward and consultant boxes have been completed.
- 4. Be sure to include all relevant clinical details on the request.
- 5. Site and specimen type are required; failure to provide may result in rejection of sample.
- 6. All additional tests must be requested by phone and a request form sent.
- 7. Requests for additional tests on urine specimens, (e.g. MRSA), or for culture of fastidious organisms, (e.g. *Neisseria* species) must be requested the day the specimen is taken.
- 8. Requests for additional tests on all other specimens must be received within 24 hours and must be requested by phone with a follow up request form.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- 9. Requests for additional tests that are not routinely carried out in the laboratory should be discussed with the consultant microbiologist.
- 10. Requests for urgent/rapid COVID-19 testing must be pre-approved by Infection control nurse or house sister out of hours
- 11. All urgent COVID-19 samples must be hand delivered to a medical scientist with clear approval communicated on the form or by phone
- 12. The hospital chute system must NOT be used for the transport of COVID-19 sample to the laboratory.

8.3 On-Call Service Repertoire in Microbiology

- Outside normal working hours the emergency service is covered by the Medical Laboratory Scientist on call, who is contactable by mobile phone through reception or security. All tests authorised are available on-line.
- Positive blood cultures are processed on call by medical scientists.
- SARS-CoV-2 (COVID-19) Testing is performed on clinically suspicious urgent cases, nonurgent will be refrigerated and testing carried out the following working day.
- Specimens of CSF received out of normal working hours will be referred to MMUH.
 The consultant Microbiologist on-call should be consulted prior to taking any CSF out of hours.
- Swabs, pus and fluids that are deemed urgent may be processed on call microscopy / Gram may be referred to the MMUH at the discretion of the consultant.
- Pregnancy testing may also be carried out on-call.

8.4 Reports

1. A member of the technical staff will telephone urgent results to the requesting clinician or ward (if verbally requested), or to the microbiology consultant.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- Important results such as positive blood cultures, salmonella isolates, etc. will be telephoned to the relevant consultant and/or infection control on the day of isolation as preliminary results.
- 3. Printed final reports will be issued on the day of completion for transport back to the specified location.
- 4. Where possible, please do not telephone for results before 11.00am to allow for cultures to be read.
- 5. Authorised results are available on-line to the wards.

8.5 Specimen Collection

All containers/swabs including red top liquid swabs for influenza/COVID-19 testing may be obtained from the Stores Department. Blood cultures, Viral swabs, Chlamydia swabs and Transwabs may be obtained from the Microbiology Department between 09:00 and 17:00.

8.6 Referral Antibiotics

ABBREV	SPECIMEN	SPECIAL PRECAUTIONS	TURN AROUND	REFERENCE RANGES
	VOLUME		TIME	
Teic	7.5ml	Trough levels to be taken	These are	The therapeutic dose
			referred to the microbiology department, MMUH. ¹	is 20-30mg/l, for MRSA infective, infecting endocarditis and osteomyelitis treatment
	Teic	VOLUME Teic 7.5ml clotted	VOLUME Teic 7.5ml clotted only, These are taken immediately before the	VOLUMETIMETeic7.5mlTrough levels to be takenThese areclottedonly, These are takenreferred to theimmediately before themicrobiologydosedepartment,

¹These are referred to the microbiology department, MMUH. Specimens must arrive to the microbiology department MMUH by 3.30pm for analysis (routine working hours). There is no on-call service available for analysis. Special arrangements for Saturdays, Sundays and Bank Holidays are in place; specimens must arrive to the microbiology department MMUH by 9:30 am on these days. Results are phoned to the requesting ward.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Other antibiotic assays NOT performed in house please discuss with department prior to sending.

8.7 Specimen Collection

8.7.1 COVID-19/Influenza Testing

All testing for SARS-CoV-2 should be conducted in consultation with a healthcare provider. Collect specimens as soon as possible once a decision has been made to pursue testing, regardless of the time of symptom onset.

For initial diagnostic testing for SARS-CoV-2, collecting and testing an upper respiratory specimen is recommended. The following are acceptable specimens:

A nasopharyngeal (NP) specimen collected by a healthcare provider and an oropharyngeal

(OP) specimen collected by a healthcare provider

Nasopharyngeal wash/aspirate or nasal wash/aspirate (NW) specimen collected by a healthcare provider.

Swabs should be placed immediately into a sterile transport tube containing 3mL of either universal transport medium (UTM), Red or White Top).

Influenza can be tested on the same specimen or just an NP swab swab sent.

Other sample types need to be discussed with the laboratory.

8.7.2 Blood Cultures

- 1. Obtain 2 blood culture bottles and 1 blood culture pack from the Specimen Reception area of the Pathology Laboratory.
- Note: The BacT/Alert 3D blood culture system is used in the Mater Private Hospital. Two bottles are used; FA for aerobic and facultative anaerobic microorganisms and FN for anaerobic microorganisms. FN contains contain 32ml of complex media and 8ml of a charcoal suspension. Bottles contain an atmosphere of nitrogen under vacuum. FA

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

contains 22ml of complex media and 8ml of a charcoal suspension, Bottles contain an atmosphere of CO2 in oxygen. It is suitable for the isolation of aerobic, anaerobic organisms and fungi.

- 2. Prior to use, the BacT/ALERT FN/ FN Culture Bottles should be examined for evidence of damage or deterioration (discoloration). Bottles exhibiting evidence of damage, leakage, or deterioration should be discarded. The media in undisturbed bottles should be clear, but there may be a slight opalescence or a trace of precipitate due to the anticoagulant SPS.
- 3. Check Name and D.O.B. with patient and same details including MRN on patients ID band and specimen card.
- 4. Prior to touching a patient, hand hygiene must be completed by the phlebotomist, by washing hands or using alcohol hand rub (moment 1 before patient contact). Identify a suitable vein (usually on the arm) from which to draw blood from the patient. Clean hands.
- 5. Open sterile pack and set up sterile field, attaching the devices needed together in preparation for the procedure
- 6. Apply the single use Tourniquet above the blood-sampling site and swab the skin over the vein vigorously for 1 minute with a 2% chlorhexidine in 70% alcohol single use sponge/swab (chloraprep). Allow to dry for 30 seconds.
- 7. Remove the flip-lid seal from the blood culture bottles and swab the rubber stopper thoroughly with sanicloth CHG 2% swab. Clean hands using alcohol hand gel or by washing them and Apply sterile gloves. Then using aseptic non-touch technique, take a sterile butterfly safety device, Insert the butterfly into the vein of the patient, taking care not to contaminate, repalpate or touch the needle insertion site and obtain up to a 10ml blood specimen (4ml for a paediatric bottle). If you need to palpate the vein again it's important to remove gloves, reclean hands and apply a new set of sterile gloves.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- 8. Place the collection cap over the blood culture bottle and fill to the required level. Then repeat for bottle two. Always collect aerobic (green) before anerobic (orange). (If you need to collect the blood via a syringe and not from the closed circuit you should enter the blood into the anerobic bottle first and then the aerobic bottle).
- Once the blood is collected, disconnect blood culture section and proceed to take any blood samples needed
- 10. Remove the tourniquet first, Then carefully remove the butterfly, ensuring the safety cover is applied as you remove it
- 11. Place a plaster or dressing over the blood-sampling site.
- 12. Place used needles and sharps into the CinBin provided. Any other clinical waste must be disposed of directly into yellow risk waste bin.
- 13. Remove gloves, clean hands.
- 14. Write patient details on bottles and samples. Place barcode from bottles onto request cards. Use Phlebotomy labels if available and then place in the plastic sleeve of the test request card and seal the sleeve.
- 15. Write the date and time of collection on the card and specimen type i.e. peripheral or specific site e.g. taken from left arm, and transfer the samples directly to the Microbiology discipline of the Pathology Laboratory. Never send Blood culture bottles in the Chute system.
- 16. Outside of routine working hours: Please bleep a porter as soon as possible after collecting the specimen. The porter will transport the blood culture bottles to the laboratory and load the bottles on to the Bac-T alert system.

8.7.3 Urine

Please send an MSU (midstream specimen of urine), in order to avoid contamination of the specimen. Please send all such specimens in a CE marked (Aseptically/ clean room manufactured) container (yellow capped) container.

1. Clean the area around the penis or vagina with a tissue.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- 2. Begin urinating into the toilet bowl.
- 3. Stop and urinate into the sterile container until it is half full.
- 4. Finish urinating into the toilet.
- 5. Close the bottle tightly, label bottle clearly with your name and date.
- 6. Wash hands.
- 7. Place in plastic form/bag provided.
- 8. Transport to the Laboratory as soon as possible after collection.
- 9. Place in the designated refrigerator after routine working hours.

For pregnancy test and investigations for AFB in urine, please send early morning specimens of urine.

NOTE: For AFB investigation of urine, send the <u>full</u> early morning collection.

8.7.4 Viral Testing

Swabs: Send in universal transport medium (UTM).

*Influenza Send a Nasopharyngeal sample in a Liquid Univeral Transport Medium

(red/white top)

*Covid-19 Send a Naso/Oro-pharyngeal sample in a Liquid Univeral Transport Medium

(red/white top)

*Full Repertory Screen Send a Naso/Oro-pharyngeal sample in a Liquid Univeral Transport

Medium (red/white top)

*CSF: Send in sterile universal container

*Faeces: Send in sterile capped universal container

Testing kits for saliva testing for Measles IgM are available on request, please allow plenty of time for the laboratory to acquire kit. Blister Fluid: Spread directly on a slide, if EM is requested.

Refer to section 8.9 below

If in doubt about any specimen collection, ring the Laboratory for advice.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

*NB: Transport medium is not added, some viruses may be thermoliable please send to lab ASAP| for storage at 2-8°C or store at 2-8°C if delay in transport, CMV urine request may require storage at -20°C.

8.7.5 Chlamydia Isolation

If you wish to request Chlamydia investigations please obtain the special Chlamydia swab / urine collection kit from laboratory.

8.7.6 CSF

Please send specimens of CSF, for the investigation of suspected meningitis. Send specimens in a sterile, universal containers. *Please note all CSF samples should be hand delivered to the laboratory and handed to a medical scientist. Do not use pneumatic shoot system.*

- Collect 3 samples, label bottle 1 (first drops), 2 and 3 (last drops), of approx. 1mL of CSF
- Samples 1 & 3 will be used for cell count.
- Sample 2 Biochemical determination (Protein and Glucose), samples with high cell counts may not be suitable for protein testing, glucose cannot be tested >1hour.
- Sample 3 for culture and Gram stain (if required)

A 4th sample may be sent if further testing is required i.e. viral studies NOTE: Always notify the Microbiology Department when you have taken a CSF. The specimen should not be refrigerated. **The consultant Microbiologist on-call should be consulted prior to taking a CSF sample out of routine hours.**

8.7.7 Pus

Send Pus in a sterile universal container wherever possible. Send pus swabs only if pus is difficult to collect.

8.7.8 Fluids e.g. Pleural, Joints

Place aliquot into a sterile container.

Fluids for cell counts only accepted if in EDTA container, this will prevent clot formation.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

8.7.9 Sputum

Please send a purulent / mucopurulent specimen. Do not send saliva for culture unless from ITU and no other specimen can be obtained. Special wide mouth sputum containers are available.

8.7.10 Swabs

Transwabs can be obtained from the microbiology department.

Pressure sores

These should be swabbed if there is evidence of infection e.g. cellulitis, pus, inflammation. Do not swab as a routine.

Swabs (drain)

These should be taken only if there is evidence of infection, e.g. cellulitis, discharge of pus.

Ulcer swabs

Ulcers should only be swabbed if there is evidence of infection e.g. if there is cellulitis or pus formation.

Do not swab as a routine.

Investigation of Whooping Cough

Please send Per-nasal swabs, ordinary throat or nose swabs are unsuitable.

Special 'fine' swabs are available from microbiology and you should contact the department prior to taking the specimen. Samples will be referred for PCR testing.

8.7.11 Stool Specimens

Please send stool specimens for culture/parasitology/virology in separate universal containers when possible.

Formed stool samples will not be tested for *C. difficle* or Norovirus unless specifically requested by consultant microbiologist

In-patient testing for routine C&S will not be carried out on patients with a hospital stay >3 days unless requested by consultant microbiologist.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

Please supply travel information and any supporting clinical information for parasitology

requests (routinely Giardia and Cryptosporida only tested unless further information supplied).

8.8 Specimen Stability and Storage

SPECIMEN	STORAGE AND SPECIMEN LIFE
Blood	These should arrive in the laboratory within 4 hours of collecting. Out of routine
Cultures	hours bleep a porter as soon as possible after specimen collection.
COVID-19 /	Samples may remain at room temperature up to 8 hours, then stored 2-8°c for
Influenza	up to 72 hours.
CSF	Immediate processing of CSF specimens is always indicated. Please advise the laboratory or the on-call staff when you have taken a specimen. If the specimen is more than 2 hours old on receipt the cell count may not be accurate due to cell disintegration. Glucose analysis must be done as soon as possible, it cannot be performed on specimens more than 1 hour old.
All other Specimens	Urine, swabs, fluids, stool, tissue sputum etc. may all be stored overnight if refrigerated. Please leave all such specimens in the specimen fridge. Microbiology specimens should not be put in the freezer. They will be collected and processed by laboratory staff each morning.

 Table 18: Specimen Stability & Storage

8.9 Notes on the Collection of Specimens for Virus Investigation

1. Request forms for virus investigations are available in each ward. Forms should be

completed in detail by a member of the medical staff and must accompany each

specimen. The date of birth of the patient must be entered on each form.

2. <u>The table that follows</u> is designed to help in collection of correct specimens for virus

investigation

Disease	Specimen	Test for Causative Virus or other agent
Aseptic	C.S.F. at 4°C, Faeces at 4°C	Culture for E.C.H.O., Coxsackie, herpes,
meningitis	Throat swab in transport medium at	mumps, polio virus.
encephalitis	4°C	Antibodies to virus isolated from other
	Serum: Acute/convalescent	specimens.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

Disease	Specimen	Test for Causative Virus or other agent
	Throat swab in transport medium at	Immunofluorescence for sputum, BAL,
	4°C.	R.S.V., influenza, para-influenza, adenovirus,
	Laryngeal swab in transport medium	some enteroviruses, cytomegalovirus.
	at 4°C.	
Lower	Sputum at 4°C.	
Lower Respiratory	Throat washing taken at bedside with	Culture for R.S.V.
Tract Infection	50% glycerol.	
	Serum: Acute/convalescent	Antibodies to isolated virus from above
		specimens and mycoplasma, Q.fever,
		psittacosis, influenza, para-infueneza, R.S.V.
		Chlamydia pneumonia.
Myocarditis	Faeces	Culture for Coxsackie B antibodies to
Pericarditis	Pericardial effusion at 4°C	psittacosis, coxiella burnetti, (Q.fever),
	Serum: Acute/convalescent	Coxsackie if isolated from specimens.
Rubella / VZV /	Serum.	Rubella / VZV / Parvovirus / Measles /
Parvovirus /	Consult Microbiologist regarding	Mumps IgG / IgM antibodies.
Measles /	further investigations.	
Mumps		
(1) Normal		
adult		
(2) Pregnancy		
Measles IgM	Saliva	Measles IgM testing
VZV	Vesicle fluid	VZV PCR
Jaundice		Antibodies to toxoplasma, cytomegalovirus,
(unexplained)	Serum: Acute convalescent	herpes, adenovirus, leptospirosis.
Gastroenteritis	Please contact the Microbiologist.	
Upper		
Respiratory	No virological examination advocated unless specifically requested.	
Tract Infection		
Conjunctivitis	Conjunctival swab in transport	Culture for herpes, adenovirus
	medium at 4°C	
	Conjunctival scraping in transport	
	medium at 4°C	

Table 19: Samples for Virus Investigation

NB: Specimens for virus culture should reach the laboratory within one to two hours of collection and should be stored in the fridge before transportation

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

8.9.1 Throat Swabs

Well moistened swabs should be taken and broken into virus transport medium. This is available in the laboratory.

8.9.2 Throat Washings

Are obtained by asking the patient to gargle 1 - 15 ml sterile saline. This is then collected in a sterile screw-capped container.

8.9.3 Faeces

Specimens should be collected in a sterile screw-capped container.

8.9.4 Sputum

Specimens should be collected in a sterile screw-capped container.

8.10 Notes on Specimens for Bacterial Culture

SPECIMEN	STORAGE TIME AND TEMPERATURE
Urine	Overnight – may be left at 4º.
Swabs	Overnight – may be left at 4º.
Sputum	Overnight – may be left at 4º.
Stool	Overnight – may be left at 4º.
Fluids	Overnight – may be left at 4º.

Table 20: Specimen Storage

- Specimens should reach the laboratory by 4.00 pm on weekdays and 10.30 am on Saturdays.
- Please contact the laboratory regarding urgent specimens after this time.
 NB: Only <u>urgent</u> specimens are processed on Saturday mornings.
- Specimens which cannot be processed after collection should be kept in the refrigerator, except:

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

- Specimens of cerebro spinal fluid keep at room temperature until bacteriological culture and microscopy complete.
- Swabs for G.C. should be cultured immediately,
 PCR testing using a suitable collection kit (urine / swab) is a preferred method for initial screening as it is sensitive and stable prior to testing.

NB: When filling out request forms, please give full clinical details, especially details of antibiotic therapy, immunosuppressive agents, site and specimen type. Interpretation of findings is impossible without this information.

 Please contact the Consultant Clinical Microbiologist when unusual or opportunistic infection is suspected, especially in patient with Acquired Immuno Deficiency Syndrome, post transplant, on chemotherapy, or otherwise immuno-suppressed, for advice on specimen collection.

8.11 Septicaemia and Endocarditis

The isolation of the organism is essential to the correct management of these patients and every effort should be made to withhold antibiotics until blood cultures have been taken. Septicaemia may follow procedures such as genito-urinary manipulation, sigmoidoscopy, bronchoscopy or may occur in other pathological conditions. At least two blood cultures should be taken, to reduce the risk of contamination. Blood cultures are also indicated in the following conditions:

- Acute purulent meningitis
- Acute osteomyelitis
- Pneumococcal pneumonia.

8.11.1 Timing and Numbers of Cultures

Cultures must be taken before antibiotic therapy commences. When treatment is urgent, two separate cultures may be taken within the hour. Where treatment can be delayed, three cultures should be taken over a 24-hour period, and if these are negative, a further

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

three cultures taken. When a patient suffers from occasional rigors and is afebrile in the intervening period positive cultures are most likely when taken at the time the patient feels the rigor coming on.

8.11.2 Method

The BacT/Alertblood culture system is in use.

See section 8.7.1 for blood culture collection.

8.11.3 Common Infecting Organisms

- Streptococcus viridans
- Enterococcus faecalis
- Staphylococcus aureus

8.11.4 Less Common Infecting Organisms

- Gram negative enteric organisms
- Q. Fever (C. Burnetti) Serological diagnosis, demonstration
- Psittacosis of rising titre
- Brucellosis
- Bartonella
- Chlamydia Pneumoniae
- Toxoplasmosis

8.11.5 Post-Operative Cardiac Surgery

• Coagulase negative staphylococci, fungi.

8.11.6 Immuno compromised patient

- Gram negative enteric micro-organisms
- Coagulase negative staphylococci
- Fungi

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

8.12 Respiratory Infections

8.12.1 Upper Respiratory Tract

Specimens - throat swab, laryngeal swab. The majority of these infections are caused by viruses.

• Common Infecting Organisms

- Streptococcus pyogenes
- Vincents Organisms
- Candida albicans

NB: Culture for *C.diptheriae* is not done routinely. Please notify the laboratory.

8.12.2 Lower Respiratory Tract

Specimen: Sputum (in screw-capped container only).

- Bronchial Washings/brushings (in screw-capped container only).
- Urine for *Legionella / Str. pneumoniae* antigen testing

Chronic Bronchitis

Three specimens of sputum should be examined as this increases the isolation rate of *H.Influenzae* significantly. Exacerbations are caused by *H.influenzae*, *Strep.pneumoniae*, *Moraxella catarrhalis*

NB: Where the patient has difficulty in producing a specimen of sputum postural drainage and physiotherapy may be required to obtain a suitable specimen. Salivary specimens are unsuitable for culture and will be discarded, unless from ITU.

Pneumonia

A gram stained film of sputum may be helpful in making the diagnosis and choosing a suitable antibiotic prior to results of cultures. The infecting organism may be isolated from blood culture in a third of cases.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

Infecting Organisms

Gram stains are available upon request.

Strep.pneumoniae	Urine for Str pneumo antigen
Staphylococcus aureus	
Klebsiella pneumoniae	
Pseudomonas aeruginosa	
Mycoplasma pneumoniae	Serological diagnosis
C.burnetii (Q Fever	Serological diagnosis made on rising titre
Psittacosis	
Pneumocystis carninii	Indirect fluorescent test available
Cytomegalovirus	Please consult Microbiologist
Legionella culture	If legionnaire's disease is suspected please notify the laboratory
Legionella serology	as soon as possible. Special culture medium is required for
	isolation from sputum or bronchial lavage. Specimens for
	culture are referred.
	Urine for legionella antigen
Bronchiectasis	
Staphylococcus aureus	
Bacteroides species	
Cystic Fibrosis	
Pseudomonas	
aeruginosa, Burkholderia	
cepacia	
Other gram negative enteric	
organisms	
Staphylococcus aureus	
Table 21: Gram Stains	

Table 21: Gram Stains

8.13 Meningitis

<u>Collect 1 ml of CS.F. into each of three sterile containers.</u> Label and return to laboratory for immediate examination. Blood cultures should also be taken.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Findings

TEST	NORMAL	ACUTE BACTERIAL MENINGITIS	TUBERCULOUS MENINGITIS	ASEPTIC MENINGITIS
Appearance	Clear/Colourless	Turbid	Clear/Opalescent	Usually Clear
Protein	15-45 mg/dl	Greatly increased	Moderately increased	Slightly increased
Glucose	2.6 – 4.3 mmol/l	Greatly reduced	Reduced	Normal
White cell	0-3 per μl	Greatly increased	Increased mainly	Increased lymphs
count		90% polymorphs	lymphs	
Culture	Sterile	Casual bacterium	M. tuberculosis	Negative
		isolated	isolated	

Table 22: Blood Culture Findings

NB: Specimen for Virus isolation should be kept at 4°C to await transport to the virus reference laboratory.

- Common Infecting Organisms:
 - N.meningitidis
 - H.influenzae
 - Strep.pneumonia
 - Listeria monocytogenes

Test	Specimen Required	Comments
Blood for PCR	EDTA specimen.	This specimen must be collected on admission as
	Older children and	antibiotic treatment rapidly causes this specimen to
	Adults 2.5-5.0 ml.	revert to negative. Fill out the Specimen Request
		Form (and send to Temple Street).
CSF for PCR	A small aliquot of the	Store and transport in a small well-sealed container,
	neat CSF specimen: a	e.g. an eppendorf tube.
	minimum 100µl (8-10	Fill out the Specimen Request Form (and send to
	drops).	Temple Street).
Paired Specimens	Clotted blood	Acute Phase: Collect within 48 hours of admission.
for serology	Specimens	Convalescent Phase: Ideally collect on day 14-21.

Table 23: Specimens for Non-Culture Diagnosis of Invasive Meningococcal Disease

8.14 Wound Sepsis

A wide variety of organisms may cause would infection.

Anaerobic organisms are especially likely to infect wounds after abdominal and

gynaecological surgery. Commonest organisms found are:

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- Staphylococcus aureus.
- E.coli.
- Klebsiella species.
- Bacteroides species.
- Specimen
- 1. Pus.
- 2. Moist swab.

NB: For isolation of anaerobic organisms, swabs or specimen of pus should be freshly taken and sent to the laboratory for immediate processing.

8.15 Urinary Tract Infection

Many different organisms cause urinary tract infection. Their sensitivity pattern may be unpredictable and treatment should be guided by results of antibiotic sensitivity testing.

• Specimens

Male: Clean midstream specimen.

Female: 1. Swab the vulva with sterile water or saline.

2. Take clean catch midstream specimen.

NB: Specimens should be examined without delay. If delay is unavoidable they should be placed in the refrigerator in the laboratory.

Diagnosis and appropriate treatment is critically dependent on getting correctly taken specimens.

Interpretation Of Results When Patient Is Not On Antibiotics.

	Normal	Contaminated	Infected
Bacterial	Sterile	10,000	100,000
Count/ml			Counts between 10,000 - 100,000 may be
			associated with symptomatic infection.
White Cell	10/µl		No count is diagnostic.
Count			Acute infection usually raised.
			Chronic infection usually low.

Table 24: Symptomatic Patients

NB: Diagnostic criteria of asymptomatic bacteriuria:

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

- two consecutive clean voided specimens
- revealing 100,000 org/ml
- with the same organisms in both specimens.

8.16 Venereal Disease

NB: All cases should be referred to the STD clinic MMUH or the Infectious Diseases

Physician

Gonorrhoea

Please contact the laboratory.

	Specimen	
Screening	Urine / Urethral /	In chlamydia / gonorrhoea transport media for
	Rectal / Cervical / Eye	PCR
	swabs	
Male	Urethral swab	Transport swab to the laboratory immediately.
	Rectal swab	Make films separately.
Female	Take cervical, urethral	As above.
	and rectal swabs.	

Table 25: Gonorrhoea Specimens

Trichomoniasis

Female: Swab of vaginal fluid from posterior fornix.

Male: Urethral secretion. First early morning urine specimen. (NB: Not M.S.U.)

Candidiasis

Vaginal Swab

Candida albicans may present as a saprophyte in the normal female genital tract. In pregnancy, oral contraception, tetracyclines or immuno-suppressive therapy, they may be of pathogenic significance.

Bacterial vaginitis / Gardnerella vaginalis

High Vaginal swab.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

8.17 Fungal Infections

Fungal Infections of the Lung

Pathogens Candida albicans

Aspergillus fumigatus and other related species.

Specimens 1.

- 1. Sputum
- 2. Serum for precipitins to *Aspergillus fumigatus* and Farmers Lung antigens.
- 3. Skin tests.

Groups	Skin Test Reaction		Eosinophilia	Precipitation
	Immediate	Late		
Asthma	+	-	+	-
Allergic Bronchopulmonary				+
Aspergillosis	+	+	+	(1-3 arcs)
				++
Mycetoma	±	±	-	(3-8 arcs)
Mycetoma + Allergic				
Bronchopulomary	+	+	+	++
Aspergillosis				(3-8 arcs)
Invasive Aspergillosis	-	-	-	±
Intrinsic Alveolitis	-	-	-	-

Table 26: Diagnostic Tests for the Major Groups of Pulmonary Aspergillus's

Dermatophytes:	Trichophyton species
	Epidermophyton species
	Microsporum species
Specimens:	Skin
	Hair
	Nails

 Table 27: Fungal Infections of the Skin, Hair and Nails, identification of positive

growth will be sent for referral testing.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

• Skin Scrapings

Clean area with 70% isopropyl alcohol allow to dry. Take scrapings from active periphery of lesion into a clean piece of paper, fold, label and send to laboratory or take scrapings onto a glass slide. Cover with second glass slide. Tape, label and send to laboratory.

o Hair

Take hair stumps, broken hairs, lusterless hairs; extract with forceps and extract any intrafollicular fragments with a Hagdorn needle. Skin scrapings should also be taken. Place in clean screw capped container. Label and send to laboratory.

• Nails

Clip off whole thickness of affected nail. Remove debris beneath infected nail. Place in a clean screw capped container. Label and send to laboratory.

NB: Please contact consultant Microbiologist where tropical infection is suspected or when unusual or rare pathogens are requested to be sought. Identification and sensitivity testing on positive fungal growth will be sent for referral testing which may add up to 4 weeks to the TAT.

8.18 Gastroenteritis

Specimen: Collect faeces in a screw-capped container. Well stained rectal swabs are acceptable if no faeces is available. This should be followed by a faecal specimen. Specimens from inpatients admitted to hospital >3days before date of specimen, are only processed for Norovirus or C.difficile Toxin A+B unless otherwise requested.

(a) Enteric group:	S.typhi, S. paratyphi A.B.C.	
(b) Food poisoning:	S.typhimurium, etc.	
es		
er		
E.coli		
<i>istolytica</i> (on request)		
<i>V.cholera</i> (not sought routinely, please contact laboratory).		
E. coli 0157		
	(b) Food poisoning: es er E.coli istolytica (on request)	

Table 28: Common Pathogens

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Food Poisoning

Specimen: Faeces in screw-capped container.

Food Specimens.

Common Pathogens
Staphylococcus aureus
Clostridium perfringens
Campylobacter
E. coli 0157

NB: Please state on the form any association with an outbreak of food poisoning. State age of patient and also state if patient is post-operative and on antibiotics. Please state if patient is mmune suppressed.

Antibiotic Associated Diarrhoea

Expected Pathogen	Clostridioides
	difficile.

Please give details of antibiotic therapy.

All diarrhoeal specimens from in-patients should have C. difficile Toxin A & B analysis.

Diarrhoeal specimens are defined as those that take up the shape of their container.

Formed stools should not be processed for *C. difficile* Toxin A & B unless specifically

requested by the consultant or infection control nurse.

Helminths and Protazoa

Specimens: Faeces (warm for *E.histolytica*).

Tests for parasitology are referred to Medlab Pathology

8.19 Eye Specimens for the Pathology Laboratory

Conjunctiva and lids – cultures

No topical anaesthetic. Avert lower lid and wipe sterile, moistened swab along entire lower fornix. Moisten swab with sterile saline. Use Transwab (transport medium containing charcoal to preserve delicate organisms prior to culture). Wipe lid margins with another moistened swab if lid culture is required.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

In special cases swab may be placed directly onto a blood or chocolate agar plate (by arrangement with the laboratory). A different swab must be used for each eye and each site.

Conjunctiva and lids – cytology

Instil a topical anaesthetic. A platinum spatula is flamed and allowed to cool to room temperature. The lid is averted (upper or lower) and the epithelial surface is gently scraped. Avoid any bleeding. Where there is local disease, take swab from site of maximum involvement. Spread material in a thin layer on a pre-cleaned glass slide. Fix and allow to dry for five minutes. Send all specimens to laboratory as soon as possible.

General ulcer (Non-viral ulcer)

Instil topical anaesthetic. Touch dry swab to central area of ulcer. Avoid contact with conjunctiva or lid margins.

Cytology

Under the slit lamp, take scrapings of the advancing edge and deeper central area of the ulcer. Spread on pre-cleaned glass slides.

Viral ulcer

Scrapings are taken, as described above, from the ulcer and placed in virus transport medium, which is available in the microbiology laboratory. A virus request form should accompany the specimens, which should be kept refrigerated until sent to the laboratory.

Endophthalmitis

Aqueous tap	0.2ml of aqueous humor taken with 25 gauge, 5/8 inch needle on a tuberculin syringe.
	Place in sterile container and send immediately to laboratory.
Vitreous tap	0.2ml of vitreous humor taken with 22 gauge needle from the site of maximum involvement.

Acanthamoebae

Please contact laboratory for special culture medium.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

8.20 Pregnancy Test

A urine specimen collected any time of day is suitable, but a first morning urine specimen which should contain the highest concentration of HCG is recommended especially when testing around the beginning of the first missed menses. Urine specimens may be collected in clean dry plastic or glass containers.

Urgent: - 30 mins

Routine: -1 Day

8.21 Availability of Microbiology Results

Microbiology Turnaround times (TAT)

Test	TAT for Negative	TAT for a Positive ¹	Urgent request ²	On-Call ²
Blood Culture	Initial report at 2d, Further report @ 5d	7 days	n/a	Not Available
CRE Screen	2 days	4 days	n/a	Not Available
CSF M, C&S	3 days ³	4 days ³	Microscopy / Gram available within 2h ³	Within 4h ³
Deep Wound / Tissue	Initial 3 days further report @ 10 days	14 days	Microscopy / Gram available within 2h	Not Available
Eye / Ear / Nose / Throat	2 days	4 days	n/a	Not Available
Faecal C. difficile	1 days	1days	Within 4h	Not Available
Faecal M,C&S	4 days	5 day	n/a	Not Available
Fungal Culture	10 days	1-8 wks	n/a	Not Available
Genital Swab	2 days	4 days	n/a	Not Available
HVS – High Vaginal Swab	2 days	4 days	N/A	Not Available
Joint Fluid	Initial 3 days further report @ 10 days	14 days	Microscopy / Gram available within 2h	Not Available
MRSA	2 days	4 days	n/a	Not Available
Norovirus	3h	3h	n/a	Not Available
Peri-Cardial Fluid	3 days	7 days	Microscopy / Gram available	Not Available

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Test	TAT for Negative	TAT for a Positive ¹	Urgent request ²	On-Call ²
			within 2h	
Pregnancy Test	30 Mins	30 Mins	n/a	30 Mins ²
Sputum / BAL / Other Resp samples	2 days	5 days	n/a	Not Available
Superficial wound / Pus	Initial 3 days further report @ 10 days	14 days	Not Available	Not Available
Tip Culture	3 days	3 days	n/a	Not Available
Urine M,C&S	1 day	3 days	Microscopy available in 2h	Not Available
VRE Screen	2 days	4 days	n/a	Not Available
Influenzae A/B & RSV	1 day	2h ²	2h ²	Not Available
COVID-19 batch	1 day ⁴	1 day ⁴	n/a	Not Available
COVID-19 Rapid/Urgent	2h ²	2h ²	2h ²	2h ²

Turnaround times are stated for all investigations and may vary from less than two hours to several weeks, depending on the nature of the investigation. Turnaround times stated in days refer to working days, and exclude week-ends and public holidays and are from the receipt of sample in the laboratory

¹ May be extended depending on Clinical details / Organism isolated

² Urgent/On call must be verbally requested with medical scientist

³ CSF specimen taken outside of routine hours **MUST** be discussed with the consultant microbiologist, MMUH cover for CSF analysis will be provided between 5pm-8pm Mon to Friday.
 ⁴Batch Testing is only available during outbreaks or high demand, routine testing hours will be organised via the GCD committee and is not readily available

Table 29: Microbiology Turnaround Times

8.22 Microbiology Critical Values

For the most up to date Critical Alert Values, please see the home page of the Hospital

Intranet / Lab Handbook & Critical Alert Values. If you are unable to access the intranet,

please contact the relevant department"

Ref.: WI-MICRO-0005 Microbiology Critical Values

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

8.23 Staff Self Testing

Please contact occupational health for all results of staff self-testing. These results will be blocked from general view on ward-enquiry in the interest of staff privacy. COVID-19 reports for travel cannot be issued with the exception of compassionate grounds which should be organised via occupational health.

8.24 Control of Antimicrobial Chemotherapy

Sensitivity testing

This is carried out using the Vitek 2 Compact and the EUCAST disc diffusion method. Tests are done on pure cultures of the isolated organism only.

Results of antimicrobial susceptibility testing are released after review by the consultant microbiologist.

8.25 Infection Control Service

The Hospital Infection Control Team provides advice and consultation on all aspects of infection control.

8.25.1 Hospital Infection Control Team

Infection Control Officer (Consultant Microbiologist) Infection Control Nurse – Beep No. 8371 Nursing Administration Representative Intensive Care Unit Sister C.S.S.D Supervisor Theatre Sister Occupational Health Physician Consultant Anaesthetist Technical Services Manager Pharmacist Chief Executive

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Staff Nurse Representative

8.25.2 Notifiable Infectious Diseases

Please notify all notifiable infectious diseases to: Dr Margaret Hannan and the infection

control nurse.

The following diseases should be notified to:

East Counties Dublin, Kildare and Wicklow Medical Officer of Health, Department of Public Health, Room G29, Dr Steevens' Hospital, Dublin 8. Phone: 01 6352145 Fax: 01 6352103of 2003)

Disease	Causative Pathogen	
Acute anterior poliomyelitis	Polio virus	
Ano-genital warts	Human papilloma virus	
Anthrax	Bacillus anthracis	
Bacillus cereus food-borne	Bacillus cereus	
infection/intoxication		
Bacterial meningitis (not otherwise		
specified)		
Botulism	Clostridium botulinum	
Brucellosis	Brucella spp.	
Campylobacter infection	Campylobacter spp.	
Carbapenem-resistant Enterobacteriaceae	Carbapenem-resistant Enterobacteriaceae	
infection		
	(invasive) (blood, CSF, other sterile site)	
Chancroid	Haemophilus ducreyi	
Chickenpox – hospitalised cases	Varicella-zoster virus	
Chikungunya disease	Chikungunya virus	
Chlamydia trachomatis infection (genital)	Chlamydia trachomatis	
Cholera	Vibrio cholerae	
Clostridioides difficile.infection	Clostridioides difficile.	
Clostridium perfringens (type A) food-	Clostridium perfringens	
borne disease		

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Creutzfeldt Jakob disease variant Creutzfeldt Jakob disease Cryptosporidiosis Cryptosporidium parvum, hominis Cytomegalovirus infection (congenital) Cytomegalovirus Dengue fever Dengue virus Diphtheria C. diphtheriae or ulcerans (toxin producing) Echinococcosis Echinococcus spp. Enterococcal bacteraemia Enterococcus spp. (blood) Escherichia coli infection (invasive) Escherichia coli (blood, CSF) Giardiasis Giardia lamblia Gonorrhoea Neisseria gonorrhoeae Granuloma inguinale Klebsiella granulomatis Haemophilus influenzae disease (invasive) Haemophilus influenzae (blood, CSF/ sterile site) Hepatitis A (acute) infection Hepatitis A virus Hepatitis B (acute and chronic) infection Hepatitis C virus Hepatitis E infection Hepatitis E virus Human immunodeficiency virus infection Human immunodeficiency virus infection Human indunodeficiency virus infection Human immunodeficiency virus of the orthopoxvirus genus Influenza Influenza A and B virus Klebsiella pneumoniae infection (invasive) Klebsiella pneumoniae (blood or CSF) Legionellosis Legion	Disease	Causative Pathogen	
Cryptosporidium parvum, hominisCytomegalovirus infection (congenital)CytomegalovirusDengue feverDengue virusDiphtheriaC. diphtheriae or ulcerans (toxin producing)EchinococcosisEchinococcus spp.Enterococcal bacteraemiaEnterococcus spp. (blood)Escherichia coli infection (invasive)Escherichia coli (blood, CSF)GiardiasisGiardia lambliaGonorrhoeaNeisseria gonorrhoeaeGranuloma inguinaleKlebsiella granulomatisHaemophilus influenzae disease (invasive)Haemophilus influenzae (blood, CSF/ sterile site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis C virusHepatitis E infectionHepatitis C virusHepatitis E infectionHepatitis C virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman immunodeficiency virus infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeptospirosisLeptospiros sp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMumpsNumps virus	Creutzfeldt Jakob disease		
Cytomegalovirus infection (congenital)CytomegalovirusDengue feverDengue virusDiphtheriaC. diphtheriae or ulcerans (toxin producing)EchinococcosisEchinococcus spp.Enterococcal bacteraemiaEnterococcus spp. (blood)Escherichia coli infection (invasive)Escherichia coli (blood, CSF)GiardiasisGiardia lambliaGonorrhoeaNeisseria gonorrhoeaeGranuloma inguinaleKlebsiella granulomatisHaemophilus influenzae disease (invasive)Haemophilus influenzae (blood, CSF/ sterile site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis B virusHepatitis C infectionHepatitis C virusHepatitis C infectionHepatitis E virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman immunodeficiency virus infectionKlebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeprosyMycobacterium lepraeLeptospirosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMenagococcal diseaseMeasles virusNon-specific urethritisMumps virus	variant Creutzfeldt Jakob disease		
Dengue feverDengue virusDiphtheriaC. diphtheriae or ulcerans (toxin producing)EchinococcosisEchinococcus spp.Enterococcal bacteraemiaEnterococcus spp. (blood)Escherichia coli infection (invasive)Escherichia coli (blood, CSF)GiardiasisGiardia lambliaGonorrhoeaNeisseria gonorrhoeaeGranuloma inguinaleKlebsiella granulomatisHaemophilus influenzae disease (invasive)Haemophilus influenzae (blood, CSF/ sterile site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis C virusHepatitis C infectionHepatitis C virusHepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis C virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman immunodeficiency virus infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeprosyMycobacterium lepraeLeptospirosisListeria monocytogenesLymehogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseMeasles virusNon-specific urethritisMumps virus	Cryptosporidiosis	Cryptosporidium parvum, hominis	
DiphtheriaC. diphtheriae or ulcerans (toxin producing)EchinococcosisEchinococcus spp.Enterococcal bacteraemiaEnterococcus spp. (blood)Escherichia coli infection (invasive)Escherichia coli (blood, CSF)GiardiasisGiardia lambliaGonorrhoeaNeisseria gonorrhoeaeGranuloma inguinaleKlebsiella granulomatisHaemophilus influenzae disease (invasive)Haemophilus influenzae (blood, CSF/ sterile site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis B virusHepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis E virusHerpes simplex (genital)Herpes simplex virusHuman immunodeficiency virus infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegitorpira spp.ListeriosisLegitorpira spp.ListeriosisLegitorpira spp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virus	Cytomegalovirus infection (congenital)	Cytomegalovirus	
EchinococcosisEchinococcus spp.Enterococcal bacteraemiaEnterococcus spp. (blood)Escherichia coli infection (invasive)Escherichia coli (blood, CSF)GiardiasisGiardia lambliaGonorrhoeaNeisseria gonorrhoeaeGranuloma inguinaleKlebsiella granulomatisHaemophilus influenzae disease (invasive)Haemophilus influenzae (blood, CSF/ sterile site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis B virusHepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis E virusHepatitis E infectionHepatitis E virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman inmunodeficiency virus infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionello spp.LeptospirosisLeptospira spp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalaria P. falciparum, vivas, knowlesi, ovale, malariaeMeasles virusMenspococcal diseaseNeisseria meningitidisMumpsMumps virus	Dengue fever	Dengue virus	
Enterococcal bacteraemiaEnterococcus spp. (blood)Escherichia coli infection (invasive)Escherichia coli (blood, CSF)GiardiaisisGiardia lambliaGonorrhoeaNeisseria gonorrhoeaeGranuloma inguinaleKlebsiella granulomatisHaemophilus influenzae disease (invasive)Haemophilus influenzae (blood, CSF/ sterile site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis B virusHepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis E virusHepatitis E infectionHepatitis E virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman immunodeficiency virus infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegtonella spp.LeptospirosisLeptospira spp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMumpsMumps virus		C. diphtheriae or ulcerans (toxin producing)	
Escherichia coli infection (invasive)Escherichia coli (blood, CSF)GiardiasisGiardia lambliaGonorrhoeaNeisseria gonorrhoeaeGranuloma inguinaleKlebsiella granulomatisHaemophilus influenzae disease (invasive)Haemophilus influenzae (blood, CSF/ sterile site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis VirusHepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis C virusHepatitis E infectionHepatitis C virusHerpes simplex (genital)Herpes simplex virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman inmunodeficiency virus infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeptospirosisLeptospira spp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virus	Echinococcosis	Echinococcus spp.	
GiardiasisGiardia lambliaGonorrhoeaNeisseria gonorrhoeaeGranuloma inguinaleKlebsiella granulomatisHaemophilus influenzae disease (invasive)Haemophilus influenzae (blood, CSF/ sterile site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis B virusHepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis C virusHepatitis E infectionHepatitis C virusHerpes simplex (genital)Herpes simplex virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman influenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeprosyMycobacterium lepraeLeptospirosisListeria monocytogenesLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virus	Enterococcal bacteraemia	Enterococcus spp. (blood)	
GonorrhoeaNeisseria gonorrhoeaeGranuloma inguinaleKlebsiella granulomatisHaemophilus influenzae disease (invasive)Haemophilus influenzae (blood, CSF/ sterile site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis B virusHepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis C virusHerpes simplex (genital)Herpes simplex virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman Monkeypox infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeptospirosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMenslesMeasles virusMumpsMumps virus	Escherichia coli infection (invasive)	Escherichia coli (blood, CSF)	
Granuloma inguinaleKlebsiella granulomatisHaemophilus influenzae disease (invasive)Haemophilus influenzae (blood, CSF/ sterile site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis B virusHepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis E virusHerpes simplex (genital)Herpes simplex virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman Monkeypox infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeptospirosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMenslesMeasles virusMumpsMumps virus	Giardiasis	Giardia lamblia	
Haemophilus influenzae disease (invasive)Haemophilus influenzae (blood, CSF/ sterile site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis B virusHepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis E virusHerpes simplex (genital)Herpes simplex virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman Monkeypox infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeptospirosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMumpsMumps virus	Gonorrhoea	Neisseria gonorrhoeae	
site)Hepatitis A (acute) infectionHepatitis A virusHepatitis B (acute and chronic) infectionHepatitis B virusHepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis E virusHerpes simplex (genital)Herpes simplex virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman Monkeypox infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeptospirosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeningococcal diseaseNeisseria meningitidisMumpsMumps virus	Granuloma inguinale	Klebsiella granulomatis	
Hepatitis B (acute and chronic) infectionHepatitis B virusHepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis E virusHerpes simplex (genital)Herpes simplex virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman Monkeypox infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeprosyMycobacterium lepraeListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMumpsMumps virus	Haemophilus influenzae disease (invasive)		
Hepatitis C infectionHepatitis C virusHepatitis E infectionHepatitis E virusHerpes simplex (genital)Herpes simplex virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman Monkeypox infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeptospirosisLeptospira spp.ListeriosisListeria monocytogenesLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virus	Hepatitis A (acute) infection	Hepatitis A virus	
Hepatitis E infectionHepatitis E virusHerpes simplex (genital)Herpes simplex virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman Monkeypox infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeprosyMycobacterium lepraeLeptospirosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisNon-specific urethritisMumps virus	Hepatitis B (acute and chronic) infection	Hepatitis B virus	
Herpes simplex (genital)Herpes simplex virusHuman immunodeficiency virus infectionHuman immunodeficiency virusHuman Monkeypox infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeprosyMycobacterium lepraeLeptospirosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMumpsMumps virus	Hepatitis C infection	Hepatitis C virus	
Human immunodeficiency virus infectionHuman immunodeficiency virusHuman Monkeypox infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeprosyMycobacterium lepraeLeptospirosisLeptospira spp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMumpsMumps virus	Hepatitis E infection	Hepatitis E virus	
Human Monkeypox infectionMonkeypox virus of the orthopoxvirus genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeprosyMycobacterium lepraeLeptospirosisLeptospira spp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisNon-specific urethritisMumps	Herpes simplex (genital)	Herpes simplex virus	
genusInfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeprosyMycobacterium lepraeLeptospirosisLeptospira spp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisNon-specific urethritisItertaria	Human immunodeficiency virus infection	Human immunodeficiency virus	
InfluenzaInfluenza A and B virusKlebsiella pneumoniae infection (invasive)Klebsiella pneumoniae (blood or CSF)LegionellosisLegionella spp.LeprosyMycobacterium lepraeLeptospirosisLeptospira spp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisNon-specific urethritisMumps virus	Human Monkeypox infection		
LegionellosisLegionella spp.LeprosyMycobacterium lepraeLeptospirosisLeptospira spp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virus	Influenza		
LegionellosisLegionella spp.LeprosyMycobacterium lepraeLeptospirosisLeptospira spp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virus	Klebsiella pneumoniae infection (invasive)	Klebsiella pneumoniae (blood or CSF)	
LeptospirosisLeptospira spp.ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virus	Legionellosis	Legionella spp.	
ListeriosisListeria monocytogenesLyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virus	Leprosy	Mycobacterium leprae	
Lyme disease (neuroborreliosis)Borrelia burgdorferiLymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virus	Leptospirosis	Leptospira spp.	
Lymphogranuloma venereumChlamydia trachomatisMalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virus	Listeriosis	Listeria monocytogenes	
MalariaP. falciparum, vivax, knowlesi, ovale, malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virusNon-specific urethritisImage: Comparison of the second	Lyme disease (neuroborreliosis)	Borrelia burgdorferi	
malariaeMeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virusNon-specific urethritisVertice of the second secon	Lymphogranuloma venereum	Chlamydia trachomatis	
MeaslesMeasles virusMeningococcal diseaseNeisseria meningitidisMumpsMumps virusNon-specific urethritis	Malaria		
Meningococcal diseaseNeisseria meningitidisMumpsMumps virusNon-specific urethritis	Measles		
Mumps Mumps virus Non-specific urethritis	Meningococcal disease		
Non-specific urethritis		0	
	•		
		Norovirus	

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Disease	Causative Pathogen	
Paratyphoid	Salmonella Paratyphi	
Pertussis	Bordetella pertussis	
Plague	Yersinia pestis	
Pseudomonas aeruginosa infection	Pseudomonas aeruginosa (blood or CSF)	
(invasive)		
Q Fever	Coxiella burnetii	
Rabies	Rabies virus	
Respiratory syncytial virus infection	Respiratory syncytial virus	
Rotavirus infection	Rotavirus	
Rubella	Rubella virus	
COVID-19	SARS-CoV-2	
Salmonellosis	Salmonella spp. (not S. Typhi and S.	
	Paratyphi)	
Severe Acute Respiratory Syndrome (SARS)	SARS-associated coronavirus	
Shigellosis	Shigella spp.	
Smallpox	Variola virus	
Staphylococcal food poisoning	Enterotoxigenic Staphylococcus aureus	
Staphylococcus aureus bacteraemia	Staphylococcus aureus (blood)	
Streptococcus group A infection (invasive)	S.pyogenes (blood, CSF, normally sterile	
	site)	
Streptococcus group B infection (invasive)	<i>S. agalactiae</i> (blood, CSF, normally sterile	
	site)	
Streptococcus pneumoniae infection	<i>S.pneumoniae</i> (blood, CSF, normally sterile	
(invasive)	site)	
Syphilis	Treponema pallidum	
Tetanus Texas de serve sis	Clostridium tetani	
Toxoplasmosis	Toxoplasma gondii	
Trichinosis	Trichinella spp.	
Trichomoniasis	Trichomonas vaginalis	
Tuberculosis	Mycobacterium tuberculosis complex	
Tularemia Turkaid	Francisella tularensis	
Typhoid	Salmonella Typhi	
Typhus	Rickettsia prowazekii	
Verotoxigenic <i>Escherichia coli</i> infection	Verotoxin producing Escherichia coli	
Viral encephalitis		
Viral haemorrhagic fevers		
Viral meningitis		
West Nile fever	West Nile virus	

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

Disease	Causative Pathogen
Yellow fever	Yellow fever virus
Yersiniosis	Y. enterocolitica, Y.pseudotuberculosis
Zika virus infection	Zika virus

8.25.3 Other Infectious Diseases

Other infections which are of importance as far as spread in hospital/patient welfare is concerned should be notified to: Dr. Margaret Hannan and the Infection Control Nurse; these are:

- 1. All methicillin (oxacillin) resistant staphylococcal infections.
- 2. All ESBL positive isolates
- 3. All positive Carbapenemase producing enterobacteriacae
- 4. All Vancomycin resistant enterococci
- 5. All positive Clostridioides Difficile A&B screens
- 6. Positive blood cultures.
- 7. Other exceptional resistant pathogens (e.g. VRSA / penicillin resistant GC)

The Infection Control Nurse should receive copies of the following reports to monitor infection within the hospital:

- CSU report with growth.
- Any swabs/fluids/sputa, etc. with sensitivities.
- All MRSA screens whether positive or negative.
- Positive VRE/ CRE screens
- All reports with ESBL
- Environmental screens.
- Staff MRSA screens.

8.25.4 Reporting Of Suspected Outbreaks of Infection

When an outbreak of infection is suspected clinical staff must inform the infection Control Team immediately, to ensure prompt control and monitoring of the situation.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

The Consultant Microbiologist may be contacted 'out of hours' via the Technician 'on call', if

required.

An outbreak is declared when two or more associated cases of infection, or possible

infection are detected and the Infection Control Nurse is informed immediately.

CODE	Specimen Type	Group
AB	Abscess	Wound
ABDS	Abdominal Sinus	Wound
ABDW	Abdominal Wound	Wound
ABS	Abscess	Wound
ADS	Abdominal Drain Site	Wound
AF	Ascitic Fluid	Fluid/Tissue
AN	Anal	Wound
ARM / ARML/ ARMR	Arm swab/ Left/ Right	Wound
AS/ ASL/ ASR/ ASLR	Axilla swab /Left /Right /L&R	Wound
AV	Aortic valve	Fluid/Tissue
BAL	Bronchio-Alveolar Lavage	Respiratory
BAL	Bronchio-Alveolar Lavage	Respiratory
BCUL	Blood Culture	Blood
BILE	Bile	Fluid/Tissue
BW	Bronchial Washings	Respiratory
BW	Bronchial Washings	Respiratory
COIF	Naso/oropharangeal Swab	Respiratory
COVM	Naso/oropharangeal Swab	Respiratory
COVS	Naso/oropharangeal Swab	Respiratory
CRST	Crystals	Fluid/Tissue
CSF	CSF	Fluid/Tissue
CSU	CSU	Urine
CW/ CWL/ CWR	Chest Wound/ Left/ Right	Wound
EAR/EARL/EARR	Ear swab /Left/ Right	Wound
EPBC	Blood Culture	Blood
EYE/ EYEL/ EYER	Eye swab/ Left/Right	Wound
FA	Faecal Analysis	Faeces
FLU	Fluid	Fluid/Tissue
FU/ FUL/ FUR	Foot Ulcer/ Left/ Right	Wound
GS/ GSL/ GSR/ GSLR	Groin swab/Left /Right/ L&R	Wound
HVS	Vaginal swab	Wound
MRSA	MRSA Screen	MRSA

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

CODE	Specimen Type	Group
MRSP	MRSA Sputum	MRSA
MRWS	MRSA Wound	MRSA
MSU	MSU	Urine
MV	Mitral Valve	Fluid/Tissue
NORO	Norovirus	Faeces
NS/ NSL/ NSR	Nasal swab /Left/ Right	Wound
NTS	Nose and Throat	Wound
OB	Occult Blood	Faeces
PER	Peritoneal swab	Wound
PERA	Perianal swab	Wound
PF	Pleural fluid	Fluid/Tissue
PNS	Perineal swab	Wound
PREG	Pregnancy Test	Urine
PS	Penile swab	Wound
PUS	Pus	Fluid/Tissue
PW	Pacing wire tip	Тір
PWS	Pacing wire site	Wound
SAC	Sacral swab	Wound
SC	Scalp swab	Wound
SP	Sputum	Respiratory
SP	Sputum	Respiratory
ST/ STL/ STU	Sternal swab/ lower/ upper	Wound
TIP	Tip of cannulae	Тір
TOEU	Toe Ulcer	Wound
ΤΟΧΑ	Clostridioides difficile.toxin	Faeces
TR	Tracheostomy	Wound
TSW	Throat	Wound
UMRS	Urinary MRSA	MRSA
US	Urethral swab	Wound
WS	Wound swab	Wound

Table 30: Codes for Microbiology Specimens

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY		
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007	
26/09/2023		
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023	
26/09/2023		
Authorised by: Fiona O'Brien	Edition No.: 20	
26/09/2023	(Review Date 26/09/2024)	
ISO 15189:2012 / JCI Standards AOP.5		

9. HISTOLOGY / CYTOLOGY

9.1 General Information

The department can be contacted at extension 8136.

The routine working hours of the Pathology Department of the Mater Private Hospital are;

Weekdays: 8am - 5pm

9.2 Reports & Turnaround Times

9.2.1 Histology Turn Around Times

The Histopathology National Quality Improvement (NQI) Programme divides Histopathology and Cytology specimens into categories according to the procedure (p) code within which turnaround times (TATs) are analysed. The NQAIS guidelines for reporting Histology cases on small specimens (PO4) aim to report 80% within 5 working days with the exception of PO2 cases (GI Biopsies), these aim to be reported within 7 working days.

Large specimens (PO3) aim to be reported within the national QI (NQAIS) guidelines of 80% within 7 working days. Non-gynaecological cytology (PO6/PO&) is usually reported within two working days.

It is presently increasingly difficult for Histopathology Departments nationally, including the MPN Histopathology Department, to meet the NQAIS Target TAT for some routine cases. A process is in place to improve staffing and resources in the laboratory as we work towards achieving NQAIS Target TAT for all sample types. Our aim is to meet the NQAIS target TATs for all urgent cases (PO1).

At present, the Histopathology Laboratory in MPH will aim to report 80% of Histology cases within 15 working Days.

Add-On Special Stain	Additional 24 hours to 1 week
Add-On Immunocytochemistry	Additional 24 hours to 1 week
Frozen Section	Immediately (within 20 mins)
	Final report 24 hours – 1 week

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY	
Owner / Date: Paul Kennedy	Document No.: LS-GEN-0007
26/09/2023	
Reviewed by: Fiona Errity	Date of Issue: 26/09/2023
26/09/2023	
Authorised by: Fiona O'Brien	Edition No.: 20
26/09/2023	(Review Date 26/09/2024)
ISO 15189:2012 / JCI Standards AOP.5	

NOTES:

Factors that may impact target TAT include the following:-

- Requirement to obtain additional clinical/radiological information
- Requirement for specimen decalcification
- Requirement to examine a large number of blocks/slides in a case
- Requirement for ancillary testing including levels, immunohistochemistry, special stains and external referral for molecular pathology.
- Requirement for Intradepartmental Consultation and multi-disciplinary review.

9.2.2 Cytology

Routine Cytology: Turn Around Time

Non-Gynaecology cytology cases (PO6/PO7) aim to be reported within 10 Working Days. Specimens from Theatre, Day therapy and X-Ray should be signed for in relevant specimen books held by those departments. Specimens that require both Histology & Cytology must be received accompanied by separate forms (one for Histology and one for Cytology). Cervical smears requests are packaged and dispatched to the Eurofins Biomnis for processing and reporting from the Histology laboratory. The laboratory accepts and logs the cervical smears on the computer at specimen reception. They are dispatched to Eurofins (WI-HIST-0018 Procedure from sending out cervical smears to Biomnis).

9.3 Medical Advice Outside Normal Working Hours

No out of hours service is provided. Urgent cases may be discussed with the Consultant staff when available. Out of hours frozen sections can **only** be performed by **prior arrangement** with the Consultant staff and Medical Scientist.

9.4 Consultant Advisory Service

Histopathology Consultants are available, either on site or in the MMUH. Consultants rota and contact numbers available in tari-folder in Histology Department.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007					
26/09/2023					
Reviewed by: Fiona ErrityDate of Issue: 26/09/2023					
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

9.5 Histopathology Investigations

The department provides a service in surgical pathology, frozen section Histology and Cytology. Specimens should be brought to the laboratory in sufficient <u>10% buffered formalin</u> unless special investigations requiring fresh tissue are requested. Any fresh specimens must be brought to the attention of a Medical Scientist. A Visual check is performed on acceptance of specimens in Histology department See section 3.14.1 non-compliant lab specimens and request forms.

Specimens delivered to Histology must be accompanied by a specimen logbook; those without a specimen logbook must be signed into the Histology Specimen Reception Logbook LF-HIST-0099. Specimens will not be accepted into Histology without being logged.

Please Note: Histology specimens WILL NOT be signed for by other staff in the Pathology Department or during the on-call service.

Specimens cannot be left in the Histology Department without being signed in.

Ref.: LF-HIST-0099 Histology Specimen Reception Logbook

Examples of tissues requiring special handling include.

9.5.1 Urgent Specimens

A. Frozen Sections

A frozen section service is offered between 8-9 am and 4.30 pm weekdays only. Frozen sections outside of these hours may be provided on an individual case basis <u>by prior</u> agreement with the relevant Consultant Pathologist and Histology staff. *Please Note* that Frozen sections can ONLY be preformed by prior arrangement with the Histology Laboratory and the Consultant Histopathologist. Frozen sections should be booked by the Consultant Surgeon 24 – 48 hours prior to the operation.

NOTE: Specimens from patients with risk of infection (HepB, HepC, HIV, TB etc.) should not be submitted for frozen section. If a suspicion of such infection exists, the clinical staff concerned has a duty to inform laboratory personnel.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007					
26/09/2023					
Reviewed by: Fiona Errity Date of Issue: 26/09/2023					
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

Procedure for Booking a Frozen Section

- Frozen Sections should be booked 24 48 hours in advance by contacting the Histology Laboratory on Ext. 8136 or at histology@materprivate.ie with details including Consultant Surgeon, patient name, type of specimen and time of surgery.
- If an emergency or unbooked (<24 hours) frozen section is required, the Consultant Surgeon involved should phone the Consultant Pathologist to discuss the requirement for frozen section and the ability of the laboratory to accommodate this request.
- The Theatre porter or Theatre staff on duty must bring the fresh specimen with completed request form and contact phone number directly to the Histology laboratory.
- Under no circumstances should a specimen for frozen section be transported via the chute.
- Please inform the laboratory in the case of cancellation of frozen section.

Reporting of Frozen Sections

• The frozen section report will be phoned to the contact number supplied on the request form. Failure to supply a contact number will result in a delay in the report being communicated to the clinician. A typed report will be available following routine paraffin processing of the specimen and the turnaround time of full diagnoses varies from specimen to specimen depending on the size and the complexity of the case.

B. Other URGENT Specimens

Urgent specimens are dealt with on an individual case basis following consultation with the Medical Scientists and/or Consultant Pathologist. The turnaround times of urgent cases varies according to the type of tissue to be processed, the optimum fixation time required and the complexity of the case.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007					
26/09/2023					
Reviewed by: Fiona Errity Date of Issue: 26/09/2023					
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

The urgent specimen should be clearly marked URGENT on the request form and be brought to the attention of a Medical Scientist upon receipt to the Histology laboratory.

9.6 Specimens Requiring Special Handling

9.6.1 Muscle Biopsies

Muscle Biopsies should be brought to the laboratory immediately. They are dispatched via specimen reception to the Neuropathology Department Beaumont Hospital.

They need to arrive at Beaumont Hospital no later than 4pm.

9.6.2 Lymph Nodes

Lymph nodes for suspected Lymphomas should be brought immediately to the Laboratory and brought to the attention of a Medical Scientist.

9.6.3 Breast Localization Biopsies

Wire guided breast biopsies are sent from Theatre to x-ray for imaging. They must be then brought to Histology accompanied by the Histopathology/Breast request form.

9.6.4 Sural Nerve Biopsies/Peripheral Nerve Biopsies

Nerve Biopsies should be brought to the laboratory immediately. They are dispatched via specimen reception to the Neuropathology Department Beaumont Hospital.

They need to arrive at Beaumont Hospital no later than 4pm.

9.6.5 Specimens Requiring Both Microbiological Culture & Histology

Specimens requiring microbiological investigation e.g. Valves should be received fresh to the laboratory and always given to Microbiology first before any formalin is added..

9.6.6 Skin Biopsies for Immunofluorescence

Skin biopsies for Immunofluorescence should be brought to the laboratory immediately in soaked saline gauze. They are dispatched via specimen reception to the Immunology Department in the MMUH. They need to arrive at MMUH no later than 4:30pm.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007					
26/09/2023					
Reviewed by: Fiona Errity Date of Issue: 26/09/2023					
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

Fresh specimens will not keep over the weekend. If delivering a Histology specimen personally to the laboratory each specimen must be handed to a Histology member of staff and signed into the specimen reception book as received.

9.7 Cytology Investigations

All cytology specimens should reach the laboratory before 4.00pm so that appropriate preparation can be performed.

9.7.1 Breast Cyst Aspirate

Place in Cytolyte solution.

9.7.2 Bronchial Aspirates

These should be sent to the Laboratory in a universal container pre filled with Cytolyt solution (Cytolyt is available from the Laboratory).

9.7.3 Brushings From Other Sites

Place the brush in Cytolyt solution (available from the Laboratory) and send to the Laboratory.

9.7.4 Cerebrospinal Fluid

CSF needs preparing within two hours to avoid cell degeneration. Send in a sterile universal container. Cytology may only be preformed if there is a white cell count of >5 (results from Microbiology).

9.7.5 Fine Needle Aspiration Cytology

Sites of aspiration include breast, thyroid and lymph nodes. The techniques require several passes of fine gauge needle through the organ with negative pressure on the syringe. Place the aspirate into Cytolyt solution (approximately 20-25mls is present within a universal container), the needle can them be washed out using the fluid. Transport to the laboratory immediately.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007					
26/09/2023					
Reviewed by: Fiona Errity Date of Issue: 26/09/2023					
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

9.7.6 Sputum

Best results are achieved with freshly obtained sputa following chest physiotherapy, with an early morning sputum before the patient has eaten. Contamination with large amounts of saliva or food leads to inadequate specimens. Multiple specimens (usually x 3) may be necessary, but these should be sent on three separate days, not all taken at one time. Send in sterile sputum pots.

9.7.7 Urine

Best results are achieved with a fresh voided specimen, preferably not the first in the morning. Specimens at cytoscopy or form catheterised patients should be labelled accordingly. No fixative is required but prompt transportation is recommended to avoid unnecessary repeat tests. Send in universal sterile container. It is not necessary to send multiple specimens.

9.7.7.1 How to take a urine specimen for Cytology

This is usually requested to screen for abnormal cells from the bladder.

- This should not be taken the first time urine is passed after waking in the morning. Any time after this is appropriate.
- 2. It is preferable to collect the urine at the end of the stream rather than the beginning.
- 3. Collect urine into the sterile container provided till half full.
- 4. Close container tightly and label the specimen.
- 5. Place in plastic form/bag provide

9.7.8 Other Cytological Examinations

Examination of fluids and aspirates may be performed on request. Please contact the laboratory beforehand.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007					
26/09/2023					
Reviewed by: Fiona Errity Date of Issue: 26/09/2023					
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

9.8 Notification of Critical Results to the Requester

Critical results including those from referral centres are telephoned by Pathologist, when appropriate, directly to the requesting clinician. Pathologists immediately notify clinicians when examination results for urgent samples/ frozen sections are available.

Critical Results include:

- Unexpected malignancy
- Fat in endometrial curetting's
- Fat in GI biopsy
- Life threatening infection
- Cardiac biopsies if rejection grade is >1R
- Acid fast bacilli
- Amended reports

Consultant Histopathologist will phone any critical results to the requesting Consultant.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007					
26/09/2023					
Reviewed by: Fiona Errity Date of Issue: 26/09/2023					
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

10. POINT OF CARE TESTING

ISO 22870: Point of care testing is testing performed near or at the site of the patient to provide timely test results that clinically and cost effectively contribute to immediate patient management decisions by a competent and trained healthcare professional.

POCT available in the mater private under the remit of the pathology department are:

- Blood Gas Analysis
- Activated clotting times (ACT)
- Finger-prick Glucose
- Finger-prick Ketone
- Finger-prick haemoglobin
- Urinalysis
- Urinary bHCG

It is the responsibility of the head of Pathology, the relevant consultants and the POCT Coordinator to oversee point of care testing. The POCT Co-ordinator can be contacted in the biochemistry department on 8314.

As with all diagnostic testing, POCT results may impact significantly on patient management and morbidity. Therefore all samples (with the exception of finger pricks) **must be labelled** with the minimum requirement outlined in *3.8* above. Similarly all patients must be identified and prepared as described above.

It is the responsibility of all staff performing POCT to ensure that;

- They are fully trained and competent in accordance with the manufacturer's instructions for use.
- They are familiar with and have read the relevant standard operating procedures and working instructions related to the specific point of care test (i.e. *CM-POCT-0001*) All point of care documentation can be found on QPULSE using the keyword POCT.

MATER PRIVATE HOSPITAL – PATHOLOGY LABORATORY					
Owner / Date: Paul Kennedy Document No.: LS-GEN-0007					
26/09/2023					
Reviewed by: Fiona Errity Date of Issue: 26/09/2023					
26/09/2023					
Authorised by: Fiona O'Brien	Edition No.: 20				
26/09/2023	(Review Date 26/09/2024)				
ISO 15189:2012 / JCI Standards AOP.5					

• Results are reported in accordance with clinical protocol and that they are aware of the critical limits for each POCT test and report as per *POL-GEN-032 Verbal and Telephone Orders/ Critical Results Policy*. Critical limits can be found in the relevant working instruction and /or *CM-POCT-0001*.

Participate in internal quality control (IQC) and external quality assurance (EQA) testing when required.

Please refer to CM- POCT-0001 Management of Point of Care testing for the full point of care policy.

11. APPENDICES

Appendix No. 1: Alphabetical Repertoire of Tests

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
Activated Partial Thromboplastin Time	Na Citrate 9NC 3 ml	Fill to line indicated on bottle. For patients on heparin. APTT needs to be measured within 2 hours of phlebotomy	2 Hours	25.1-32.9 seconds	Haematology
Alanine Aminotrasferase	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	M <41 IU/L F <33 IU/L	Biochemistry
Albumin	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	<14yr 38-54 g/L 14-18yr 32-45 g/L >18yr 35-52 g/L	Biochemistry
Alkaline Phosphatase	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	<10yr 142-335 IU/L 10-<13yr 129-417 IU/L 13-15yr M 116-468 IU/L 13-15yr F 57-254 IU/L 15-17 M 82-331 IU/L 15-17 F 50-117 IU/L 17-19 M 55-149 IU/L 17-19 F 45-87 IU/L >19 M 40-130 IU/L >19 F 35-105 IU/L	Biochemistry
Amylase	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	28-100 IU/L	Biochemistry
*Anti LKM Antibody	7.5 ml clotted	Spin, separate and store at 2-8°C	1 Week	<80	Immunology
*Anti Mitochondrial Antibody	7.5 ml clotted	Spin, separate and store at 2-8°C	1 Week	<80	Immunology

Appendix No. 1: Alphabetical Repertoire of Tests

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
*Anti Nuclear Antibody (Anti Nuclear Factor)	7.5ml clotted	Spin, separate and store at 2-8°C	1Week	<80	Immunology
*Anti Nuclear Antibody Patterns (Hep 2 Pat)	7.5 ml clotted	Spin, separate and store at 2-8°C	1 Week	N/A	Immunology
*Anti Smooth Muscle Antibody	7.5ml clotted	Spin, separate and store at 2-8°C	1 Week	<80	Immunology
*Antibody Screen Auto Antibody Screen	7.5 ml clotted	Spin, separate and store at 2-8°C	1 Week	<80	Immunology
*Anti-HBc	7.5 ml clotted	Spin and store at 2-8°C	3 Days	Positive/Not detected	Serology
*AntiHBs	7.5 ml clotted	Spin and store at 2-8°C	3 Days	Positive/Not detected	Serology
Arterial Blood Gas	ABG Heparin Syringe	Ensure there are no air bubbles and analyse immediately. Use Lithium Hep. Syringe	30 Minutes	PH: 7.35 -7.45 kPa PCO2: 4.5-6.0 kPa PO2: 11.0-14.5 kPa Std. Bicarb: 22.4-25.8mmol/L O2 Sat: 95-98% Base Excess -2.3-+2.3 mmol/L	Point of Care
Aspartate Aminotransferase	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	M <40 IU/L F <32 IU/L	Biochemistry
*B12	7.5ml Serum		1 Day	197 – 771 pg/L	Biochemistry
*Bence Jones Protein	24 hr urine collection (Plain Container)	Urines should be fresh for analysis and stored at 2-8°C. A 24 Hour collection is preferable. An early morning urine specimen	1 Week	Positive/Negative	Immunology

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
		may be analysed. However, if Bence Jones protein is present it cannot be quantified.			
*Beta-2 Microglobulin	7.5ml clotted	Spin, and store at 2-8°C	1 week	0.8-2.4 mg/L	Immunology
BHCG /Human chorionic gonadotropin beta	Serum-Gel 7.5mls	Analyse as soon as possible or spin/separate	Daily or 90 mins STAT	<5 IU/L Can be up to 9 in menopausal woman due to pituitary secretion	Biochemistry
BHCG /Human chorionic gonadotropin beta (POCT)	Spot Urine	Performed in Siemens Clinitek Status +	10 minutes	>25 IU/ml = positive >10<25 IU/ml = borderline <10 IU/ml – negative	Point of Care
Bicarbonate	Serum-Gel 7.5ml	Send to the lab promptly.	2.5hrs or 70 Minutes STAT	22-29 mmol/L	Biochemistry
Blood Culture	Blood	N/A	Neg: 2 Days Pos: 7 Days	N/A	Microbiology
Blood Film Review	Blood Film		2 Working Days	N/A	Haematology
*Ca125	Serum-Gel 7.5ml	Analyse as soon as possible	1 Day Weekday	0-35U/ml	Biochemistry
*Ca153	Serum-Gel 7.5ml	Analyse as soon as possible	1 Day Weekday	<26.4 U/ml	Biochemistry

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
Calcium	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	2-12yr 2.20-2.70 mmol/L 18-60yr 2.2-2.55 mmol/L 60-90yr 2.20-2.55 mmol/L >90yr 2.05-2.40 mmol/L	Biochemistry
*CEA	Serum-Gel 7.5ml	Analyse as soon as possible	1 Day Weekday	0.0-5.2 μg/l	Biochemistry
Chloride	Serum-Gel 7.5ml	Analyse as soon as possible	2.5hrs or 70 Minutes STAT	95-108 mmol/L	Biochemistry
Cholesterol	Serum-Gel 7.5ml	12 hour fast. Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	<5.2 mmol/L optimal	Biochemistry
*Correction Studies	Na Citrate 9NC 3 ml		½ Day	Reduction of Original Results (secs)	Haematology
*Cortisol	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 90mins STAT	133-537 nmol/L for morning samples (6-10am)	Biochemistry
COVID-19	NP/OP in UTM	Hand deliver to Lab ASAP	2hrs (Genxpert) Same day <12:00 12 (Seegene) Following day >12:00 (Seegeen)	N/A	Microbiology
*CRE Screen	Rectal swab/ Stool	Blue top amies swab	Neg: 2 Days Pos: 4 Days	N/A	Microbiology

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
C-Reactive Protein	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	0-5.0 mg/L	Biochemistry
Creatine Kinase	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate. Samples must be centrifuged within 2hrs of venepuncture.	2.5hrs or 70 Minutes STAT	M=39-308 IU/L F=26-192 IU/L	Biochemistry
Creatinine	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate. Sample must be received in lab within 2 hrs of venepuncture.	2.5hrs or 70 Minutes STAT	5-7yr 25-42 μmol/L 7-9yr 30-47 μmol/L 9-11yr 29-56 μmol/L 11-13yr 39-60 μmol/L 13-15yr 40-68 μmol/L F : 45-84 μmol/L M: 59-104 μmol/L	Biochemistry
*Cryoglobulin	2 x 7.5ML clotted 1 x 2.7ml EDTA	Contact phlebotomist regarding special requirements	1 Week	Positive/Negative	Immunology
*CSF Microscopy, C&S	CSF	Must be received within 1 hour for glucose analysis.	Neg: 3 Days Pos: 4 Days	N/A	Microbiology
*CSF Protein & Glucose	1.0ml CSF	Send to Laboratory immediately.	70 Minutes	15-45 mg/dL 2.22-3.89 mmol/L	Biochemistry
D Dimers	Na Citrate 9NC 3ml		2 Hours	<0.50ug/ml	Haematology
*Deep Wound / Tissue	Tissue	N/A	Neg: 2 Days Pos: 14 Days	N/A	Microbiology

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
*Differential	K EDTA 2.7 ml		Same Day	$\begin{tabular}{ c c c c c c c } \hline NEUT & & & & & & & & & & & & & & & & & & &$	Haematology
Digoxin	Clotted 7.5ml (plain)	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	0.77-1.5 nmol/L	Biochemistry
*Erythrocyte Sedimentation Rate	Na Citrate 4NC 3.5 ml		2 Hours	0-10 Male 0-20 Female	Haematology
*Eye / Ear / Nose / Throat	Swab/ pus	Blue top amies swab	Neg: 2 Days Pos: 4 Days	N/A	Microbiology
*Faecal C. difficle	Faeces	N/A	2 Days	N/A	Microbiology
*Faecal M, C&S	Faeces	N/A	Neg: 4 Days Pos: 5 days	N/A	Microbiology
*Ferritin	7.5ml Serum		1 Day	(m) 30 – 400ug/L (f) 13 – 150 ug/L	Biochemistry

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
Fibrinogen	Na Citrate 9NC 3 ml		2 Hours	2.0-4.0 g/l.	Haematology
*Folate	7.5ml Serum		1 Day	3.9 – 26.8 ng/L	Biochemistry
Full Blood Count	K EDTA	Haemoglobin: it is important to	1 Hour	WBC	Haematology
	2.7 ml	avoid haemolysis either during or after the collection of the blood specimen, otherwise the result is invalid. Red cell count: there is a moderate fluctuation during the 24 hours of about 4 per cent probably related to exercise meals and fluid intake etc. Strong emotions such as fear cause a temporary increase in the red cell count. Platelets: pseudo thrombocytopenia due to platelet aggregation (clumping) in EDTA blood may be found. This artefact is of no clinical significance, can be identified in the laboratory and resolved by supplying Thromboexact specimen for platelet count only. While red cell white cell and		12 years 4.5-13.5 x $10^{9/L}$ Adult 4.00-11.00 x $10^{9/L}$ <u>RBC</u> 12 years 4.00-5.40 x $10^{12/L}$ Adult (f)3.80-5.80 x $10^{12/L}$ Adult (m)4.50-6.50 x $10^{12/L}$ <u>HGB</u> 12 years 11.5-14.5 g/dL Adult (f) 11.5-16.5 g/dL Adult (m) 13.0-18.0 g/dL <u>HCT</u> 12 years 0.37-0.44 x L/L Adult (f) 0.37-0.47 x L/L Adult (f) 0.37-0.47 x L/L Adult (m) 0.40-0.54 x L/L <u>MCV</u> 12 years 77.0-91.0 f/L Adult 80.0-100.0 f/L <u>MCH</u> 12 years 24.0-30.0pg Adult 28.0-32.0pg <u>MCHC</u> 32.0-36.0 g/dL RDW 11.0-15.0%	

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
		platelet numbers are stable for at least 24hours in EDTA, progressive morphological changes in a blood film are however inevitable		<u>PLTS</u> 150-400 x 10 ^{9/} L	
Gamma Glutamyl Transferase	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	M: 10-71 U/L F: 6-42 U/L	Biochemistry
*Genital Swab	Swab	Blue top amies swab	Neg: 2 Days Pos: 4 Days	N/A	Microbiology
Gentamicin	Clotted 7.5ml (Plain)	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	Refer to Consultant Microbiologist	Biochemistry
Glucose	Finger prick sample , Nova StatStrip meter	N/A	1 minute	3.85-6.10 mmol/L	Point od Care
Glucose	Fluoride Oxalate Bottle 2.5ml	12 hour fast. Analyse as soon as possible. Serum sample must be received within one hour of venepuncture. Fluoride Oxalate tubes should be used	2.5hrs or 70 Minutes STAT	3.85-6.10 mmol/L	Biochemistry
Glucose Tolerance Test	2 x 2.5ml bottles Fluoride Oxalate Bottle	See instructions for modified GTT testing.	2.5hrs or 70 Minutes STAT	Fasting <6.1 mmol/L 2hrs pp <7.8 mmol/L	Biochemistry
*Haemoglobin A1C	Whole Blood (EDTA) 2.5mls	Use EDTA Sample	1 Day (Weekday)	20-42 mmol/mol	Biochemistry

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
*Hepatitis A	7.5 ml clotted	Spin and store at 2-8°C	3 Days	Positive/Not detected	Serology
*Hepatitis B (HBsAg)	7.5 ml clotted	Spin and store at 2-8°C	3 Days	Positive/Not detected	Serology
*Hepatitis C	7.5 ml clotted	Spin and store at 2-8°C	3 Days	Positive/Not detected	Serology
High Density Lipoprotein	Serum-Gel 7.5mls	12 hour fast	2.5hrs	>1.55 mmol/L <1.04 confers CV risk.	Biochemistry
*HIV	7.5 ml clotted	Spin and store at 2-8°C	3 Days	Positive/Not detected	Serology
Hs-Troponin T	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	75 Minutes	0-14 ng/L Female 0-22 ng/L Male Values > 300 ng/L indicates a significant degree of myocardial damage, which may be consistent with MI. Values 22-300 ng/L In patients with symptoms of ACS requires Clinical Correlation.	Biochemistry
*HVS – High Vaginal Swab	Swab	Blue Top Amies Swab	Neg: 2 Days Pos: 4 days	N/A	Microbiology
*Immunofixation of serum.	7.5 ml clotted	Spin, separate and store at 2-8°C	2 Weeks	Interpretative comment	Immunology
*Immunofixation of urine	24 hr urine collection (Plain Container)	As Above	2 Weeks	Interpretative Comment	Immunology

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
*Immunoglobulins	7.5ml clotted	Spin and store at 2-8°C	1 Week	IgG 6.10-16.16g/L IgA 0.85-4.99 g/L IgM 0.35-2.42g/L	Immunology
Influenza / RSV	NP Swab in UTM	Hand deliver to Lab ASAP	2hrs (Genxpert)	N/A	Microbiology
Inorganic Phosphate	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	4-6yr 1.05-1.80 mmol/L M:7-9yr 0.95-1.75mmol/L F:7-9yr 1.00-1.80 mmol/L M:10-12yr 1.05-1.85 mmol/L F:10-12yr 1.05-1.70 mmol/L M:13-15yr 0.95-1.65 mmol/L F:13-15yr 0.90-1.55 mmol/L M:16-18yr 0.85-1.60 mmol/L F:16-18 0.80-1.55 mmol/L Adult 0.81-1.45 mmol/L	Biochemistry
International Normalised Ratio	Na Citrate 9NC 3 ml		2 Hours	Determined by clinical state	Haematology
Iron	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate. Sample must be received in lab within one hour of venepuncture.	2.5hrs or 80 Minutes STAT	5.83-34.5 μmol/L	Biochemistry
*Iron Stain	Bone Marrow Aspirate Slide		2 Days	Reduced/Normal/Raised	Haematology
*Joint Fluid	Fluids	N/A	14 Days	N/A	Microbiology

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
Ketones	Finger prick, Nova StatStrip meter	N/A	1 minute	0-0.6 mmol/l	Point of Care
Lactate	ABG Heparin Syringe (venous/ arterial sample)	Analyse as soon as possible or spin/separate. Must be received in lab within 2hrs of venepuncture.	30 Minutes	0.5-2.0mmol/l	Point of Care
Lactate Dehydrogenase	Serum-Gel 7.5ml	Ensure there are no air bubbles and analyse immediately.	2.5hrs or 70 Minutes STAT	2-15yr 120-300 IU/L F: 135-214 IU/L M: 135-225 IU/L	Biochemistry
Low Density Lipoprotein	Serum-Gel Cl 7.5mls	Analyse as soon as possible or spin/separate	2.5hrs	<2.6 mmol/L optimal	Biochemistry
Magnesium	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	6-12yr 0.70-0.86 mmol/L 12-20yr 0.70-0.91 mmol/L 20-60yr 0.66-1.07 mmol/L 60-90yr 0.66-0.99 mmol/L >90yr 0.70-0.95 mmol/L	Biochemistry
*May Grunwald /Giemsa	Bone Marrow Aspirate Blood Film		2 Days Same Day	N/A	Haematology
*MRSA	Nose/Throat/ Groin swabs	N/A	Neg: 2 Days Pos: 3 Days	N/A	Microbiology
NT-pro-BNP	Serum-Gel 7.5mls	Analyse as soon as possible	90 mins	<125 pg/ml	Biochemistry
*Parietal Cell Antibody	7.5ml clotted	Spin, separate and store at 2-8°C	1 Week	<80	Immunology

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
*Peri-Cardial Fluid	Fluid	N/A	Neg: 3 Days Pos: 7 Days	N/A	Microbiology
Potassium	Serum-Gel 7.5ml	Send to lab within 2 hrs of venepuncture	2.5hrs or 70 Minutes STAT	3.5-5.3 mmol/L	Biochemistry
Pregnancy Test	Urine	N/A	30 Mins	N/A	Microbiology
*Prostate Specific Antigen	Serum-Gel 7.5mls	Analyse as soon as possible or spin/separate	Batched every 2hrs. ~3hrs	0-2.9 ug/L <50 yrs 0-2.9 ug/L 50-59 yrs 0-3.9 ug/L 60-69 yrs 0-5 ug/L >70yrs	Biochemistry
*Protein Electrophoresis Quantitative Paraprotein	7.5 ml clotted	Spin, separate and store at 2-8°C	1 Week	Total Protein 64-82 g/L Albumin 35-50 g/L Alpha-1 1-2 g/L Alpha-2 6-9 g/L Beta-1 4-7 g/L Beta-2 2-5 g/L Gammaglobulin 6-13 g/L Interpretative comment	Immunology
*Protein/Creatinine Ratio	MSU	UK eCKD guidelines	24 Hours (weekdays)	1-15 mg/mmol	Biochemistry
Prothrombin Time	Na Citrate 9NC 3 ml556f6ff		2 Hours	11.4-15.0 seconds	Haematology
*PTH	Whole Blood (EDTA) 2.5mls	Analyse as soon as possible or spin/separate	Daily or 90 mins STAT	1.6-6.9 pmol/L	Biochemistry

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
*Reticulocytes	K EDTA 2.7 ml		Same Day	35-132x10 ^{9/} L	Haematology
*Serum Free Light Chains	7.5ml clotted	Spin, and store at 2-8°C	14 days	Kappa: 3.3-19.40 mg/L Lambda: 5.71-26.30 mg/L K/L Ratio: 0.26-1.65	Immunology
*Sickledex	K EDTA 2.7 ml		Same Day	Positive/Negative	Haematology
Sodium	Serum-Gel Clotted 7.5ml	Analyse as soon as possible. Sample should be received in lab within 1 hour of venepuncture.	2.5hrs or 70 Minutes STAT	133-146 mmol/L	Biochemistry
*Sputum / BAL / Other Resp Samples	Sputum	N/A	Neg: 2 Days Pos: 5 Days	N/A	Microbiology
*Superficial Wound / Pus	Swab/ pus	Blue top amies swab	Neg: 3 Days Pos: 14 Days	N/A	Microbiology
*Syphillis	7.5 ml clotted	Spin and store at 2-8°C	3 Days	Positive/Not detected	Serology
*Thyroid Simulating Hormone	Serum-Gel 7.5ml	Analyse as soon as possible	Daily or 90mins STAT	0.270-4.45 mIU/L	Biochemistry
*Thyroxine Free	Serum-Gel 7.5ml	Analyse as soon as possible	Daily or 90 mins STAT	12-22 pmol/L	Biochemistry
*Tips Culture	Tips and lines and pacing wires	Only processed if blood cultures received within 24 hours	3 Days	N/A	Microbiology
Total Bilirubin	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	M <24 μmol/L F <15 μmol/L	Biochemistry

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
Total Protein	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	60-80 g/L	Biochemistry
Transferrin	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs	2.0-3.6 g/L	Biochemistry
Triglycerides	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs	<1.7 mmol/L	Biochemistry
Urate	Serum-Gel 7.5ml	Analyse as soon as possible or spin/separate	2.5hrs or 80 Minutes STAT	M: 202-417 μmol/L F: 142-339 μmol/L	Biochemistry
Urea	Serum Gel 7.5ml	12 hour fast. Analyse as soon as possible or spin/separate	2.5hrs or 70 Minutes STAT	18-60yr 2.14-7.14 mmol/L 60-90yr 2.86-8.21 mmol/L	Biochemistry
*Urinary Amylase	MSU Container	Analyse as soon as possible	2 hours	M: 16-491 U/L F: 21-447 U/L	Biochemistry
*Urinary Calcium	24hr acid container	Analyse as soon as possible	24 Hours (weekdays)	2.5-7.5 mmol/24hr	Biochemistry
*Urinary Creatinine Creatinine Clearance	24hr container/MSU container	Analyse as soon as possible	24 Hours (weekdays)	M: 3540-24600 μmol/L F: 2550-20000 μmol/L 66-143 ml/min	Biochemistry
*Urinary Glucose	MSU container	WHO	2 hours	0.06-0.083 mmol/L	Biochemistry
*Urinary Protein	24 hr urine container	Analyse as soon as possible	24 Hours (weekdays)	<0.14 g/24 Hours	Biochemistry
*Urinary Urea	24hr Plain Urine container	Analyse as soon as possible	24 Hours (weekdays)	428-741 mmol/24hrs	Biochemistry

Test *Tests are not performed on call	Sample Type	Special Precautions	Turn Around Time	Adult Reference Ranges	Department
*Urine Microscopy, C&S	Urine	N/A	Neg: 1 Day Pos: 3 Days	N/A	Microbiology
Vancomycin	Clotted 7.5ml Sample to be taken 5 minutes pre-dose and 1 hour post dose	Analyse as soon as possible or spin/separate	2.5hrs or 80 Minutes STAT	Refer to Consultant Microbiologist	Biochemistry
*VRE Screen	Rectal swab/ Stool	Blue top amies swab	Neg: 3 Days Pos: 4 Days	N/A	Microbiology